

NOTICE AND DISCLAIMER

This publication is intended to be a resource for physicians and other healthcare professionals who provide care and treatment to patients in resource poor settings. Reasonable efforts have been made to ensure that the material presented here is accurate, reliable, and in accord with current standards *as of the date of publication*. However, as new research and experience expand our knowledge, recommendations for care and treatment change. Your use of this publication is provided on an “as is” basis without warranty of any kind, and none of the individuals or entities listed below represent or warrant that the information contained herein is complete or accurate or free from error. It is therefore the responsibility of the individual physician or healthcare professional to use his/her best medical judgment in determining appropriate patient care or treatment.

To the maximum extent permitted under applicable laws, no responsibility is assumed by any party involved in the production or publication of this publication, including without limitation, each of the contributors and authors; Partners In Health; the Program in Infectious Disease and Social Change, Harvard Medical School; Harvard Medical School Division of AIDS; the Division of Social Medicine and Health Inequalities, Brigham and Women's Hospital; and each of their affiliates, divisions, directors, officers, trustees, agents and employees (referred to collectively as the “Publishers and Contributors”). The Publishers and Contributors hereby disclaim all liability for errors, omissions, or any injury and/or damage (actual or perceived) to persons or property as a result of any actual or alleged product liability, libelous statement, or infringement of intellectual property or privacy rights, whether resulting from negligence or otherwise, including without limitation, from any reliance upon, use or operation of, any ideas, instructions, procedures, products or methods contained in the material included in this publication.

References to specific drugs or products within this publication do not constitute endorsement by the Publishers and Contributors. Individual patient needs may vary on a case-by-case basis, and physicians and other healthcare professionals should consult their standard resources before prescribing specific drugs or products to their patients.

This disclaimer and your use of this publication are and shall be governed and construed in accordance with the internal laws of the Commonwealth of Massachusetts, without regard to its rules concerning conflicts of laws. In the event of any conflict between foreign laws, rules and regulations and those of the United States, the laws, rules and regulations of the United States shall govern.

By choosing to use this publication, you acknowledge and agree to the terms of this disclaimer.

Published in the United States by Partners In Health.

Subject to the rights of Partners In Health, this publication may be freely reviewed, abstracted, reproduced or translated, provided that all copyright, trademark and other proprietary notices are included in each such use.

The foregoing notwithstanding, no portion of this publication may be sold or otherwise used or distributed in conjunction with any commercial purpose.

PIH and Partners In Health are trademarks of Partners In Health, and the PIH logo is a United States registered service mark of Partners In Health. All other trademarks, service marks, trade names and logos appearing in this publication, including drug brands and names, are the property of their respective owners.

Copyright 2003 - 2004 © Partners In Health
All rights reserved under International and Pan-American Copyright Convention

References

- Antimicrobial Susceptibility Testing. Proposed Standard. NCCLS.
- Physician's Desk Reference. 55th edition. Montvale: Medical Economics, 2001.
- Abadco DL, Steiner P. Gastric lavage is better than bronchoalveolar lavage for isolation of *Mycobacterium tuberculosis* in childhood pulmonary tuberculosis. *Pediatr Infect Dis J* 1992; 11(4):735-8.
- Abate G, Miörner H. Susceptibility of multidrug-resistant strains of *Mycobacterium tuberculosis* to amoxicillin in combination with clavulanic acid and ethambutol. *J Antimicrob Chemother* 1998; 42(6):735-40.
- Abate G, Miörner H, Ahmed O, Hoffner SE. Drug resistance in *Mycobacterium tuberculosis* strains isolated from re-treatment cases of pulmonary tuberculosis in Ethiopia: susceptibility to first-line and alternative drugs. *Int J Tuberc Lung Dis* 1998; 2(7):580-4.
- Abderrahim K, Chaulet P, Oussedik N, Amrane R, Hassen CS, Mercer N. Practical results of standard first-line treatment in pulmonary tuberculosis: influence of primary resistance. *Bull Int Union Tuberc* 1976; 51(1):359-66.
- Abdool Karim SS. Measuring effectiveness of tuberculosis control programmes. *S Afr Med J* 1997; 87(8 Suppl):1040-1.
- Accinelli RA, Adachi R, Valdez LM. [Epidemiology of tuberculosis in Peru]. [Spanish]. Lima: Trabajo presentado en el V Congreso Panamericano de Infectología, 1991.
- Acuña D, Ferrer X, Galvez B et al. [Pulmonary tuberculosis: interval between the first symptoms and the initiation of therapy]. [Spanish]. *Rev Med Chil* 1981; 109(7):628-33.
- Addington WW. Patient compliance: the most serious remaining problem in the control of tuberculosis in the United States. *Chest* 1979; 76(6 Suppl.):741-3.
- Adhikari N, Menzies R. Community-based tuberculin screening in Montreal: a cost-outcome description. *Am J Public Health* 1995; 85(6):786-90.
- Agasino CB, Ponce de León A, Jasmer RM, Small PM. Epidemiology of *Mycobacterium tuberculosis* strains in San Francisco that do not contain IS6110. *Int J Tuberc Lung Dis* 1998; 2(6):518-20.
- Agerton T, Valway S, Gore B et al. Transmission of a highly drug-resistant strain (strain W1) of *Mycobacterium tuberculosis*: community outbreak and nosocomial transmission via a contaminated bronchoscope. *JAMA* 1997; 278(13):1073-7.
- Agrons GA, Markowitz RI, Kramer SS. Pulmonary tuberculosis in children. *Semin Roentgenol* 1993; 28(2):158-72.
- Agus ZS. Hypomagnesemia. *J Am Soc Nephrol* 1999; 10(7):1616-22.
- Ahmad I, Clark L. Isoniazid hypersensitivity reaction involving the eyes: report of a case. *Dis Chest* 1967; 52:112-13.
- Ahmed AS, Shore C. *The Future of Anthropology: Its Relevance to the Contemporary World*. London: Athlone, 1995.
- Ahuja GK, Mohan KK, Prasad K, Behari M. Diagnostic criteria for tuberculous meningitis and their validation. *Tuber Lung Dis* 1994; 75(2):149-52.
- Aisu T, Raviglione MC, van Praag E et al. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre. *AIDS* 1995; 9(3):267-73.
- Aita J, Barrera L, Reniero A et al. Hospital transmission of multidrug-resistant *Mycobacterium tuberculosis* in Rosario, Argentina. *Medicina (B Aires)* 1996; 56(1):48-50.
- Akhtar AJ, Crompton GK, Schonell MM. Para-aminosalicylic acid as a cause of intestinal malabsorption. *Tubercle* 1968; 49(3):328-31.
- al-Kassimi FA, Abdullah AK, al-Hajjaj MS, al-Orainey IO, Bamgboye EA, Chowdhury MN. Nationwide community survey of tuberculosis epidemiology in Saudi Arabia. *Tuber Lung Dis* 1993; 74(4):254-60.
- Alangaden GJ, Manavathu EK, Vakulenko SB, Zvonok NM, Lerner SA. Characterization of fluoroquinolone-resistant mutant strains of *Mycobacterium tuberculosis* selected in the laboratory and isolated from patients. *Antimicrob Agents Chemother* 1995; 39(8):1700-3.
- Alausa KO, Osoaba AO, Montefiore D, Sogbetun OA. Laboratory diagnosis of tuberculosis in a developing country 1968-1975. *Afr J Med Med Sci* 1977; 6(2):103-8.
- Alcaide Megias J, Altet Gómez MN, Taberner Zaragoza JL, Garrido Morales P, Salleras Sanmarti L. [Tuberculosis epidemiology in Catalonia: 1982-1989]. [Spanish]. *Med Clin (Barc)* 1990; 95(14):529-34.
- Ali J. Hepatotoxic effects of tuberculosis therapy: A practical approach to a tricky management problem. *Postgrad Med* 1996; 99(5):217-20, 230-1, 235-6.
- Allan WG, Girling DJ, Fayers PM, Fox W. The symptoms of newly diagnosed pulmonary tuberculosis and patients' attitudes to the disease and to its treatment in Hong Kong. *Tubercle* 1979; 60(4):211-23.
- Alland D, Kalkut GE, Moss AR et al. Transmission of tuberculosis in New York City: an analysis by DNA fingerprinting and conventional epidemiologic methods. *N Engl J Med* 1994; 330(24):1710-6.
- Allen BW, Mitchison DA, Chan YC, Yew WW, Allen WG, Girling DJ. Amikacin in the treatment of pulmonary tuberculosis. *Tubercle* 1983; 64(2):111-8.
- Allen S, Batungwanayo J, Kerlikowske K et al. Two-year incidence of tuberculosis in cohorts of HIV-infected and uninfected urban Rwandan women. *Am Rev Respir Dis* 1992; 146:1439-44.
- Alpert PL, Munsiff SS, Gurevitch MN, Greenberg B, Klein RS. A prospective study of tuberculosis and human immunodeficiency virus infection: clinical manifestations and factors associated with survival. *Clin Infect Dis* 1997; 24(4):661-8.
- Aluoch JA, Edwards EA, Stott H, Fox W, Sutherland I. A fourth study of case-finding methods for pulmonary tuberculosis in Kenya. *Trans R Soc Trop Med Hyg* 1982; 76(5):679-91.

- Aluoch JA, Karuga WK, Nsanzumuhire H et al. A second study of the use of community leaders in case-finding for pulmonary tuberculosis in Kenya. *Tubercle* 1978; 59(4):233-43.
- Aluoch JA, Oyoo D, Swai OB et al. A study of the use of maternity and child welfare clinics in case-finding for pulmonary tuberculosis in Kenya. *Tubercle* 1987; 68(2):93-103.
- Aluoch JA, Stott H. Case-finding studies in pulmonary tuberculosis in Kenya. *East Afr Med J* 1983; 60(3):542-5.
- Aluoch JA, Swai OB, Edwards EA et al. Studies of case-finding for pulmonary tuberculosis in outpatients at 4 district hospitals in Kenya. *Tubercle* 1985; 66(4):237-49.
- Alvarez FG, Guntupalli KK. Isoniazid overdose: four case reports and review of the literature. *Intensive Care Med* 1995; 21(8):641-4.
- Alvarez-Gordillo GC, Halperin-Frisch D, Blancarte-Melendres L, Vásquez-Castellanos JL. [Risk factors for antitubercular drug resistance in Chiapas, Mexico]. [Spanish]. *Salud Publica Mex* 1995; 37(5):408-16.
- Alwood K, Keruly J, Moore-Rice K, Stanton D, Chaulk CP, Chaisson RE. Effectiveness of supervised, intermittent therapy for tuberculosis in HIV-infected patients. *AIDS* 1994; 8(8):1103-8.
- American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders (DSM IV)*. 4th edition. Washington DC: 1997.
- American Society of Health-System Pharmacists. ASHP therapeutic position statement on strategies for preventing and treating multidrug-resistant tuberculosis. *Am J Health Syst Pharm* 1997; 54(4):428-31.
- American Thoracic Society. Control of tuberculosis in the United States. *Am Rev Respir Dis* 1993; 146(6):1623-33.
- American Thoracic Society, Centers for Disease Control and Prevention. Treatment of tuberculosis and tuberculosis infection in adults and children. *Am J Respir Crit Care Med* 1994; 149:1359-74.
- Amorosa JK, Smith PR, Cohen JR, Ramsey C, Lyons HA. Tuberculous mediastinal lymphadenitis in the adult. *Radiology* 1978; 126(2):365-8.
- Anastasatu C, Mihailescu P, Didilescu C, Ibraim E, Lugoji D, Chiotan D. [Tuberculosis in the elderly: sociomedical aspects]. [Romanian]. *Pneumoftiziologia* 1993; 42(1-2):23-7.
- Anastasis D, Pillai G, Rambirth A, Abdool-Karim SS. A retrospective study of human immunodeficiency virus infection and drug-resistant tuberculosis in Durban, South Africa. *Int J Tuberc Lung Dis* 1997; 1(3):220-4.
- Anastasis D, Pillai G, Rambirth V. Multidrug-resistant tuberculosis in patients without HIV infection. *S Afr Med J* 1996; 86(10):1294-6.
- Andersson N, Marks S. Apartheid and health in the 1980s. *Soc Sci Med* 1988; 27(7):667-81.
- Andrews AB, Williams H, Kinney J. Three models of social work intervention with tuberculosis patients. *Health Soc Work* 1988; 13(4):288-95.
- Ang'awa JO. Case finding programmes in the control of pulmonary tuberculosis in Kenya. *East Afr Med J* 1965; 42(11):666-72.
- Angarano G, Carbonara S, Costa D, Gori A. Drug-resistant tuberculosis in human immunodeficiency virus infected persons in Italy. The Italian Drug-Resistant Tuberculosis Study Group. *Int J Tuberc Lung Dis* 1998; 2(4):303-11.
- Anglaret X, Dabis F, Batungwanayo J et al. [Primary chemoprevention of tuberculosis in HIV-infected patients in non-industrialized countries]. [French]. *Sante* 1997; 7(2):89-94.
- Anglaret X, Saba J, Perronne C et al. Empiric antituberculosis treatment: benefits for earlier diagnosis and treatment of tuberculosis. *Tuber Lung Dis* 1994; 75(5):334-40.
- Annett H, Nickson PJ. Community involvement in health: why is it necessary? *Trop Doct* 1991; 21(1):3-5.
- Anonymous. [Anti-tuberculosis campaign at Ishimaki City. Cooperation of public health nurses and the public health clinic]. [Japanese]. *Hokenfu Zasshi* 1970; 26(3):38-42.
- Anonymous. Benefits of Orphan Drug Act. *Washington Post*. 2 July 1991: Health Page Z4.
- Anonymous. Biogen commends FDA ruling upholding Orphan Drug Act with regard to AVONEX(R). *PR Newswire* 1999.
- Anonymous. Buying into the orphan drug market. *Lancet* 1995; 346:917.
- Anonymous. CDC issues guidelines for multidrug-resistant tuberculosis. *Am Fam Physician* 1992; 46(4):1303-5.
- Anonymous. Community participation in tuberculosis control. *Bull Int Union Tuberc* 1974; 49(Suppl. 1):198-204.
- Anonymous. Consensus statements: medical management of epilepsy. *Neurology* 1998; 51(5 Suppl. 4):S39-43.
- Anonymous. Control of tuberculosis in the United States. American Thoracic Society. *Am Rev Respir Dis* 1992; 146(6):1623-33.
- Anonymous. EU parliamentary views drug industry vs public health. *Marketletter* 1995.
- Anonymous. Euro commission's orphan drug incentive. *Marketletter* 1998.
- Anonymous. Guidelines for the identification, investigation and treatment of individuals with concomitant tuberculosis and HIV infection. Bureau of Communicable Disease Epidemiology, Canada Department of National Health and Welfare. *Can Med Assoc J* 1993; 148(11):1963-70.
- Anonymous. The management of pulmonary tuberculosis in adults notified in England and Wales in 1988. The British Thoracic Society Research Committee and the Medical Research Council Cardiothoracic Epidemiology Group. *Respir Med* 1991; 85(4):319-23.
- Anonymous. MMV: new medicines for malaria venture. *Tropical Diseases Research Newsletter* 1999; 58:1-2.
- Anonymous. Money isn't the issue; it's (still) political will. *TB Monitor* 1998; 5(5):53.

- Anonymous. National survey of notifications of tuberculosis in England and Wales in 1988. Medical Research Council Cardiothoracic Epidemiology Group. *Thorax* 1992; 47(10):770-5.
- Anonymous. New regulation to cover orphan drugs. *Pharmaceutical Manufacturing Review* 1998; 10(5):36.
- Anonymous. Orphan Drug Act. Public Law 97-414: 1983.
- Anonymous. Orphan drug battle grows in Washington: changes in law governing patents on drugs for rare disorders. *Chemical Marketing Reporter* 1992; 241(4):3.
- Anonymous. Orphan drug law for the EU? *Business Law Europe* 1996.
- Anonymous. [Pulmonary tuberculosis case finding]. [Spanish]. *Salud Publica Mex* 1971; 13(5):623-5.
- Anonymous. Regulation to help "orphan drug" producers proposed to EC. *Chemist and Druggist* 1998; 33.
- Anonymous. Rifampicin or ethambutol in the routine treatment of tuberculosis. *BMJ* 1973; 4:56.
- Anonymous. Standards for tuberculosis treatment in the 1970's. A statement by the Ad Hoc Committee on Quality Care for Tuberculosis. *Bull Natl Tuberc Respir Dis Assoc* 1971; 57(3):9-11.
- Anonymous. Tuberculosis control. Part 4: staff development and training. The South African tuberculosis control programme. *Nurs RSA* 1993; 8(11-12):41-3.
- Anonymous. Tuberculosis in children: a national survey of notifications in England and Wales in 1988. Medical Research Council Cardiothoracic Epidemiology Group. *Arch Dis Child* 1994; 70(6):497-500.
- Antoine D, Schwoebel V, Veen J, Raviglione MC, Rieder HL. Surveillance of tuberculosis in the WHO European region, 1995-1996. *Eurosurveillance* 1998; 3(11):103-7.
- Aoki M. [Characteristics of tuberculosis in Japan compared with those in other developed countries]. [Japanese]. *Kekkaku* 1993; 68(8):533-8.
- Arens FJ. [Significance of chronic pulmonary tuberculosis for the control of tuberculosis as a common disease with regard to its epidemiology]. [German]. *Beitr Klin Erforsch Tuberk Lungenkr* 1969; 140(1):1-7.
- Arnadottir T. Assessment of tuberculosis: is 'rapid assessment' needed? *Tuber Lung Dis* 1995; 76(5):375-6.
- Arnadottir T, Rieder HL, Enarson DA. International Union Against Tuberculosis and Lung Disease. *Tuberculosis programs. Review, planning, technical support. A manual of methods and procedures*. 1998.
- Arnholdt R. [The significance of chronic pulmonary tuberculosis for the control of tuberculosis as a common disease with regard to tuberculosis health service]. [German]. *Beitr Klin Erforsch Tuberk Lungenkr* 1969; 140(1):8-13.
- Arno PS, Murray CJ, Bonuck KA, Alcades P. The economic impact of tuberculosis in hospitals in New York City: a preliminary analysis. *J Law Med Ethics* 1993; 21(3-4):317-23.
- Aronson B, Kochi A. WHO/tuberculosis information systems. Computerized selective tuberculosis bibliography. *Bull Int Union Tuberc Lung Dis* 1990; 65(1):60-1.
- Asbury CH. Evolution and current status of the Orphan Drug Act. *Int J Technol Assess Health Care* 1992; 8(4):573-82.
- Asencios L, Sanabria H, Diaz S, Quispe N. [Initial resistance of *M. tuberculosis* to antituberculous drugs (1988-1989)]. [Spanish]. *Rev Med Hered* 1993; 4(2):62-6.
- Ashley MJ. Epidemiology of tuberculosis in Canada. *N Engl J Med* 1975; 293(17):880.
- Ashurst M. WHO warns that multidrug resistant TB will spread. *BMJ* 1996; 313:9.
- Atkinson ML. A new method for the evaluation of tuberculosis control programs. *Health Serv Rep* 1973; 88(6):489-92.
- Auregan G, Rakotomanana F, Ratsitorahina M et al. [Tuberculosis in the prison milieu at Antananarivo from 1990 to 1993]. [French]. *Arch Int Pasteur Madagascar* 1995; 62(1):18-23.
- Ausina V, Riutort N, Viñado B et al. Prospective study of drug-resistant tuberculosis in a Spanish urban population including patients at risk for HIV infection. *Eur J Clin Microbiol Infect Dis* 1995; 14(2):105-10.
- Avorn J, Chen M, Hartley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. *Am J Med* 1982; 73(1):4-8.
- Babaniyi OA. A 10-year review of morbidity from childhood preventable diseases in Nigeria: how successful is the expanded programme on immunization (EPI)? An update. *J Trop Pediatr* 1990; 36(6):306-13.
- Babu Swai O, Aluoch JA, Githui W, Darbyshire JH. Short course chemotherapy for pulmonary tuberculosis in routine service in Kenya. *East Afr Med J* 1990; 67(11):748-55.
- Bachev BI. [Development of surgical aid to patients with osteoarticular tuberculosis in the Kostroma region]. [Russian]. *Probl Tuberk* 1968; 46(8):4-6.
- Bachinskii IS, Kunovskii BV. [Active case-finding of patients suffering from bone-joint tuberculosis]. [Russian]. *Feldsher Akush* 1969; 34(5):19-20.
- Backhaus R. [Critical considerations on the legal principles and regulations including the economic tuberculosis assistance]. [German]. *Offentl Gesundheitswes* 1971; 33(Suppl. 2):43-9.
- Baer HA. Medical pluralism in the United States: a review. *Med Anthropol Q* 1995; 9(4):493-502.
- Baily GJ, Savic D, Gothi GD, Naidu VB, Nair SS. Potential yield of pulmonary tuberculosis cases by direct microscopy of sputum in a district of South India. *Bull World Health Organ* 1967; 37(6):875-92.
- Balasubramanian R, Sadacharam K, Selvaraj R et al. Feasibility of involving literate tribal youths in tuberculosis case-finding in a tribal area in Tamil Nadu. *Tuber Lung Dis* 1995; 76(4):355-9.

- Balasubramanian R, Sivasubramanian S, Vijayan K et al. Five year results of a 3-month and two 5-month regimens for the treatment of sputum-positive pulmonary tuberculosis in South India. *Tubercle* 1990; 71(4):253-8.
- Balint J, Nyarady I. [Epidemiology of urogenital tuberculosis in Hungary]. [German]. *Z Urol Nephrol* 1969; 62(6):429-38.
- Ball P, Tillotson G. Tolerability of fluoroquinolone antibiotics: past, present, and future. *Drug Saf* 1995; 13(6):343-58.
- Banatvala N, Matic S, Kimerling ME, Farmer PE, Goldfarb A. Tuberculosis in Russia. *Lancet* 1999; 354:1036.
- Banatvala N, Peremitin GG. Tuberculosis, Russia and the holy grail. *Lancet* 1999; 353:999-1000.
- Banerji D, Andersen S. A sociological study of awareness of symptoms among persons with pulmonary tuberculosis. *Bull World Health Organ* 1963; 29:665-83.
- Barber PG, Goldman WJ, Stahl AJ et al. Antitubercular drugs. In: Lutwick L, ed. *Tuberculosis: a Clinical Handbook*. New York: Chapman and Hall Medical, 1995: 252-94.
- Barber TW, Craven DE, McCabe WR. Bacteremia due to *Mycobacterium tuberculosis* in patients with human immunodeficiency virus infection. A report of 9 cases and a review of the literature. *Medicine* 1990; 69(6):375-83.
- Barnes PF. The influence of epidemiologic factors on drug resistance rates in tuberculosis. *Am Rev Respir Dis* 1987; 136(2):325-8.
- Barnes PF. Reducing ongoing transmission of tuberculosis. *JAMA* 1998; 280(19):1702-3.
- Barnes PF. Tuberculosis among the inner city poor. *Int J Tuberc Lung Dis* 1998; 2(9 Suppl. 1):S41-S45.
- Barnes PF, El-Hajj H, Preston-Martin S et al. Transmission of tuberculosis among the urban homeless. *JAMA* 1996; 275(4):305-7.
- Barnes PF, Yang Z, Preston-Martin S et al. Patterns of tuberculosis transmission in central Los Angeles. *JAMA* 1997; 278(14):1159-63.
- Barnett M, Bushby SRM, Mitchison DA. Tubercle bacilli resistant to isoniazid: virulence and response to treatment with isoniazid in guinea-pigs and mice. *Br J Exp Pathol* 1953; 34:568-81.
- Barnhoorn F, Adriaanse H. In search of factors responsible for noncompliance among tuberculosis patients in Wardha District, India. *Soc Sci Med* 1992; 34(3):291-306.
- Barnum HN. Cost savings from alternative treatments for tuberculosis. *Soc Sci Med* 1986; 23(9):847-50.
- Barnwell MD, Chitkara R, Lamberta F. Tuberculosis prevention project. *J Natl Med Assoc* 1992; 84(12):1014-8.
- Barr RG, Menzies R. The effect of war on tuberculosis: results of a tuberculin survey among displaced persons in El Salvador and a review of the literature. *Tuberc Lung Dis* 1994; 75(4):251-9.
- Barrett-Connor E. The epidemiology of tuberculosis in physicians. *JAMA* 1979; 241(1):33-8.
- Barry VC, Conalty ML, Gaffney E. Isoniazid-resistant strains of *Mycobacterium tuberculosis*. *Lancet* 1953; i:978-9.
- Basch PF. Technology transfer to the developing world: does new technology have any relevance for developing countries? *Tuberc Lung Dis* 1993; 74(6):353-8.
- Bass JB, Farer LS, Hopewell PC, Jacobs RF, Snider DE Jr. Diagnostic standards and classification of tuberculosis. *Am Rev Respir Dis* 1990; 142(3):725-35.
- Bass JB, Farer LS, Hopewell PC et al. Treatment of tuberculosis and tuberculosis infection in adults and children. *Am J Respir Crit Care Med* 1994; 149:1359-74.
- Bastian I, Portaels F. *Multidrug-resistant tuberculosis*. Boston: Kluwer, 2000.
- Bastien JW. Community health workers in Bolivia: adapting to traditional roles in the Andean community. *Soc Sci Med* 1990; 30(3):281-7.
- Bastien P. Public-health epidemiology in Vanuatu. *Med J Aust* 1990; 152(1):13-7.
- Bayer R, Dupuis LJ. Ethical and legal issues in tuberculosis control. In: Rom WN, Garay SM. *Tuberculosis*. Boston: Little, Brown and Co, 1996: 965-72.
- Bayer R, Wilkinson D. Directly observed therapy for tuberculosis: history of an idea. *Lancet* 1995; 345:1545-8.
- Bayona J, Furin JJ, Palacios E et al. DOTS-Plus in the northern cone of Lima, Peru. Poster presentation. International Colloquium of the Institute of Tropical Medicine. *Tuberculosis, the real millenium bug: addressing the threat in developing and industrialised countries*. Antwerp: 1999.
- Becerra MC. Epidemiology of tuberculosis in the northern shantytowns of Lima, Peru [Sc.D. thesis]. Boston: Harvard University, 1999.
- Becerra MC, Bayona J, Freeman J, Farmer PE, Kim JY. Redefining MDR-TB transmission "hot spots". *Int J Tuberc Lung Dis* 2000; 4(5):387-94.
- Becerra MC, Freeman J, Bayona J et al. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis. *Int J Tuberc Lung Dis* 2000; 4(2):108-14.
- Becerra MC, Freeman J, Celi R et al. Sensitivity of passive case finding of tuberculosis in a Peruvian shantytown. Working Paper No. 2, Boston: Program in Infectious Disease and Social Change, 1999.
- Beck-Sague C, Dooley SW, Hutton MD et al. Hospital outbreak of multidrug-resistant *Mycobacterium tuberculosis* infections: factors in transmission to staff and HIV-infected patients. *JAMA* 1992; 268(10):1280-6.
- Becton Dickinson Diagnostic Instrument Systems. *Bactec TB System. Product and Procedure Manual*. MA-0029. Towson: Becton Dickinson Diagnostic Instrument Systems, 1995.
- Behr MA, Warren SA, Salamon H et al. Transmission of *Mycobacterium tuberculosis* from patients smear-negative for acid-fast bacilli. *Lancet* 1999; 353:444-9.
- Bellin E. Failure of tuberculosis control. A prescription for change. *JAMA* 1994; 271(9):708-9.
- Bellin EY, Fletcher DD, Safyer SM. Association of tuberculosis infection with increased time in or admission to the New York City jail system. *JAMA* 1993; 269(17):2228-31.

- Belogurova VP [Virulence and dynamics of the degree of drug resistance of *Mycobacterium tuberculosis*]. [Russian]. *Probl Tuberk* 1965; 43(3):60-6.
- Bender DE, Pitkin K. Bridging the gap: the village health worker as the cornerstone of the primary health care model. *Soc Sci Med* 1987; 24(6):515-28.
- Bender TR, Chick EW, Bauman DS. Inter-agency collaboration in screening for tuberculosis and histoplasmosis. *WV Med J* 1970; 66(6):191-2.
- Bennett W, McDougall J, Potocnik S, Wright RD, Whitworth JA. Renal handling and acute urinary electrolyte effects of aminoglycoside antibiotics: use of a solitary renal autotransplant in the conscious sheep. *Life Sci* 1983; 32(3):205-12.
- Benson WM, Stefko PL, Roe MD. Pharmacologic and toxicologic observations on the hydrazine derivatives of isonicotinic acid. *Am Rev Tuberc* 1952; 65:376-91.
- Berggren WL, Ewbank DC, Berggren GG. Reduction of mortality in rural Haiti through a primary-health-care program. *N Engl J Med* 1981; 304(22):1324-30.
- Berkelman RL, Hughes JM. The conquest of infectious disease: who are we kidding? *Ann Intern Med* 1993; 119(5):426-7.
- Berman PA, Gwatkin DR, Burger SE. Community-based health workers: head start or false start towards health for all? *Soc Sci Med* 1987; 25(5):443-59.
- Berman S, Kibel MA, Fourie PB, Strebel PM. Childhood tuberculosis and tuberculous meningitis: high incidence rates in the Western Cape of South Africa. *Tuber Lung Dis* 1992; 73(6):349-55.
- Bernejo A, Bekui A. Community participation in disease control. *Soc Sci Med* 1993; 36(9):1145-50.
- Bernard HR. *Research Methods in Cultural Anthropology*. Newbury Park: Sage Publications, 1988.
- Beser E. The prevalence of pulmonary tuberculosis using different methods in group screenings. *East Afr Med J* 1993; 70(12):768-71.
- Beyers N, Gie RP, Schaaf HS et al. Delay in the diagnosis, notification and initiation of treatment and compliance in children with tuberculosis. *Tuber Lung Dis* 1994; 75(4):260-5.
- Beyers N, Gie RP, Schaaf HS et al. A prospective evaluation of children under the age of 5 years living in the same household as adults with recently diagnosed pulmonary tuberculosis. *Int J Tuberc Lung Dis* 1997; 1(1):38-43.
- Bhat BV, Puri RK. Diagnosis of tuberculosis current status. *Indian Pediatr* 1993; 31(1):91-6.
- Bhattacharji S, Abraham S, Muliyl J, et al. Evaluating community health worker performance in India. *Health Policy Plann* 1986; 1(3):232-9.
- Bialy H. Detecting drug-resistant tuberculosis: beacons in the dark. *Nature Biotechnol* 1998; 16:331.
- Bifani PJ, Plikaytis BB, Kapur V et al. Origin and interstate spread of a New York City multidrug-resistant *Mycobacterium tuberculosis* clone family. *JAMA* 1996; 275(6):452-7.
- Bignall JR. Failure to control tuberculosis: A personal view. *Tubercle* 1982; 63:171-4.
- Bilaçeroglu S, Perim K, Büyüksirin M, Celikten E. Prednisolone: a beneficial and safe adjunct to antituberculosis treatment? A randomized controlled trial. *Int J Tuberc Lung Dis* 1999; 3(1):47-54.
- Bilancia R, Chianese R, Roselli P, Margiotta D, Quaranta A, Gramiccioni E. Follow-up study of patients with normal chest X-ray and hemoptysis: our preliminary data. *Tuber Lung Dis* 1994; 75(Suppl.):142.
- Binder S, Levitt AM. Preventing emerging infectious diseases: a strategy for the 21st century. *MMWR* 1998; 47(RR-15):1-14.
- Birenbaum A. *In the Shadow of Medicine: Remaking the Division of Labor in Health Care*. Dix Hills: General Hall, 1990.
- Bishai WR, Graham NMH, Harrington S et al. Molecular and geographic patterns of tuberculosis transmission after 15 years of directly observed therapy. *JAMA* 1998; 280(19):1679-84.
- Black W, Ganter B, Grzybowski S, Sanchez-Hernandez M, Hopewell P. Prevalence of initial bacillary resistance to antituberculous drugs in Peruvian patients with newly-discovered tuberculosis. *Am Rev Respir Dis* 1985; 131(Suppl.):A225.
- Blancarte L, Anzaldo G, Balandrano S. [Primary resistance of *Mycobacterium tuberculosis*]. [Spanish]. *Salud Publica Mex* 1982; 24(3):321-7.
- Blanchard JS. Molecular mechanisms of drug resistance in *Mycobacterium tuberculosis*. *Annu Rev Biochem* 1996; 65:215-39.
- Blaser J, Konig C, Fatio R et al. Multicenter quality control study of amikacin assay for monitoring once-daily dosing regimens. *Ther Drug Monit* 1995; 17(2):133-6.
- Blaser MJ, Cohn DL. Opportunistic infections in patients with AIDS: clues to the epidemiology of AIDS and the relative virulence of pathogens. *Rev Infect Dis* 1986; 8(1):21-30.
- Bleiker MA. The annual tuberculosis infection rate, the tuberculin survey and the tuberculin test. *Bull Int Union Tuberc Lung Dis* 1991; 66(1):53-6.
- Bleiker MA, Sutherland I, Styblo K, ten Dam HG, Misljenovic O. Guidelines for estimating the risks of tuberculous infection from tuberculin test results in a representative sample of children. *Bull Int Union Tuberc Lung Dis* 1989; 64(2):7-12.
- Bloch AB, Advisory Council for the Elimination of Tuberculosis. Screening for tuberculosis and tuberculosis infection in high-risk populations: recommendations of the Advisory Council for the Elimination of Tuberculosis. *MMWR* 1995; 44(RR-11):19-34.
- Bloch AB, Cauthen GM, Onorato IM et al. Nationwide survey of drug-resistant tuberculosis in the United States. *JAMA* 1994; 271(9):665-71.
- Bloch AB, Rieder HL, Kelly GD, Cauthen GM, Hayden CH, Snider DE Jr. The epidemiology of tuberculosis in the United States. Implications for diagnosis and treatment. *Clin Chest Med* 1989; 10(3):297-313.
- Bloch AB, Simone PM, McCray E, Castro KG. Preventing multidrug-resistant tuberculosis. *JAMA* 1996; 275(6):487-9.
- Bloom BR. Tuberculosis. Back to a frightening future. *Nature* 1992; 358:538-9.
- Bloom BR, Murray CJ. Tuberculosis: commentary on a reemergent killer. *Science* 1992; 257:1055-64.

- Bloom BS, Wierzbicki DJ, Pauly MV. Cost and price of comparable branded and generic pharmaceuticals. *JAMA* 1986; 256(18):2523-30.
- Blower SM, Gerberding JL. Understanding, predicting and controlling the emergence of drug-resistant tuberculosis: a theoretical framework. *J Mol Med* 1998; 76(9):624-36.
- Blower SM, McLean AR. AIDS: modeling epidemic control. *Science* 1995; 267:252-3.
- Blower SM, Porco TC, Lietman N. Tuberculosis: the evolution of antibiotic resistance and the design of epidemic control strategies. In: Horn M, Simonett G, Webb G, eds. *Mathematical Models in Medical and Health Sciences*. Nashville: Vanderbilt University Press, 1998: 1-24.
- Blumberg HM. The "new tuberculosis" and its changing epidemiology. Nosocomial transmission and hospital discharge standards. *J Med Assoc Ga* 1995; 84(5):209-14.
- Bock NN, McGowan JE, Blumberg HM. Few opportunities found for tuberculosis prevention among the urban poor. *Int J Tuberc Lung Dis* 1998; 2(2):124-9.
- Bondesson JD, Saperston AR. Hepatitis. *Emerg Med Clin North Am* 1996; 14(4):695-718.
- Bonnlander H. Migrant TB treatment in Haiti resulting in U.S. policy change at Guantánamo Bay, Cuba. *Bull Pan Am Health Organ* 1996; 30(3):206-11.
- Bonvin L, Zellweger JP. Mass miniature X-ray screening for tuberculosis among immigrants entering Switzerland. *Tuber Lung Dis* 1992; 73(6):322-5.
- Bor DH, Epstein PR. Pathogenesis of respiratory infection in the disadvantaged. *Semin Respir Infect* 1991; 6(4):194-203.
- Borchardt J, Kirsten D, Jörres R, Kroeger C, Magnussen H. Drug-resistant tuberculosis in Northern Germany: a retrospective hospital-based study of 1,055 patients from 1984 until 1993. *Eur Respir J* 1995; 8(7):1076-83.
- Borgdorff MW, Nagelkerke NJ, van Soolingen D, Broekmans JF. Transmission of tuberculosis between people of different ages in The Netherlands: an analysis using DNA fingerprinting. *Int J Tuberc Lung Dis* 1999; 3(3):202-6.
- Borgman RJ. Development of an orphan drug by a start-up company. *Int J Technol Assess Health Care* 1992; 8(4):566-72.
- Borsary. [Organization of the control of extrapulmonary tuberculosis in Hungary]. [German]. *Z Tuberk Erkr Thoraxorg* 1966; 125(3):404-5.
- Boskovich SJ. New concepts in nursing management of the TB patient: a community training program. *J Community Health Nurs* 1994; 11(1):45-9.
- Boudreau AY, Baron SL, Steenland NK et al. Occupational risk of *Mycobacterium tuberculosis* infection in hospital workers. *Am J Ind Med* 1997; 32(5):528-34.
- Boulahbal F, Khaled S, Tazir M. The interest of follow-up of resistance of the tubercle bacillus in the evaluation of a programme. *Bull Int Union Tuberc Lung Dis* 1989; 64(3):23-5.
- Bourgeois PI. In *Search of Respect: Selling Crack in El Barrio*. New York: Cambridge University Press, 1995.
- Bouros D, Demoioliopoulos J, Panagou P et al. Incidence of tuberculosis in Greek armed forces from 1965-1993. *Respiration* 1995; 62(6):336-40.
- Brander E, Aho K, Päätilä J. Spread of drug-resistant tubercle bacilli. *Am Rev Respir Dis* 1968; 98:407-15.
- Braun MM, Kilburn JO, Smithwick RW et al. HIV infection and resistance to antituberculosis drugs in Abidjan, Côte d'Ivoire. *AIDS* 1992; 6(11):1327-30.
- Braun MM, Truman BI, Maguire B et al. Increasing incidence of tuberculosis in a prison inmate population: association with HIV infection. *JAMA* 1989; 261(3):393-7.
- Braunwald E. *Harrison's Principles of Internal Medicine*. 15th edition. New York: McGraw-Hill, 2001.
- Braverman LE, Utiger RD, eds. *Werner & Ingbar's the Thyroid: A Fundamental and Clinical Text*. 8th edition. Philadelphia: Lippincott Williams and Wilkins, 2000.
- Breathnach AS, De Ruiter A, Holdsworth GMC et al. An outbreak of multi-drug-resistant tuberculosis in a London teaching hospital. *J Hosp Infect* 1998; 39(2):111-7.
- Brennan PJ, MacGregor RR. New treatments for new TB strains. *Pa Med* 1996; 99(7):26-7.
- Bretzel G, Wendl-Richter U, Adatu F, Aisu T, Sticht-Groh V. Drug resistance in Uganda. *Int J Tuberc Lung Dis* 1999; 2(11 Suppl. 2):S324.
- Brewer TF, Colditz GA. Bacille Calmette-Guérin vaccination for the prevention of tuberculosis in health care workers. *Clin Infect Dis* 1995; 20(1):136-42.
- Brewer TF, Colditz GA. Relationship between Bacille Calmette-Guérin (BCG) strains and the efficacy of BCG in the prevention of tuberculosis. *Clin Infect Dis* 1995; 20(1):126-35.
- Brewer TF, Heymann SJ. Reducing the impact of tuberculosis transmission in institutions: beyond infection control measures. *Int J Tuberc Lung Dis* 1998; 2(9 Suppl. 1):S118-23.
- Brewer TF, Heymann SJ, Colditz GA et al. Evaluation of tuberculosis control policies using computer simulation. *JAMA* 1996; 276(23):1898-903.
- Brewer TF, Heymann SJ, Ettinger M. An effectiveness and cost analysis of presumptive treatment for *Mycobacterium tuberculosis*. *Am J Infect Control* 1998; 26(3):232-8.
- Brewer TF, Heymann SJ, Harris JB. Tuberculosis control in Asia and the Western Pacific: a role for computer modelling. *Ann Acad Med Singapore* 1997; 26(5):642-46.
- Brewer TF, Wilson ME, Nardell EA. BCG immunization: review of past experience, current use, and future prospects. *Curr Clin Top Infect Dis* 1995; 15:253-70.
- Brindle R. Aspects of tuberculosis in Africa. 2. The value of microbiology in the management of tuberculosis in Nairobi, Kenya. *Trans R Soc Trop Med Hyg* 1992; 86(5):470-1.
- Brinton K, Ladyzhensky A. Clinical management of immigrants' immunization histories: a focus on Soviet health records and BCG. *Nurse Pract* 1992; 17(4):21-32.
- Brodt HR, Staszewski S, Enzensberger R et al. [Epidemiology of tuberculosis in patients with HIV infection of the Frankfurt University Clinic]. [German]. *Med Klin* 1993; 88(5):279-86.
- Broekmans JF. Control strategies and programme management. In: Porter JD, McAdam KP, eds. *Tuberculosis: Back to the Future*. Chichester: John Wiley and Sons Ltd, 1994.

- Broekmans JF. Maintenance of a tuberculosis programme in the elimination phase. *Bull Int Union Tuberc Lung Dis* 1990; 65(2-3):92-3.
- Bromberg MB. Peripheral neurotoxic disorders. *Neurol Clin* 2000; 18(3):681-94.
- Brooks JV, Furney SK, Orme IM. Metronidazole therapy in mice infected with tuberculosis. *Antimicrob Agents Chemother* 1999; 43(5):1285-8.
- Brost BC, Newman RB. The maternal and fetal effects of tuberculosis therapy. *Obstet Gynecol Clin North Am* 1997; 24(3):659-73.
- Brown RE, Miller B, Taylor WR et al. Health-care expenditures for tuberculosis in the United States. *Arch Intern Med* 1995; 155(15):1595-600.
- Brownstein JN, Cheal N, Ackermann SP, Bassford TL, Campos-Outcalt D. Breast and cervical cancer screening in minority populations: a model for using lay health educators. *J Cancer Educ* 1992; 7(4):321-6.
- Brudney K, Dobkin J. Resurgent tuberculosis in New York City: human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs. *Am Rev Respir Dis* 1991a; 144(4):745-9.
- Brudney K, Dobkin J. A tale of two cities: tuberculosis control in Nicaragua and New York City. *Semin Respir Infect* 1991b; 6(4):261-72.
- Bruhl P, Walpert J. [Current epidemiology, diagnosis and therapy of urogenital tuberculosis]. [German]. *Dtsche Med Wochenschr* 1994; 119(33):1121-5.
- Bucco T, Meligrana G, De Luca V. Neurotoxic effects of cycloserine therapy in pulmonary tuberculosis of adolescents and young adults. *Scand J Respir Dis* 1970; 71(Suppl.):259-65.
- Buchholz U. The role of restriction fragment length polymorphism in the public health and epidemiology of tuberculosis: an update for Maryland physicians. *Md Med J* 1995; 44(8):601-4.
- Buckner CB, Leithiser RE, Walker CW, Allison JW. The changing epidemiology of tuberculosis and other mycobacterial infections in the United States: implications for the radiologist. *Am J Roentgenol* 1991; 156(2):255-64.
- Bugiani M, Piccioni P, Cavallero M, Carosso A, Arossa W. [The impact of immigration from high incidence countries on the epidemiology of tuberculosis]. [Italian]. *Epidemiol Prev* 1993; 17:267-71.
- Buri PS, Vathesatogkit P, Charoenpan P, Kiatboonsri S, Buranaratchada S. A clinic model for a better tuberculosis treatment outcome and factors influencing compliance. *J Med Assoc Thai* 1985; 68(7):356-60.
- Burke RM, Schwartz LP, Snider DE Jr. The Ottawa County Project: a report of a tuberculosis screening project in a small mining community. *Am J Public Health* 1979; 69(4):340-7.
- Burks A. Anaphylaxis and food hypersensitivity. *Immunology and Allergy Clinics of North America* 1999; 19(3):533-52.
- Burman WJ, Cohn DL, Rietmeijer CA, Judson FN, Sbarbaro JA, Reves RR. Noncompliance with directly observed therapy for tuberculosis: Epidemiology and effect on the outcome of treatment. *Chest* 1997; 111(5):1168-73.
- Burns DN, Gellert GA, Crone RK. Tuberculosis in eastern Europe and the former Soviet Union: how concerned should we be? *Lancet* 1994; 343(8911):1445-6.
- Butenko GE, Noreiko BV, Skubko AI, Kokina PS. [Certain characteristics of the epidemiology of fibro-cavernous tuberculosis of the lungs]. [Russian]. *Probl Tuberk* 1973; 51(3):11-4.
- Butz AM, Malveaux FJ, Eggleston P et al. Use of community health workers with inner-city children who have asthma. *Clin Pediatr (Phila)* 1994; 33(3):135-41.
- Buzzard M. Twenty-four hour dietary recall and food record methods. In: Willett W, ed. *Nutritional Epidemiology*. 2nd edition. New York: Oxford University Press, 1998.
- Cabezudo Hernando IA, Virto Bajo FJ, Soría Ruíz S, Martínez Castellanos F, Otero Mauricio G. [Is urogenital tuberculosis a current disease still?]. [Spanish]. *Arch Esp Urol* 1994; 47(5):445-8.
- Cabie A, Matheron S, Vallée E, Coulaud JP. [Tuberculosis in Africans hospitalized in Paris. Impact of infection by the human immunodeficiency virus]. [French]. *Presse Med* 1995; 24(13):601-5.
- Cameron N, Scheepers LD. An anthropometric study of pulmonary tuberculosis patients from Taung, Bophuthatswana, South Africa. *Hum Biol* 1986; 58(2):251-9.
- Cameron RJ, Harrison AC. Multidrug resistant tuberculosis in Auckland, 1988-1995. *N Z Med J* 1997; 110(1):119-22.
- Caminero J, Pavón J, Rodríguez de Castro F et al. Evaluation of a directly observed six months fully intermittent treatment regimen for tuberculosis in patients suspected of poor compliance. *Thorax* 1996; 51(11):1130-3.
- Caminero Luna JA. [Basic steps for the control of tuberculosis in a community]. [Spanish]. *Med Clin (Barc)* 1994; 102(2):67-73.
- Campbell AH, Siegel CC, Guilfoyle P. Trends in the epidemiology of tuberculosis in ex-service personnel. *Med J Aust* 1968; 2(21):923-6.
- Canetti G. Present aspects of bacterial resistance in tuberculosis. *Am Rev Respir Dis* 1965; 92(5):687-703.
- Cano-Domínguez C, Villarreal-Urenda C, Gómez-Campos G, Ramírez-Cruz F, Becerra-Carmona G. [The importance of tuberculosis in the acquired immunodeficiency syndrome. The clinical and therapeutic aspects]. [Spanish]. *Gac Med Mex* 1991; 127(2):137-41.
- Canova CR, Kuhn M, Reinhart WH. [Problems in the diagnosis and therapy of lymph node tuberculosis in HIV-negative patients]. [German]. *Schweiz Med Wochenschr* 1995; 125(51-52):2511-7.
- Cantwell MF, Binkin NJ. Impact of HIV on tuberculosis in sub-Saharan Africa: a regional perspective. *Int J Tuberc Lung Dis* 1997; 1(3):205-14.
- Cantwell MF, Binkin NJ. Tuberculosis in sub-Saharan Africa: a regional assessment of the impact of the human immunodeficiency virus and National Tuberculosis Control Program quality. *Tuberc Lung Dis* 1996; 77(3):220-5.
- Cantwell MF, Snider DE Jr, Cauthen GM, Onorato IM. Epidemiology of tuberculosis in the United States, 1985 through 1992. *JAMA* 1994; 272(7):535-9.
- Capewell S, France AJ, Anderson M, Leitch AG. The diagnosis and management of tuberculosis in common hostel dwellers. *Tubercle* 1986; 67(2):125-31.

- Carlen R. Public health and tuberculosis. *Chest* 1994; 105(1):326-7.
- Carpels G, Fissette K, Limbana V, Van Deun A, Vandenbulcke W, Portaels F. Drug resistant tuberculosis in sub-Saharan Africa: an estimation of incidence and cost for the year 2000. *Tuber Lung Dis* 1995; 76(6):480-6.
- Carvalho AC, Signorini L, Castelli F, Parravicini M, Di Lorenzo S. Migration medicine: The challenge to tuberculosis. *Chest* 1994; 105(6):1911.
- Casal M, Gutiérrez J, Vaquero M. Drug resistance of *M. tuberculosis* in a university hospital in Spain. *Tuber Lung Dis* 1996; 77(Suppl. 2):64.
- Casarini M, Ameglio F, Alemanno L et al. Cytokine levels correlate with a radiologic score in active pulmonary tuberculosis. *Am J Respir Crit Care Med* 1999; 159:143-8.
- Casper C, Singh SP, Rave S et al. The transcontinental transmission of tuberculosis: a molecular epidemiological assessment. *Am J Public Health* 1996; 86(4):551-3.
- Cassel J. The contribution of the social environment to host resistance. *Am J Epidemiol* 1976; 104(2):107-23.
- Cassels A, Heineman E, LeClerq S, Gurung PK, Rahut CB. Tuberculosis case-finding in Eastern Nepal. *Tubercle* 1982; 63(3):175-85.
- Castillo-Chávez C, Feng Z. To treat or not to treat: the case of tuberculosis. *J Math Biol* 1997; 35(6):629-56.
- Castro KG. Global tuberculosis challenges. *Emerg Infect Dis* 1998; 4(3):408-9.
- Castro KG, Snider DE Jr. The good news and the bad news about multidrug-resistant tuberculosis. *Clin Infect Dis* 1995; 21(5):1265-6.
- Castro KG, Valdiserri RO, Curran JW. Perspectives on HIV/AIDS epidemiology and prevention from the Eighth International Conference on AIDS. *Am J Public Health* 1992; 82(11):1465-70.
- Catanzaro A. Nosocomial tuberculosis. *Am Rev Respir Dis* 1982; 125(5):559-62.
- Cauthen GM, Dooley SW, Onorato IM et al. Transmission of *Mycobacterium tuberculosis* from tuberculosis patients with HIV infection of AIDS. *Am J Epidemiol* 1996; 144(1):69-77.
- Cavalier GM. Pushing parentless pharmaceuticals: toward an international home for "orphan drugs" and a cure for "zebra" diseases. *Law and Policy in International Business* 1996; 27(2):447-76.
- Cavaliere SJ, Biehle JR, Sanders WE. Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 1995; 39(7):1542-5.
- Cave MD, Eisenach KD, McDermott PF, Bates JH, Crawford JT. IS6110: conservation of sequence in the *Mycobacterium tuberculosis* complex and its utilization in DNA fingerprinting. *Mol Cell Probes* 1991; 5(1):73-80.
- Cayla JA, Jansa JM, Iglesias B, Artazcoz L, Plasencia A. [The epidemiology of the acquired immunodeficiency syndrome in Barcelona (1981-1991) (I). A descriptive study and time trends]. [Spanish]. *Med Clin (Barc)* 1993; 101(8):286-93.
- Cebrián J, Alvarez JP. [Causes of irregular tuberculosis treatment in one health care unit]. [Spanish]. *Bol Oficina Sanit Panam* 1969; 67(1):43-51.
- Cegielski JP, Lwakatare J, Dukes CS et al. Tuberculous pericarditis in Tanzanian patients with and without HIV infection. *Tuber Lung Dis* 1994; 75(6):429-34.
- Ceino O. [The epidemiology of tuberculosis in Italy today]. [Italian]. *Lotta Contro Tuberc* 1966; 36(5 Suppl.):175-93.
- Centers for Disease Control and Prevention. Development of new vaccines for tuberculosis: recommendations of the Advisory Council for the Elimination of Tuberculosis (ACET). *MMWR* 1998a; 47(RR-13):1-6.
- Centers for Disease Control and Prevention. Exposure of passengers and flight crew to *Mycobacterium tuberculosis* on commercial aircraft, 1992-1995. *MMWR* 1995; 44(8):137-40.
- Centers for Disease Control and Prevention. *Improving Patient Adherence to Tuberculosis Treatment*. Atlanta: Centers for Disease Control and Prevention, 1994.
- Centers for Disease Control and Prevention. Initial therapy for tuberculosis in the era of multidrug resistance: recommendations of the Advisory Council for the Elimination of Tuberculosis. *MMWR* 1993; 42(RR-7):1-8.
- Centers for Disease Control and Prevention. Management of persons exposed to multidrug-resistant tuberculosis. *MMWR* 1992a; 41(RR-11):59-71.
- Centers for Disease Control and Prevention. Meeting the challenge of multidrug-resistant tuberculosis: summary of a conference. *MMWR* 1992b; 41(RR-11):51-7.
- Centers for Disease Control and Prevention. Multidrug-resistant tuberculosis outbreak on an HIV ward – Madrid, Spain, 1991-1995. *MMWR* 1996a; 45(16):330-3.
- Centers for Disease Control and Prevention. National action plan to combat multidrug-resistant tuberculosis. *MMWR* 1992c; 41(RR-11):5-48.
- Centers for Disease Control and Prevention. Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons – Florida and New York, 1988-1991. *MMWR* 1991a; 40(34):585-91.
- Centers for Disease Control and Prevention. Outbreak of multi-drug resistant tuberculosis – Texas, California, and Pennsylvania. *MMWR* 1990a; 39:369-73.
- Centers for Disease Control and Prevention. Population-based survey for drug resistance of tuberculosis – Mexico, 1997. *MMWR* 1998b; 47(18):371-5.
- Centers for Disease Control and Prevention. Prevention and control of tuberculosis in correctional institutions: recommendations of the Advisory Committee for the Elimination of Tuberculosis. *MMWR* 1989; 38(18):313-20, 325.
- Centers for Disease Control and Prevention. Primary multidrug-resistant tuberculosis – Ivanovo Oblast, Russia, 1999. *MMWR* 1999a; 48(30):661-3.
- Centers for Disease Control and Prevention. Progress toward the elimination of tuberculosis – United States, 1998. *MMWR* 1999b; 48(33):732-6.
- Centers for Disease Control and Prevention. The role of BCG vaccine in the prevention and control of tuberculosis in the United States. A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices. *MMWR* 1996b; 45(RR-4):1-18.

- Centers for Disease Control and Prevention. Screening for tuberculosis and tuberculosis infection in high-risk populations. *MMWR* 1990b; 39(RR-8):1-7.
- Centers for Disease Control and Prevention. Transmission of multidrug-resistant tuberculosis for an HIV-positive client in a residential substance-abuse treatment facility – Michigan. *MMWR* 1991b; 40(8):129-31.
- Centers for Disease Control and Prevention, American Thoracic Society. Initial therapy for tuberculosis in the era of multidrug resistance: Recommendations of the Advisory Council for the Elimination of Tuberculosis. *JAMA* 1993; 270(6):694-8.
- Central Tuberculosis Research Institute (CTRI). *Tuberculosis in Russia*. Moscow: RAMS, 1994.
- Chacón L, Cruz JR, Tardencilla A. Primary resistance and MDR-TB in Nicaragua. *Int J Tuberc Lung Dis* 1999; 2(11 Suppl. 2):S332.
- Chaffee BH, Moehring S, Pruden S. HIV, sexually transmitted disease, and tuberculosis testing at community sites in upstate New York. *Am J Public Health* 1995; 85(6):867-8.
- Chahtane A, Rhrab B, Jirari A, Ferhati D, Kharbach A, Chaoui A. [Hypertrophic tuberculosis of the cervix. Three cases]. [French]. *J Gynecol Obstet Biol Reprod (Paris)* 1992; 21(4):424-7.
- Chailleux PE. [Pulmonary tuberculosis and primary tuberculous infection. Epidemiology, diagnosis, course prognosis, treatment, prevention]. [French]. *Rev Prat* 1991; 41(1):89-94.
- Chaisson RE, Claremont CH, Holt EA et al. Six-month supervised intermittent tuberculosis therapy in Haitians with and without HIV infection. *Am J Respir Crit Care Med* 1996; 154(4 Pt. 1):1034-8.
- Chaisson RE, Coberly JS, De Cock KM. DOTS and drug resistance: a silver lining to a darkening cloud. *Int J Tuberc Lung Dis* 1999; 3(1):1-3.
- Chaisson RE, Keruly JC, McAvinue S, Gallant JE, Moore RD. Effects of an incentive and education program on return rates for PPD test reading in patients with HIV infection. *J Acquir Immune Defic Syndr Hum Retroviral* 1996; 11(5):455-9.
- Chakraborty AK. Drugs are not enough: the dynamics of antituberculosis treatment in India. *Tuber Lung Dis* 1994; 75(4):316-8.
- Chakraborty AK, Chaudhuri K, Sreenivas TR, Murthy MS, Shashidhara AN, Channabasavaiah R. Tuberculous infection in a rural population of south India: 23-year trend. *Tuber Lung Dis* 1992; 73(4):213-8.
- Chalk CH. Acquired peripheral neuropathy. *Neurol Clin* 1997; 15(3):501-28.
- Chan CH, Woo J, Or KK, Chan RC, Cheung W. The effect of age on the presentation of patients with tuberculosis. *Tuber Lung Dis* 1995; 76(4):290-4.
- Chan S. Chemotherapy of tuberculosis. In: Davies P, ed. *Clinical Tuberculosis*. New York: Chapman and Hall Medical, 1994: 141-56.
- Charles C, DeMaio S. Lay participation in health care decision making: a conceptual framework. *J Health Polit Policy Law* 1993; 18(4):881-904.
- Chaulet P. [The anti-tuberculosis campaign throughout the world: strategies and actions in the field]. [French]. *Respiration* 1990; 57(3):145-59.
- Chaulet P. Compliance with anti-tuberculosis chemotherapy in developing countries. *Tubercle* 1987; 68(2 Suppl.):19-24.
- Chaulet P. Integrating tuberculosis control activities into the primary health care system at district level. *Bull Int Union Tuberc Lung Dis* 1989; 64(2):33-5.
- Chaulet P. [The new tuberculosis]. [French]. *TB and HIV* 1996; 6(4):6-8.
- Chaulet P. Proposal of an improved score method for the diagnosis of pulmonary tuberculosis. *Tuber Lung Dis* 1992a; 73(5):309.
- Chaulet P. The supply of antituberculosis drugs and national drug policies. *Tuber Lung Dis* 1992b; 73(5):295-304.
- Chaulet P. The supply of antituberculosis drugs: price evolution. *Tuber Lung Dis* 1995; 76(3):261-3.
- Chaulet P, Benachenhou A, Viroit JB, Fekar A, Ait Khaled N. Results of the international co-operative inquiry into the cost of antituberculosis drugs. *Bull Int Union Tuberc* 1978; 53(4):263-9.
- Chaulet P, Boulahbal F, Grosset J. Surveillance of drug resistance for tuberculosis control: why and how? *Tuber Lung Dis* 1995; 76(6):487-92.
- Chaulet P, Raviglione M, Bustreo F. Epidemiology, control and treatment of multidrug-resistant tuberculosis. *Drugs* 1996; 56(Suppl. 2):103-8.
- Chaulk CP, Chaisson RE, Lewis JN, Rizzo RT. Treating multidrug-resistant tuberculosis: compliance and side effects. *JAMA* 1994; 271(2):103-5.
- Chaulk CP, Grady M. Evaluating tuberculosis control programs: strategies, tools and models. *Int J Tuberc Lung Dis* 2000; 4(2 Suppl. 1):S55-60.
- Chaulk CP, Moore-Rice K, Rizzo R, Chaisson RE. Eleven years of community-based directly observed therapy for tuberculosis. *JAMA* 1995; 274(12):945-51.
- Chaves F, Dronda F, Cave MD et al. A longitudinal study of transmission of tuberculosis in a large prison population. *Am J Respir Crit Care Med* 1997; 155(2):719-25.
- Chavis DM. Building community capacity to prevent violence through coalitions and partnerships. *J Health Care Poor Underserved* 1995; 6(2):234-45.
- Chen H. [Epidemiology of tuberculosis and its prevalence in China]. [Chinese]. *Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih* 1984; 7(6):373-6.
- Chevallay B, de Haller R, Bernheim J. [Epidemiology of pulmonary tuberculosis in the prison environment]. [French]. *Schweiz Med Wochenschr* 1983; 113(7):261-5.
- Chevrel-Dellagi D, Abderrahman A, Haltiti R, Koubaji H, Gicquel B, Dellagi K. Large-scale DNA fingerprinting of *Mycobacterium tuberculosis* strains as a tool for epidemiological studies of tuberculosis. *J Clin Microbiol* 1993; 31(9):2446-50.
- Chiang W, Goldfrank L. The medical complications of drug abuse. *Med J Aust* 1990; 152(2):83-8.
- Chin DP, Osmond D, Page-Shafer K et al. Reliability of anergy skin testing in persons with HIV infection. The pulmonary Complications of HIV Infection Study Group. *Am J Respir Crit Care Med* 1996; 153(6 Pt 1):1982-4.
- China Tuberculosis Control Collaboration. Results of directly observed short-course chemotherapy in 122,842 Chinese patients with smear-positive tuberculosis. *Lancet* 1996; 347:358-62.
- Chintu C, Mwinga A. An African perspective on the threat of tuberculosis and HIV/AIDS: can despair be turned to hope? *Lancet* 1999; 353:997.

- Christensen PB, Karlqvist S. Community health workers in a Peruvian slum area: an evaluation of their impact on health behavior. *Bull Pan Am Health Organ* 1990; 24(2):183-96.
- Chuah SY. Factors associated with poor patient compliance with antituberculosis therapy in Northwest Perak, Malaysia. *Tubercle* 1991; 72(4):261-4.
- Chum HJ, Ilmolelian G, Rieder HL et al. Impact of the change from an injectable to a fully oral regimen on patient adherence to ambulatory tuberculosis treatment in Dar es Salaam, Tanzania. *Tuber Lung Dis* 1995; 76(4):286-9.
- Chum HJ, O'Brien RJ, Chonde TM, Graf P, Rieder HL. An epidemiological study of tuberculosis and HIV infection in Tanzania, 1991-1993. *AIDS* 1996; 10(3):299-309.
- Ciesielski SD, Seed JR, Esposito DH, Hunter N. The epidemiology of tuberculosis among North Carolina migrant farm workers. *JAMA* 1991; 265(13):1715-9.
- Clemens JD, Chuong JJ, Feinstein AR. The BCG controversy: a methodological and statistical reappraisal. *JAMA* 1993; 249(17):2362-9.
- Cleveland JL, Kent J, Gooch BF et al. Multidrug-resistant *Mycobacterium tuberculosis* in an HIV dental clinic. *Infect Control Hosp Epidemiol* 1995; 16(1):7-11.
- Clinique Bon Sauveur, Zanmi Lasante, Partners In Health, Harvard Medical School. *Normes et Procédures du Traitement de la Tuberculose [Protocols and Treatment of Tuberculosis]*. Cange: Clinique Bon Sauveur, 1998.
- Clissold DB. Prescription for the Orphan Drug Act: the impact of the FDA's 1992 regulations and the latest congressional proposals for reform. *Food Drug Law J* 1995; 50:125-47.
- Co MC J. *Mycobacterium tuberculosis* in persons infected with the human immunodeficiency virus. *Am J Crit Care* 1994; 3(5):389-97.
- Coates AR, Mitchison DA. [The role of sensitivity tests in short course chemotherapy]. [French]. *Bull Int Union Tuberc* 1983; 58(2):111-4.
- Codecasa LR, Besozzi G, Cuoghi M et al. Incidence of TB in a migrant population: the Peruvians in Milan. *Tuber Lung Dis* 1996; 77(Suppl. 2):52.
- Codecasa LR, Porretta AD, Gori A et al. Tuberculosis among immigrants from developing countries in the province of Milan, 1993-1996. *Int J Tuberc Lung Dis* 1999; 3(7):589-95.
- Codina G, Vidal R, Martin-Casabona N, Miravittles M, Martin C. Multidrug-resistant tuberculosis caused by 'W'-related strains in three immunocompetent foreign-born patients. *Int J Tuberc Lung Dis* 1999; 3(1):82-4.
- Coetzee N, Yach D, Joubert G. Crowding and alcohol abuse as risk factors for tuberculosis in the Mamre population. Results of a case-control study. *S Afr Med J* 1988; 74(7):352-4.
- Cohen ML. Epidemiology of drug resistance: implications for a post-antimicrobial era. *Science* 1992; 257:1050-5.
- Cohn DL. Treatment of multidrug-resistant tuberculosis. *J Hosp Infect* 1995; 30(Suppl.):322-8.
- Cohn DL. Use of the Bacille Calmette-Guérin vaccination for the prevention of tuberculosis: renewed interest in an old vaccine. *Am J Med Sci* 1997; 313(6):372-6.
- Cohn DL, Bustreo F, Raviglione MC. Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD Global Surveillance Project. *Clin Infect Dis* 1997; 24 (Suppl. 1):S121-30.
- Cohn DL, Catlin BJ, Peterson KL, Judson FN, Sbarbaro JA. A 62-dose, 6-month therapy for pulmonary and extra pulmonary and extra pulmonary tuberculosis. *Ann Intern Med* 1990; 112(6):407-15.
- Cohn DL, Iseman MD. Treatment and prevention of multidrug-resistant tuberculosis. *Res Microbiol* 1993; 144(2):150-3.
- Cohn DL, O'Brien RJ. The use of restriction fragment length polymorphism (RFLP) analysis for epidemiological studies of tuberculosis in developing countries. *Int J Tuberc Lung Dis* 1998; 2(1):16-26.
- Colditz GA, Brewer TF, Berkey CS et al. Efficacy of BCG vaccine in the prevention of tuberculosis: Meta-analysis of the published literature. *JAMA* 1994; 271(9):698-702.
- Cole ST, Telenti A. Drug resistance in *Mycobacterium tuberculosis*. *Eur Respir J* 1995; 8(S 20):701S-13S.
- Colebunders R, Dujardin B, Taelman H, Portaels F. Multidrug-resistant tuberculosis: what will happen in developing countries? *Ann Soc Belg Med Trop* 1994; 74(4):263-7.
- Colebunders RL, Ryder RW, Nzilambi N et al. HIV infection in patients with tuberculosis in Kinshasa, Zaire. *Am Rev Respir Dis* 1989; 139:1082-5.
- Collaborative Group for the Study of Tuberculosis in Spain. Epidemiological trends of tuberculosis in Spain from 1988 to 1992. Collaborative group for the study of tuberculosis in Spain. *Tuber Lung Dis* 1995; 76(6):522-8.
- Collins CH, Grange JM. Tuberculosis acquired in laboratories and necropsy rooms. *Commun Dis Public Health* 1999; 2(3):161-7.
- Collins CH, Grange JM, Yates MD. *Tuberculosis Bacteriology: Organization and Practice*. Boston: Butterworth-Heinemann, 1997.
- Collins FM. The immunology of tuberculosis. *Am Rev Respir Dis* 1982; 125(3 Pt. 2):566-9.
- Collins TF. Tuberculosis case-finding procedures. *S Afr Med J* 1980; 57(15):566.
- Combs DL, O'Brien RJ, Geiter LJ. USPHS tuberculosis short-course chemotherapy trial 21: effectiveness, toxicity, and acceptability. *Ann Intern Med* 1990; 112(6):397-406.
- Comstock GW. Early studies of tuberculosis. *Nat Cancer Inst Monogr* 1985; 67:23-7.
- Comstock GW. Epidemiology of tuberculosis. *Am Rev Respir Dis* 1982; 125(3 Pt. 2):8-15.
- Comstock GW. Frost revisited: the modern epidemiology of tuberculosis. *Am J Epidemiol* 1975; 101(5):363-82.
- Comstock GW. Tuberculosis – a bridge to chronic disease epidemiology. *Am J Epidemiol* 1986; 124(1):1-16.

- Comstock GW. Variability of tuberculosis trends in a time of resurgence. *Clin Infect Dis* 1994; 19(6):1015-22.
- Comstock GW, Livesay VT, Woolpert SE. The prognosis of a positive tuberculin reaction in childhood and adolescence. *Am J Epidemiol* 1974; 99(2):131-8.
- Condos R, Rom WN, Schluger NW. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-alpha via aerosol. *Lancet* 1997; 349:1513-5.
- Coninx R, Eshaya-Chauvin B, Reyes H. Tuberculosis in prisons. *Lancet* 1995; 346(8984):1238-9.
- Coninx R, Mathieu C, Debacker M et al. First-line tuberculosis therapy and drug-resistant *Mycobacterium tuberculosis* in prisons. *Lancet* 1999; 353:969-73.
- Coninx R, Pfyffer GE, Mathieu C et al. Drug resistant tuberculosis in prisons in Azerbaijan: case study. *BMJ* 1998; 316:1423-5.
- Connolly C, Davies GR, Wilkinson D. Impact of the human immunodeficiency virus epidemic on mortality among adults with tuberculosis in rural South Africa, 1991-1995. *Int J Tuberc Lung Dis* 1998; 2(11):919-25.
- Conrad P. The meaning of medications: Another look at compliance. *Soc Sci Med* 1985; 20(1):29-37.
- Contrepois A, Brion N, Garaud JJ et al. Renal disposition of gentamicin, dibekacin, tobramycin, netilmicin, and amikacin in humans. *Antimicrob Agents Chemother* 1985; 27(4):520-4.
- Coronado VG, Beck-Sague CM, Hutton MD et al. Transmission of multidrug-resistant *Mycobacterium tuberculosis* among persons with human immunodeficiency virus infection in an urban hospital: epidemiologic and restriction fragment length polymorphism analysis. *J Infect Dis* 1993; 168(4):1052-5.
- Costello HD, Caras GJ, Snider DE Jr. Drug resistance among previously treated tuberculosis patients, a brief report. *Am Rev Respir Dis* 1980; 121(2):313-6.
- Coster JM. Recombinant erythropoietin: orphan product with a silver spoon. *Int J Technol Assess Health Care* 1992; 8(4):635-46.
- Couper MR. Strategies for the rational use of antimicrobials. *Clin Infect Dis* 1997; 24(Suppl. 1):S154-6.
- Cowie RL. The epidemiology of tuberculosis in gold miners with silicosis. *Am J Respir Crit Care Med* 1994; 150(5 Pt. 1):1460-2.
- Cowie RL, Langton ME, Becklake MR. Pulmonary tuberculosis in South African gold miners. *Am Rev Respir Dis* 1989; 139(5):1086-9.
- Crawford JT. Applications of molecular methods to epidemiology of tuberculosis. *Res Microbiol* 1993; 144(2):111-6.
- Crawford JT. Epidemiology of tuberculosis: the impact of HIV and multidrug-resistant strains. *Immunobiology* 1994; 191(4-5):337-43.
- Crignet JP, Pagnier F, Demarest P et al. [Tuberculosis in Denain from 1975 to 1980. Epidemiology – evaluation of the cost]. [French]. *LARC Med* 1983; 3(6):377-80.
- Croft RA, Croft RP. Expenditure and loss of income incurred by tuberculosis patients before reaching effective treatment in Bangladesh. *Int J Tuberc Lung Dis* 1998; 2(3):252-4.
- Crofton J. The contribution of chemotherapy to the control of tuberculosis as a community disease. *Torax* 1971; 20(1):49-54.
- Crofton J. The contribution of treatment to the prevention of tuberculosis. *Bull Int Union Tuberc* 1962; 32:643-53.
- Crofton J. The prevention and management of drug resistant tuberculosis. *Bull Int Union Tuberc Lung Dis* 1987; 62(1-2):6-11.
- Crofton J, Chaulet P, Maher D. *Guidelines on the management of drug-resistant tuberculosis*. Geneva: World Health Organization, 1996.
- Crofton J, Mitchison D. Streptomycin resistance in pulmonary tuberculosis. *BMJ* 1948; 2:1009-15.
- Crowle AJ, Sbarbaro JA, Judson FN, Douvas GS, May MH. Inhibition by streptomycin of tubercle bacilli within cultured human macrophages. *Am Rev Respir Dis* 1984; 130:839-44.
- Crowle AJ, Sbarbaro JA, Judson FN, May MH. The effect of ethambutol of tubercle bacilli within cultured human macrophages. *Am Rev Respir Dis* 1985; 132:742-5.
- Crowle AJ, Sbarbaro JA, May MH. Effects of isoniazid and of ceforanide against virulent tubercle bacilli in cultured human macrophages. *Tubercle* 1988; 69:15-25.
- Cruz JR, Heldal E, Arnadottir T, Juarez I, Enarson DA. Tuberculosis case-finding in Nicaragua: evaluation of routine activities in the control programme. *Tuber Lung Dis* 1994; 75(6):417-22.
- Currey B. Maternal mortality and mothers' deaths as development indicators. *BMJ* 2000; 321(7264):835.
- Curry FJ. Neighborhood clinics for more effective outpatient treatment of tuberculosis. *N Engl J Med* 1968; 279(23):1262-7.
- Curry FJ. A new approach for improving attendance at tuberculosis clinics. *Am J Public Health Nations Health* 1968; 58(5):877-81.
- Cynamon MH, Zhang Y, Harpster T, Cheng S, DeStefano MS. High-dose isoniazid therapy for isoniazid-resistant murine *Mycobacterium tuberculosis* infection. *Antimicrob Agents Chemother* 1999; 43(12):2922-4.
- Daddi G, Giobbi A, Lucchesi M. Primary resistance of mycobacteria in tuberculosis patients. *Boll Ist Sieroter Milan* 1976; 55(71):75-9.
- Daina E. Rare diseases and orphan drugs. *Lancet* 1994; 343:1560-1.
- Daley CL, Small PM, Schecter GF et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus: an analysis using restriction-fragment-length polymorphisms. *N Engl J Med* 1992; 326(4):231-5.
- Daniel TM. Rapid diagnosis of tuberculosis: laboratory techniques applicable in developing countries. *Rev Infect Dis* 1989; 11(Suppl. 2):S471-8.
- Dankova D. Epidemiological and clinical study of tuberculosis in the Kolin district, Czechoslovakia. *Bull Int Union Tuberc Lung Dis* 1991; 66(4):187-8.
- Danziger R. An overview of HIV prevention in central and eastern Europe. *AIDS Care* 1996; 8(6):701-7.
- Datta M, Radhamani MP, Selvaraj R et al. Critical assessment of smear-positive pulmonary tuberculosis patients after chemotherapy under the district tuberculosis programme. *Tuber Lung Dis* 1993; 74(3):180-6.

- Davidson PT. Treating tuberculosis: what drugs, for how long? *Ann Intern Med* 1990; 112(6):393-5.
- Davidson PT, Le HQ. Drug treatment of tuberculosis – 1992. *Drugs* 1992; 43(5):651-73.
- Davies GR, Pillay M, Strum AW, Wilkinson D. Emergence of multi-drug resistant tuberculosis in rural South Africa. *Int J Tuberc Lung Dis* 1998; 2(11 Suppl. 2):S327.
- Davies P. Problems in the management of tuberculosis. In: Davies P, ed. *Clinical Tuberculosis*. New York: Chapman and Hall Medical, 1994: 163-9.
- Davis LE, Rastogi KR, Lambert LC, Skipper BJ. Tuberculous meningitis in the southwest United States: a community-based study. *Neurology* 1993; 43(9):1775-8.
- Dawson DJ, Cheah DF, Chew WK, Haverkort FC, Lumb R, Sievers AS. Tuberculosis in Australia, 1989-1992: bacteriologically confirmed cases and drug resistance. *Med J Aust* 1995; 162(6):287-90.
- De Beenhouwer H, Lhiang Z, Jannes G et al. Rapid detection of rifampicin resistance in sputum and biopsy specimens from tuberculosis patients by PCR and line probe assay. *Tuber Lung Dis* 1995; 76(5):425-30.
- De Cock KM. Tuberculosis control in resource-poor settings with high rates of HIV infection. *Am J Public Health* 1996; 86(8 Pt. 1):1071-3.
- De Cock KM, Binkin NJ, Zuber PLF, Tappero JW, Castro KG. Research issues involving HIV-associated TB in resource-poor countries. *JAMA* 1996; 276(18):1502-7.
- De Cock KM, Gnaore E, Adjorlolo G et al. Risk of tuberculosis in patients with HIV-I and HIV-II infections in Abidjan, Ivory Coast. *BMJ* 1991; 302:496-9.
- De Cock KM, Lucas SB, Lucas S, Agness J, Kadio A, Gayle HD. Clinical research, prophylaxis, therapy, and care for HIV disease in Africa. *Am J Public Health* 1993; 83(10):1385-9.
- De Cock KM, Soro B, Coulibaly IM, Lucas SB. Tuberculosis and HIV infection in sub-Saharan Africa. *JAMA* 1992; 268(12):1581-7.
- De Cock KM, Wilkinson D. Tuberculosis control in resource-poor countries: alternative approaches in the era of HIV. *Lancet* 1995; 346:675-7.
- De Jonghe E, Murray CJ, Chum HJ, Nyangulu DS, Salomao A, Styblo K. Cost-effectiveness of chemotherapy for sputum smear-positive pulmonary tuberculosis in Malawi, Mozambique and Tanzania. *Int J Health Plann Manage* 1994; 9:151-81.
- de Kantor IN. Drug resistant tuberculosis. How common is it? *Tuber Lung Dis* 1996; 77(Suppl. 2):9.
- de Ville de Goyet CA, Kleeberg HH. Comparison of tuberculosis case-finding in a high prevalence area. *S Afr Med J* 1974; 48(62):2582-7.
- de Ville de Goyet CA, Kleeberg HH. Technical and bacteriological aspects of a continuous survey of drug resistance in tuberculosis in South Africa. *Tubercle* 1972; 53(1):9-26.
- Debacker M, Ismailov A, Aresheva A. Prisoners as a risk population for MDR tuberculosis. *Int J Tuberc Lung Dis* 1998; 2(11 Suppl. 2):S329.
- Degtiarev VP. [Feldsher's role in the ambulatory treatment of patients with tuberculosis]. [Russian]. *Feldsher Akush* 1976; 41(4):7-9.
- DeHovitz JA. Directly observed therapy initiative: a 1990's tuberculosis treatment imperative [and accompanying articles]. *J Public Health Manag Pract* 1995; 1(vi-viii):1-54.
- Deleyiannis FW, Ramirez Ronda CH. The re-emergence of scrofula with HIV infection: a review of epidemiology, pathogenesis, diagnosis and treatment. *Bol Asoc Med P R* 1991; 83(11):487-8.
- Deschamps M, Pape JW, Hafner A, Johnson WD Jr. Heterosexual transmission of HIV in Haiti. *Ann Intern Med* 1996; 125(4):324-30.
- Desormeaux J, Johnson MP, Coberly JS et al. Widespread HIV counseling and testing linked to a community-based tuberculosis control program in a high-risk population. *Bull Pan Am Health Organ* 1996; 30(1):1-8.
- Devadatta S, Dawson JY, Fox W et al. Attack rate of tuberculosis in a 5-year period among close family contacts of tuberculosis patients under domiciliary treatment with isoniazid plus PAS or isoniazid alone. *Bull World Health Organ* 1970; 42(3):337-51.
- Devadatta S, Menon NK, Nazareth O et al. A double-blind study to determine the maximum tolerance dose of ethionamide when administered twice-weekly to patients with pulmonary tuberculosis. *Tubercle* 1970; 51(3):263-9.
- DeVincenzo JP, Berning SE, Peloquin CA, Husson RN. Multidrug-resistant tuberculosis meningitis: clinical problems and concentrations of second-line antituberculous medications. *Ann Pharmacother* 1999; 33(11):1184-8.
- Dhillon J, Allen BW, Hu YM, Coates AR, Mitchison DA. Metronidazole has no antibacterial effect in Cornell model murine tuberculosis. *Int J Tuberc Lung Dis* 1998; 2(9):736-42.
- Di Perri G, Cadeo GP, Castelli F et al. Transmission of HIV-associated tuberculosis to healthcare workers. *Infect Control Hosp Epidemiol* 1993; 14(2):67-72.
- Di Perri G, Gruciani M, Danzi M et al. Nosocomial epidemic of active tuberculosis among HIV-infected patients. *Lancet* 1989; 1502-4.
- Dias MH. [Epidemiology of tuberculosis in children under 15 years of age in the municipality of São Paulo, Brazil, 1984]. [Portuguese]. *Rev Saude Publica* 1991; 25(6):426-34.
- Díaz R, Kremer K, de Haas PEW et al. Molecular epidemiology of tuberculosis in Cuba outside of Havana, July 1994-June 1995: utility of spoligotyping versus IS6110 restriction fragment length polymorphism. *Int J Tuberc Lung Dis* 1998; 2(9):743-50.
- Diaz T. Drug resistant tuberculosis: determination of effective drug therapy for the Indochinese population in Kansas and Sedgwick county. *J Kans Med Soc* 1983; 84(7):389-91.
- Dick J, Clarke M, Tibbs J, Schoeman H. Combating tuberculosis – lessons learnt from a rural community project in the Klein Drakenstein area of the Western Cape. *S Afr Med J* 1997; 87(8 Suppl.):1042-7.
- Dick J, Schoeman JH. Tuberculosis in the community: 2. The perceptions of members of a tuberculosis health team towards a voluntary health worker programme. *Tuber Lung Dis* 1996; 77(4):380-3.

- Dick J, Schoeman JH, Mohammed A, Lombard C. Tuberculosis in the community: 1. Evaluation of a volunteer health worker programme to enhance adherence to anti-tuberculosis treatment. *Tuber Lung Dis* 1996; 77(3):274-9.
- Dick J, Van der Walt H, Hoogendoorn L, Tobias B. Development of a health education booklet to enhance adherence to tuberculosis treatment. *Tuber Lung Dis* 1996; 77(2):173-7.
- Dickson M. The pricing of pharmaceuticals: an international comparison. *Clin Ther* 1992; 14(4):604-11.
- Ditiu L. National Tuberculosis Programme in Romania 1997-2000: how it works. *Cent Eur J Public Health* 1999; 7(4):189-90.
- Diwan VK, Thorson A. Sex, gender and tuberculosis. *Lancet* 1999; 353:1000-1.
- Dlugy Y. The prisoners' plague: overcrowded jails are fueling a frightening new epidemic of drug-resistant tuberculosis. *Newsweek* 1999; 18-20.
- Doctors Without Borders. Access to essential medicines in poor countries: a lost battle. 1999.
- Doerr CA, Starke JR, Ong LT. Clinical and public health aspects of tuberculous meningitis in children. *J Pediatr* 1995; 127(1):27-33.
- Donahoe M. Nutritional support in advanced lung disease. The pulmonary cachexia syndrome. *Clin Chest Med* 1997; 18(3):547-61.
- Donald PR. Children and tuberculosis: protecting the next generation. *Lancet* 1999; 353:1001-2.
- Donald PR, van Zyl LE, de Villiers J. BCG vaccination status of children with tuberculous meningitis and the use of unsupervised isoniazid prophylaxis. *S Afr Med J* 1995; 85(3):167-70.
- Donnelly J, Montgomery D. World's next epidemic: resistant tuberculosis. *The Gazette (Montreal)*. 1999.
- Donnelly R, Davies P. Surgical management of pulmonary tuberculosis. In: Davies P, ed. *Clinical Tuberculosis*. New York: Chapman and Hall Medical, 1994: 157-61.
- Dooley DP, Carpenter JL, Rademacher S. Adjunctive corticosteroid therapy for tuberculosis: a critical reappraisal of the literature. *Clin Infect Dis* 1997; 25(4):872-87.
- Dooley S, Simone P. The extent and management of drug-resistant tuberculosis: the American experience. In: Davies P, ed. *Clinical Tuberculosis*. New York: Chapman and Hall Medical, 1994: 171-89.
- Dooley SW, Jarvis WR, Martone WJ, Snider DE Jr. Multidrug-resistant tuberculosis. *Ann Intern Med* 1992; 117(3):257-9.
- Dosso M, Bonnard D, Msellati P et al. Surveillance des résistances secondaires aux antituberculeux en Côte d'Ivoire 1995-1996. *Tuber Lung Dis* 1996; 77(Suppl. 2):64.
- Downs AM, Heisterkamp SH, Brunet JB, Hamers FF. Reconstruction and prediction of the HIV/AIDS epidemic among adults in the European Union and in the low prevalence countries of central and eastern Europe. *AIDS* 1997; 11(5):649-62.
- Driver CR, Braden CR, Nieves RL et al. Completeness of tuberculosis case reporting, San Juan and Caguas regions, Puerto Rico, 1992. *Public Health Rep* 1996; 111(2):157-61.
- Driver CR, Luallen JJ, Good WE, Valway SE, Frieden TR, Onorato IM. Tuberculosis in children younger than five years old: New York City. *Pediatr Infect Dis J* 1995; 14(2):112-7.
- Driver CR, Valway SE, Morgan WM, Onorato IM, Castro KG. Transmission of *Mycobacterium tuberculosis* associated with air travel. *JAMA* 1994; 272(13):1031-5.
- Drlica K. The future of fluoroquinolones. *Ann Med* 2000; 32:585-7.
- Drobniewski FA. Is death inevitable with multiresistant TB plus HIV infection? *Lancet* 1997; 349(9045):71-2.
- Drobniewski FA. Tuberculosis in prisons – forgotten plague. *Lancet* 1995; 346:948-9.
- Drobniewski FA, Kent RJ, Stoker NG, Uttley AH. Molecular biology in the diagnosis and epidemiology of tuberculosis. *J Hosp Infect* 1994; 28(4):249-63.
- Drobniewski FA, Pozniak AL. Molecular diagnosis, detection of drug resistance and epidemiology of tuberculosis. *Br J Hosp Med* 1996; 56(5):204-8.
- Drobniewski FA, Pozniak AL, Uttley AH. Tuberculosis and AIDS. *J Med Microbiol* 1995; 43(2):85-91.
- Drobniewski FA, Taylor E, Ignatenko N et al. Tuberculosis in Siberia: 1. An epidemiological and microbiological assessment. *Tuber Lung Dis* 1996a; 77(3):199-206.
- Drobniewski FA, Taylor E, Ignatenko N et al. Tuberculosis in Siberia: 2. Diagnosis, chemoprophylaxis and treatment. *Tuber Lung Dis* 1996b; 77(4):297-301.
- Drobniewski FA, Wilson SM. New biomolecular assays must be tested by direct study in the developing world. *BMJ* 1998; 316:940.
- Drobniewski FA, Wilson SM. The rapid diagnosis of isoniazid and rifampicin resistance in *Mycobacterium tuberculosis* – a molecular story. *J Med Microbiol* 1998; 47:189-96.
- Drucker D, Eggo M, Salit E, Burrow GN. Ethionamide-induced goitrous hypothyroidism. *Ann Intern Med* 1984; 100(6):837-39.
- Drucker E, Alcades P, Bosworth W, Sckell B. Childhood tuberculosis in the Bronx, New York. *Lancet* 1994; 343:1482-5.
- Drucker E, Vermund SH. Estimating population prevalence of human immunodeficiency virus infection in urban areas with high rates of intravenous drug use: a model of the Bronx in 1988. *Am J Epidemiol* 1989; 130(1):133-42.
- Duchin JS, Jereb JA, Nolan CM, Smith P, Oronato IM. Comparison of sensitivities to two commercially available tuberculin skin test reagents in person with recent tuberculosis. *Clin Infect Dis* 1997; 25:661-3.
- Duff P. Antibiotic selection in obstetric patients. *Infect Dis Clin North Am* 1997; 11(1):1-12.
- Duncan K. The impact of genomics on the search for novel tuberculosis drugs. *Genetics and Tuberculosis* 1998; 228-38.
- Duncan K. Towards the next generation of drugs and vaccines for tuberculosis. *Chem Ind* 1997; 21.
- Dunlap NE, Kimerling ME. Drug-resistant tuberculosis in adults: implications for the health care worker. *Infect Agents Dis* 1994; 3:245-55.
- Duric O, Maric J, Videnovic V, Vucinic V, Skodric V. Appearance of resistant tuberculosis in other diseases. *Int J Tuberc Lung Dis* 1999; 2(11 Suppl. 2):S250.

- Dutt JS, Baker PT. Environment, migration and health in southern Peru. *Soc Sci Med* 1978; 12(1B):29-38.
- Dwyer B, Jackson K, Raios K, Sievers A, Wilshire E, Ross B. DNA restriction fragment analysis to define an extended cluster of tuberculosis in homeless men and their associates. *J Infect Dis* 1993; 167(2):490-4.
- Dye C, Espinal MA. Will tuberculosis become resistant to all antibiotics? *Proc R Soc Lond B Biol Sci* 2001; 268:45-52.
- Dye C, Garnett GP, Sleeman K, Williams BG. Prospects for worldwide tuberculosis control under the WHO DOTS strategy. *Lancet* 1998; 352:1886-91.
- Edginton ME. Tuberculosis patient care decentralised to district clinics with community-based directly observed treatment in a rural district of South Africa. *Int J Tuberc Lung Dis* 1999; 3(5):445-50.
- Edlin B, Attoe L, Grieco M et al. Recognition and treatment of multidrug-resistant tuberculosis in HIV infected patients. IX International Conference on AIDS. 1993.
- Edlin BR, Tokars JI, Grieco MH et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. *N Engl J Med* 1992; 326(23):1514-21.
- Edwards D, Rowlands E, Trotter W. The mechanism of goitrogenic action of p-aminosalicylic acid. *Lancet* 1954; 1051-52.
- Edwards PQ. Screening for tuberculosis. *Chest* 1975; 68(3 Suppl.):451-5.
- Eierlsen E. Details of the epidemiology of tuberculosis in Norway in recent years; with particular reference to tuberculin-testing and BCG-vaccination. *Scand J Respir Dis* 1968; 65(Suppl.):13-24.
- el-Sadr W, Medard F, Barthaud V. Directly observed therapy for tuberculosis: the Harlem hospital experience, 1993. *Am J Public Health* 1996; 86(8 Pt. 1):1146-9.
- Ellard G. The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis. *Tubercle* 1984; 65:211-21.
- Elliott AM, Halwiindi B, Hayes RJ et al. The impact of human immunodeficiency virus on presentation and diagnosis of tuberculosis in a cohort study in Zambia. *J Trop Med Hyg* 1993; 96:1-11.
- Elliott AM, Hayes R, Halwiindi B et al. The impact of HIV infectiousness of pulmonary tuberculosis: a community study in Zambia. *AIDS* 1993; 7(7):981-7.
- Elliott AM, Mwinga AG, Foster SD. Treatment of tuberculosis in developing countries. *Lancet* 1995; 346:1098-9.
- Elliott AM, Namaambo K, Allen BW et al. Negative sputum smear results in HIV-positive patients with pulmonary tuberculosis in Zambia, Zaire. *Tuber Lung Dis* 1993; 74(3):191-4.
- Ellner JJ. Multidrug-resistant tuberculosis. *Adv Intern Med* 1995; 40:155-96.
- Ellner JJ. Scientific advances necessary for tuberculosis control. *Int J Tuberc Lung Dis* 1998; 2(9 Suppl.):S124-S126.
- Ellner JJ, Hinman AR, Dooley SW et al. Tuberculosis symposium: emerging problems and promise. *J Infect Dis* 1993; 168(3):537-51.
- Elovic E. Pharmacological therapeutics in nutritional management. *J Head Trauma Rehabil* 2000; 15(3):962-4.
- Eltringham JJ, Drobniewski F. Multiple drug resistant tuberculosis: aetiology, diagnosis and outcome. *Br Med Bull* 1998; 54(3):569-78.
- Enarson D, Ashley MJ, Grzybowski S. Tuberculosis in immigrants to Canada: A study of present-day patterns in relation to immigration trends and birthplace. *Am Rev Respir Dis* 1979; 119(1):11-8.
- Enarson DA. Failure of diagnosis: a key indicator in quality assurance of tuberculosis control. *Tuber Lung Dis* 1995; 76(4):279-80.
- Enarson DA. The International Union Against Tuberculosis and Lung Disease model national tuberculosis programmes. *Tuber Lung Dis* 1995; 76(2):95-9.
- Enarson DA. Principles of IUATLD collaborative tuberculosis programmes. *Bull Int Union Tuberc Lung Dis* 1991; 66(4):195-200.
- Enarson DA. Strategies for the fight against tuberculosis. *Pneumologie* 1994; 48:140-3.
- Enarson DA, Fanning EA, Allen EA. Case-finding in the elimination phase of tuberculosis: high risk groups in epidemiology and clinical practice. *Bull Int Union Tuberc Lung Dis* 1990; 65(2-3):73-4.
- Enarson DA, Wang JS, Grzybowski S. Case-finding in the elimination phase of tuberculosis: tuberculosis in displaced people. *Bull Int Union Tuberc Lung Dis* 1990; 65(2-3):71-2.
- Enarson P, Enarson DA. International Union Against Tuberculosis and Lung Disease. *Management of the child with cough or difficult breathing: a guide for low income countries*. 1997.
- Epstein DM, Kline LR, Albelda SM, Miller WT. Tuberculous pleural effusions. *Chest* 1987; 91(1):106-9.
- Errezola Saizar M, Aristegui Fernández J, Gutiérrez Villamayor C, Pérez Díaz L, Zubillaga Huici P. [Epidemiology of childhood tuberculosis in the Basque autonomous community 1980-89. Efficacy of BCG vaccination]. [Spanish]. *An Esp Pediatr* 1992; 36(3):177-80.
- Escreet BC, Langton ME, Cowie RL. Short-course chemotherapy for silicotuberculosis. *S Afr Med J* 1984; 66(9):327-30.
- Espinal MA, Kim SJ, Suárez PG et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. *JAMA* 2000; 283(19):2537-45.
- Espinal MA. Report: multidrug resistant tuberculosis (MDR TB): basis for the development of an evidence-based case-management strategy for MDR TB within the WHO's DOTS strategy. Proceedings of 1998 meetings and protocol recommendations. Geneva: World Health Organization, 1999.
- Espinal MA, Báez J, Soriano G et al. Drug-resistant tuberculosis in the Dominican Republic: results of a nationwide survey. *Int J Tuberc Lung Dis* 1998; 2(6):490-8.
- Espinal MA, Dye C, Raviglione MC, Kochi A. Rational 'DOTS Plus' for the control of MDR-TB. *Int J Tuberc Lung Dis* 1999; 3(7):561-3.

- Espinal MA, Kim SJ, Hong YP et al. Treatment outcome of multidrug resistant (MDR) tuberculosis (TB) cases under programme conditions. *Int J Tuberc Lung Dis* 1998; 2(11 Suppl. 2):S371-2.
- Espinal MA, Simonsen L, WHO/IUATLD Working Group on Drug Resistance Surveillance. Global threats of drug-resistant tuberculosis. *Int J Tuberc Lung Dis* 1999; 3(9 Suppl. 1):S7.
- Estadística e Informática SRS Lima Norte. Registros del programa del control de la tuberculosis: distrito de Carabayllo [Tuberculosis control program registers: district of Carabayllo]. 1993.
- Etkind SC. The role of the public health department of tuberculosis. *Med Clin N Am* 1993; 77(6):1303-14.
- Etkind SC, Boutotte J, Ford J et al. Treating hard-to-treat tuberculosis patients in Massachusetts. *Semin Respir Infect* 1991; 6(4):273-82.
- Evans C, Devadatta S, Fox W et al. A 5-year study of patients with pulmonary tuberculosis treated at home in a controlled comparison of isoniazid plus PAS with 3 regimens of isoniazid alone. *Bull World Health Organ* 1969; 41(1):1-16.
- Fagbule D, Kalu A. Case management by community health workers of children with acute respiratory infections: implications for national ARI control programme. *J Trop Med Hyg* 1995; 98(4):241-6.
- Fairley IM, Heap BJ. Pulmonary tuberculosis in Gurkhas in Hong Kong in the period 1984-1987 and the role played by routine radiology in case detection. *J R Army Med Corps* 1989; 135(1):31-2.
- Fairshter DD, Randazzo GP, Garlin J, Wilson AF. Failure of isoniazid prophylaxis after exposure to isoniazid-resistant tuberculosis. *Am Rev Respir Dis* 1975; 112(1):37-42.
- Fang Z, Doing C, Rayner A, Kenna DT, Watt B, Forbes KJ. Molecular evidence for heterogeneity of the multiple-drug resistant *Mycobacterium tuberculosis* population in Scotland (1990 to 1997). *J Clin Microbiol* 1999; 37(4):998-1003.
- Fanning A. The importance of education, training and supervision in global TB control. *Int J Tuberc Lung Dis* 2000; 4(12 Suppl 2):S208-14.
- Farabee D, Leukefeld CG. Opportunities for AIDS prevention in a rural state in criminal justice and drug treatment settings. *Subst Use Misuse* 1999; 34(4-5):617-31.
- Farga V. [New standards for the treatment of tuberculosis]. [Spanish]. *Rev Chil Enf Respir* 1996; 12:51-60.
- Farga V. [Tuberculosis, present and future]. [Spanish]. *Rev Chil Enf Respir* 1995; 11:48-59.
- Farga V, Valenzuela P, Valenzuela MT, Yañez A, Garcíá P, Scheel G. [A decade of abbreviated antituberculous chemotherapy in Chile]. [Spanish]. *Rev Chil Enf Respir* 1991; 7(2):94-106.
- Farmer PE. The consumption of the poor: tuberculosis in the 21st century. *Ethnography* 2000; 1(2):211-44.
- Farmer PE. Cruel and unusual: drug-resistant tuberculosis as punishment. In: Stern V, Jones R, eds. *Sentenced to Die? The Problem of TB in Prisons in East and Central Europe and Central Asia*. London: Penal Reform International, 1999a: 70-88.
- Farmer PE. Haiti's lost years: lessons for the Americas. *Current Issues in Public Health* 1996a; 2:143-51.
- Farmer PE. Hidden epidemics of tuberculosis. Infectious disease and social inequalities: from hemispheric insecurity to global cooperation. A working paper of the Latin American Program at the Woodrow Wilson Center for Scholars. Washington DC: Wilson Center, 1999b: 31-55.
- Farmer PE. *Infections and Inequalities: The Modern Plagues*. Berkeley: University of California Press, 1999c.
- Farmer PE. Managerial successes, clinical failures. *Int J Tuberc Lung Dis* 1999d; 3(5):365-7.
- Farmer PE. Pathologies of power: rethinking health and human rights. *Am J Public Health* 1999e; 89(10):1486-96.
- Farmer PE. Pestilence and restraint: Haitians, Guantánamo, and the logic of quarantine. Hannaway C, Harden VA, Parascandola J, eds. *AIDS and the Public Debate: Historical and Contemporary Perspectives*. Burke: IOS Press, 1995: 139-52.
- Farmer PE. Social inequalities and emerging infectious diseases. *Emerg Infect Dis* 1996b; 2(4):259-69.
- Farmer PE. Social scientists and the new tuberculosis. *Soc Sci Med* 1997; 44(3):347-58.
- Farmer PE. TB superbugs: the coming plague on all our houses. *Natural History* 1999f; 108(3):46-53.
- Farmer PE, Bayona J, Becerra MC et al. Poverty, inequality, and drug resistance: meeting community needs. *Proceedings of the International Union Against Tuberculosis and Lung Disease North American Region Conference*. 1997a: 88-102.
- Farmer PE, Bayona J, Becerra MC et al. The dilemma of MDRTB in the global era. *Int J Tuberc Lung Dis* 1998a; 2(11):869-76.
- Farmer PE, Bayona J, Becerra MC et al. DOTS plus strategy in resource-poor countries. *Int J Tuberc Lung Dis* 1999; 3(9):844.
- Farmer PE, Bayona J, Becerra MC, Kim JY, Shin SS. Reducing transmission through community-based treatment of multidrug-resistant tuberculosis. *Int J Tuberc Lung Dis* 1998b; 2(11 Suppl. 1):S190.
- Farmer PE, Bayona J, Becerra MC et al. The emergence of MDRTB in urban Peru: a population-based study using conventional, molecular, and ethnographic methods. *Int J Tuberc Lung Dis* 1997b; 1(5 Suppl. 1):S44.
- Farmer PE, Bayona J, Shin SS et al. Preliminary results of community-based MDRTB treatment in Lima, Peru. *Int J Tuberc Lung Dis* 1998; 2(11 Suppl. 2):S371.
- Farmer PE, Furin JJ, Bayona J et al. Management of MDR-TB in resource-poor countries. *Int J Tuberc Lung Dis* 1999; 3(8):643-5.
- Farmer PE, Furin JJ, Shin SS. The clinical management of multidrug-resistant tuberculosis. *Journal of Respiratory Diseases* 2000; 21(1):53-6.
- Farmer PE, Kim JY. Community-based approaches to the control of multidrug-resistant tuberculosis: introducing "DOTS-plus". *BMJ* 1998; 317(7159):671-4.
- Farmer PE, Kim JY, Mitnick CD, Timperi R. Responding to outbreaks of MDRTB: Introducing DOTS-Plus. In: Reichman LB, Hershfield ES, eds. *Tuberculosis: A Comprehensive International Approach*. 2nd edition. New York: Marcel Dekker Inc., 2000: 447-69.

- Farmer PE, Leandre F, Mukherjee J, Gupta R, Tarter L, Kim JY. Community-based treatment of advanced HIV disease: introducing DOT-HAART (directly observed therapy with highly active antiretroviral therapy). *Bull World Health Organ* 2001b; 79(12):1145-51.
- Farmer PE, Leandre F, Mukherjee JS et al. Community-based approaches to HIV treatment in resource-poor settings. *Lancet* 2001; 358(9279):404-9.
- Farmer PE, Nardell EA. Nihilism and pragmatism in tuberculosis control. *Am J Public Health* 1998; 88(7):4-5.
- Farmer PE, Robin S, Ramilus SL, Kim JY. Tuberculosis, poverty, and "compliance": lessons from rural Haiti. *Semin Respir Infect* 1991; 6(4):254-60.
- Farmer PE, Shin SS, Bayona J, Kim JY, Furin JJ, Brenner JG. Making DOTS-Plus work. In: Bastian I, Portaels F, eds. *Multidrug-resistant Tuberculosis*. Boston: Kluwer, 2000.
- Farmer PE, Walton DA, Becerra MC. International tuberculosis control in the 21st century. In: Friedman LN, ed. *Tuberculosis: Current Concepts and Treatment*. 2nd edition. Boca Raton: CRC Press, 2001: 475-96.
- Feldberg GD. *Disease and Class: Tuberculosis and the Shaping of Modern North American Society*. New Brunswick: Rutgers University Press, 1995.
- Felten MK. Is rifabutin needed in South Africa for the treatment of tuberculosis? *S Afr Med J* 1987; 72(8):578-9.
- Fendall NR. Auxiliary personnel in specialized programs with special reference to tuberculosis. *Bull Int Union Tuberc* 1970; 43:170-3.
- Ferlinz R, Schlegel J. [Does AIDS influence the epidemiology of tuberculosis?]. [German]. *Pneumologie* 1995; 49(8):449-54.
- Ferrer X, Kirshbaum A, Toro J, Jadue J, Muñoz M, Espinoza A. [Compliance with tuberculosis treatment in adults in Santiago, Chile]. [Spanish]. *Bol Oficina Sanit Panam* 1991; 111(5):423-31.
- Ferreira RA. [Epidemiology of tuberculosis in the Argentine Republic]. [Spanish]. *Arch Monaldi* 1980; 35(1-2):3-13.
- Ferrie BG, Rundle JS, McLelland A. Notification and epidemiology of genito-urinary tuberculosis in Glasgow 1970 to 1979. *Health Bull (Edinb)* 1984; 42(2):97-100.
- Field MG. Dismantling Soviet socialized medicine and the uncertain future of health insurance. *Eurohealth* 1998-1999; 4(6):54-6.
- Field MG, Kotz DM, Bukham G. Neoliberal economic policy, "state desertion", and the Russian health crisis. In: Kim JY, Millen JV, Gershman J, Irwin A, eds. *Dying for Growth: Global Inequality and the Health of the Poor*. Monroe: Common Courage Press, 2000.
- Field MJ, ed. *Tuberculosis in the Workplace*. Washington DC: National Academy Press, 2001.
- Fields CL, Roy TM, Ossorio MA, Mercer PJ, Anderson WH. Tuberculosis in the intensive care unit: a chemotherapeutic controversy. *J Ky Med Assoc* 1991; 89(10):502-6.
- Figueroa-Damián R, Arredondo-García JL. Neonatal outcome of children born to women with tuberculosis. *Arch Med Res* 2001; 32(1):66-9.
- Fine PE. The BCG story: lessons from the past and implications for the future. *Rev Infect Dis* 1989; 11(Suppl. 2):S353-9.
- Fine PE. BCG vaccines and vaccination. In: Reichman LB, Hershfield ES, eds. *Tuberculosis: A Comprehensive International Approach*. New York: Marcel Dekker Inc., 2000: 503-22.
- Fineberg HV, Wilson ME. Social vulnerability and death by infection. *N Engl J Med* 1996; 334(13):859-60.
- Fischer B. Epidemiology of mycobacterial resistance (especially *Mycobacterium tuberculosis*). *Chemotherapy* 1999; 45(2):109-20.
- Fischer DA, Lester W, Dye WE, Moulding TS. Re-treatment of patients with isoniazid-resistant tuberculosis: analysis and follow-up of 146 cases. *Am Rev Respir Dis* 1968; 97(3):392-8.
- Fischl MA, Daikos GL, Uttamchandani RB et al. Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple-drug-resistant bacilli. *Ann Intern Med* 1992; 117(3):184-90.
- Fischl MA, Uttamchandani RB, Daikos GL et al. An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection. *Ann Intern Med* 1992; 117(3):177-83.
- Fitzgerald JM. The downside of isoniazid chemoprophylaxis. *Lancet* 1995; 345:404.
- Fitzgerald JM, Grzybowski S, Allen EA. The impact of human immunodeficiency virus infection on tuberculosis and its control. *Chest* 1991; 100(1):191-200.
- Fivchuk PI. [The experience of team work in the control of tuberculosis in rural conditions]. [Russian]. *Probl Tuberk* 1966; 44(2):11-3.
- Flanagan PM, McIlwain JC. Tuberculosis of the larynx in a lepromatous patient. *J Laryngol Otol* 1993; 107(9):845-7.
- Floyd K, Wilkinson D, Gilks C. Comparison of cost effectiveness of directly observed treatment (DOT) and conventionally delivered treatment for tuberculosis: experience from rural South Africa. *BMJ* 1997; 315:1407-11.
- Fodor T, Vadász I, Lőrinczi I. Drug-resistant tuberculosis in Budapest. *Int J Tuberc Lung Dis* 1998; 2(9):732-5.
- Foster SD. Pricing, distribution and use of antimalarial drugs. *Bull World Health Organ* 1991; 69(3):349-63.
- Fox W. Compliance of patients and physicians: experience and lessons from tuberculosis-I. *BMJ* 1983; 287:33-5.
- Fox W. Whither short-course chemotherapy? *Br J Dis Chest* 1981; 75(4):331-57.
- Fox W, Mitchison DA. Community-based short-course treatment of pulmonary tuberculosis in a developing nation. *Am Rev Respir Dis* 1992; 146(2):536-7.
- Fox W, Mitchison DA. Tuberculosis in the third world. *Thorax* 1992; 47(4):327.
- Franckhauser M. Tuberculosis in the 1990s. *Nurse Practitioner Forum* 1993; 4(1):30-6.
- Franks AL, Binkin NJ, Snider DE, Rokaw WM, Becker S. Isoniazid hepatitis among pregnant and postpartum Hispanic patients. *Public Health Rep* 1989; 104(2):151-5.
- Franzblau SG, Witzig RS, McLaughlin JC et al. Rapid, low-technology MIC determination with clinical *Mycobacterium tuberculosis* isolates by using the microplate almar blue assay. *J Clin Microbiol* 1998; 36(2):362-6.

- Freer MJ. Health technologies for the developing world: addressing the unmet needs. *Int J Technol Assess Health Care* 1992; 8(4):623-34.
- Freeman P. A culturally orientated curriculum for Aboriginal health workers. *World Health Forum* 1993; 14(3):262-6.
- Freeman TM. Anaphylaxis: diagnosis and treatment. *Prim Care* 1998; 25(4):809-17.
- Frenkel LD, Lynch JM, Quigley CF, Cox E. Automated tuberculosis surveillance and control. *J Occup Med* 1974; 16(2):86-90.
- Freudenberg N. A new role for community organizations in the prevention and control of tuberculosis. *J Community Health* 1995; 20(1):15-28.
- Freudenberg N, Eng E, Flay B, Parcel G, Rogers T, Wallerstein N. Strengthening individual and community capacity to prevent disease and promote health: in search of relevant theories and principles. *Health Educ Q* 1995; 22(3):290-306.
- Freyer HU. [Epidemiology of children's tuberculosis in Hamburg]. [German]. *Beitr Klin Erforsch Tuberk Lungenkr* 1968; 137(2):167-70.
- Fridkin SK, Manangan L, Bolyard E, Jarvis WR. SHEA-CDC TB survey, part I: status of TB infection control programs at member hospitals, 1989-1992. Society for Healthcare Epidemiology of America. *Infect Control Hosp Epidemiol* 1995; 16(3):129-34.
- Fridkin SK, Manangan L, Bolyard E, Jarvis WR. SHEA-CDC TB survey, part II: efficacy of TB infection control programs at member hospitals, 1992. Society for Healthcare Epidemiology of America. *Infect Control Hosp Epidemiol* 1995; 16(3):135-40.
- Frieden TR. Clarifying the issues in tuberculosis control. *Am J Public Health* 1996; 86(2):267-8.
- Frieden TR. Directly observed treatment for tuberculosis. *Lancet* 1999; 353:146.
- Frieden TR. The proven advantages of specialized care in the control of TB: the New York experience. *TB and HIV* 1995; 6:18-21.
- Frieden TR, Fujiwara E, Washko R, Hamburg M. Tuberculosis in New York City: turning the tide. *N Engl J Med* 1995; 333(4):229-33.
- Frieden TR, Sherman LF, Maw KL et al. A multi-institutional outbreak of highly drug-resistant tuberculosis – epidemiology and clinical outcomes. *JAMA* 1996; 276(15):1229-35.
- Frieden TR, Sterling T, Pablos-Méndez A, Kilburn JO, Cauthen GM, Dooley SW. The emergence of drug-resistant tuberculosis in New York City. *N Engl J Med* 1993; 328(8):521-6.
- Frieden TR, Woodley CL, Crawford JT, Lew D, Dooley SM. The molecular epidemiology of tuberculosis in New York City: the importance of nosocomial transmission and laboratory error. *Tuber Lung Dis* 1996; 77(5):407-13.
- Friedland IR, McCracken GH. Management of infections caused by antibiotic-resistant *Streptococcus pneumoniae*. *N Engl J Med* 1994; 331(6):377-81.
- Friedland JS, Simoes G. Treatment strategies will need to be changed because of drug resistance. *BMJ* 1996; 313:45-6.
- Friedman CR, Riley L, Kreiswirth B et al. Molecular epidemiology of tuberculosis in New York City. *Abstracts of the Annual Meeting of the American Society of Microbiology* 1994; 94(559):Abstract No. C-342.
- Friedman CR, Stoeckle MY, Kreiswirth BN et al. Transmission of multidrug-resistant tuberculosis in a large urban setting. *Am J Respir Crit Care Med* 1995; 152(1):355-9.
- Friedman LN. Skin testing and chemoprophylaxis. In: Friedman LN ed. *Tuberculosis: Current Concepts and Treatment*. Boca Raton: CRC Press, 2001: 377-412.
- Friedman LN. *Tuberculosis: Current Concepts and Treatment*. 2nd edition. Boca Raton: CRC Press, 2001.
- Frisch LE. Adolescent cavitary tuberculosis. Secondary case finding using a social contact scale. *J Adolesc Health Care* 1985; 6(6):463-7.
- Fryatt RJ. Review of published cost-effectiveness studies on tuberculosis treatment programmes. *Int J Tuberc Lung Dis* 1997; 1(2):101-9.
- Fujiwara PI, Cook SV, Rutherford CM et al. A continuing survey of drug-resistant tuberculosis, New York City, April, 1994. *Arch Intern Med* 1997; 157(5):531-6.
- Furcolow ML. Tuberculosis case finding by tuberculin testing a complete population, with follow-up. *Chest* 1975; 68(3 Suppl.):443-5.
- Furin JJ, Becerra MC, Shin SS, Kim JY, Bayona J, Farmer PE. Effect of administering short-course, standardized regimens in individuals infected with drug-resistant *Mycobacterium tuberculosis* strains. *Eur J Clin Microbiol Infect Dis* 2000; 19(2):132-6.
- Furin JJ, Mitnick CD, Shin SS et al. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. *Int J Tuberc Lung Dis* 2001; 5(7):648-55.
- Furin JJ, Mitnick CD, Becerra MC et al. Absence of serious adverse effects in a cohort of Peruvian patients receiving community-based treatment for multidrug-resistant tuberculosis (MDR-TB). *Int J Tuberc Lung Dis* 1999; 3(9 Suppl. 1):S81.
- Gagnon AJ. The training and integration of village health workers. *Bull Pan Am Health Organ* 1991; 25(2):127-38.
- Galkin VB, Isaeva NI. [Dynamics of tuberculosis prevalence in children]. [Russian]. *Probl Tuberk* 1995; 17-9.
- Gallegos Morante EA, Asencios L, Valdivia A. [Multidrug-resistant mycobacteria in Arequipa]. [Spanish]. In. *Programa de Control de la Tuberculosis, Perú* 1994. Lima: Ministerio de Salud, 1995: 169.
- Galzerano G, Borrelli G, De Angelis CP, D'Eliseo R, Gnasso P. [Data on tuberculosis epidemiology in medical students of the University of Naples]. [Italian]. *Arch Monaldi* 1980; 35(3):134-42.
- Gangadharam PR. Chemotherapy of tuberculosis under program conditions. With special relevance to India. *Tuber Lung Dis* 1994; 75(4):241-4.
- Garay SM, Plottel CS. Pulmonary effects of AIDS: nosocomial transmission. *Clin Chest Med* 1988; 9(3):519-33.
- García García ML, Ponce de León A, Jiménez Corona ME et al. Clinical consequences and transmissibility of drug-resistant tuberculosis in southern Mexico. *Arch Intern Med* 2000; 160(5):630-6.

- García García ML, Valdespino Gómez JL, García Sancho MC, Salcedo Alvarez RA, Zacarias F, Sepulveda Amor J. Epidemiology of AIDS and tuberculosis. *Bull Pan Am Health Organ* 1995; 29(1):37-58.
- García García ML, Valdespino Gómez JL, Palacios M et al. The impact of drug resistance on the transmission of tuberculosis in southern Mexico. *Tuber Lung Dis* 1996; 77 (Suppl. 2):212.
- García Martínez FD, Mayorga Hernández H. Relapse after short-course chemotherapy of patients with sputum smear-positive pulmonary tuberculosis under routine conditions with additional information on side effects and contact tracing. *Tuber Lung Dis* 1996; 77:425-8.
- García-Rosell O. Worldwide chest medicine: tuberculosis in Peru. *Dis Chest* 1965; 48(3):334-5.
- Garfield JJ. The auditory, vestibular, and renal effects of capreomycin in humans. *Ann NY Acad Sci* 1996; 135:1039-46.
- Garrett L. A bacterial breeding ground: infections rage through the former Soviet Union because of antibiotic abuse, archaic hygiene and poverty. *Newsday* 1997; C04.
- Garzelli C, Lari N, Nguin B, Falcone G. Evidence of nosocomial transmission of tuberculosis among AIDS patients by DNA fingerprinting. *New Microbiol* 1996; 19(4):285-91.
- Gatner EM, Burkhardt KR. Correlation of the results of X-ray and sputum culture in tuberculosis prevalence surveys. *Tubercle* 1980; 61(1):27-31.
- Gatner EM, Glatthaar E, Imkamp FM, Kok SH. Association of tuberculosis and leprosy in South Africa. *Lepr Rev* 1980; 51(1):5-10.
- Gaudette LA, Ellis E. Tuberculosis in Canada: a focal disease requiring distinct control strategies for different risk groups. *Tuber Lung Dis* 1993; 74(4):244-53.
- Geefhuysen J, Freiman I. Tuberculosis notwithstanding BCG vaccination. *S Afr Med J* 1975; 49(41):1706-8.
- Gelband H, Corrigan J, McDonough R. Methodology of OTA's report on drug labeling in developing countries. *Int J Technol Assess Health Care* 1993; 9(2):238-50.
- Gellert GA, Pyle NG. Pharmacy practice and antibiotic-resistant tuberculosis along the US-Mexico border. *JAMA* 1994; 271(20):1577-8.
- Genewein A, Telenti A, Bernasconi C et al. Molecular approach to identifying route of transmission of tuberculosis in the community. *Lancet* 1993; 342:841-4.
- Getchell WS, Davis CE, Gilman J, Urueta G, Ruíz-Huidobro E, Gilman RH. Basic epidemiology of tuberculosis in Peru: a prevalence study of tuberculin sensitivity in a pueblo joven. *Am J Trop Med Hygiene* 1992; 47(6):721-9.
- Ghana Health Assessment Project Team. A quantitative method of assessing the health impact of different diseases in less developed countries. *Int J Epidemiol* 1981; 10:73-80.
- Ghebreyesus TA, Alemayehu T, Bosman A, Witten KH, Teklehaimanot A. Community participation in malaria control in Tigray region Ethiopia. *Acta Trop* 1996; 61(2):145-56.
- Giblin PT. Effective utilization and evaluation of indigenous health care workers. *Public Health Rep* 1989; 104(4):361-8.
- Gilbert GL. Multidrug-resistant tuberculosis: prevention is better than cure. *Med J Aust* 1996; 164(2):121-4.
- Gilman RH. Lecture delivered at IX National Congress of Internal Medicine, Lima, Peru. 1996.
- Gilpin TP, Hammond M. Active case-finding – for the whole community or for tuberculosis contacts only? *S Afr Med J* 1987; 72(4):260-2.
- Giorgis GE, Moschini MT, Bardessono F, Amelio M. [Changes in the primary resistance to *Mycobacterium tuberculosis* in Piedmont 1965-1979]. [Italian]. *Minerva Med* 1981; 72(25):1581-6.
- Girardi E, Antonucci G, Ippolito G et al. Association of tuberculosis risk with the degree of tuberculin reaction in HIV-infected patients. *Arch Intern Med* 1997; 157(7):797-800.
- Girgis NI, Farid Z, Kilpatrick ME, Sultan Y, Mikhail IA. Dexamethasone adjunctive treatment for tuberculous meningitis. *Pediatr Infect Dis J* 1991; 10(3):179-83.
- Githui W, Nunn P, Juma E et al. Cohort study of HIV-positive and HIV-negative tuberculosis, Nairobi, Kenya: comparison of bacteriological results. *Tuber Lung Dis* 1992; 73(4):203-9.
- Githui WA, Juma ES, van Gorkom J, Kibuga D, Odhiambo J, Drobniowski F. Antituberculous drug resistance surveillance in Kenya, 1995. *Int J Tuberc Lung Dis* 1998; 2(6):499-505.
- Gittler J. Controlling resurgent tuberculosis: public health agencies, public policy, and law. *J Health Polit Policy Law* 1994; 19(1):107-47.
- Glatthaar E. Tuberculosis control in South Africa. 'Where have we gone wrong?' and 'a look at the future'. *S Afr Med J* 1982; (Special Issue):36-41.
- Glæssberg V. The threat of multidrug resistance: is tuberculosis ever untreatable? *Lancet* 1999; 353:998-9.
- Glisson J, Mehta JB. Difficulties in the diagnosis and treatment of drug-resistant tuberculosis and tuberculous empyema. *J Tenn Med Assoc* 1992; 85(9):419-22.
- Gninafon M. Evolution of case-finding and treatment of tuberculosis over the last 3 years following the introduction of short-course chemotherapy of 8 months duration in Benin. *Bull Int Union Tuberc Lung Dis* 1989; 64(3):42-3.
- Goble M. Drug-resistant tuberculosis. *Semin Respir Infect* 1986; 1(4):220-9.
- Goble M, Horsburgh C, Waite D et al. Treatment of isoniazid and rifampin-resistant tuberculosis. *Am Rev Respir Dis* 1988; 137(Suppl.):24.
- Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. *N Engl J Med* 1993; 328(8):527-32.
- Gocmean A, Kiper N, Ertan U, Kalayci O, Ozcelik U. Is the BCG test of diagnostic value in tuberculosis? *Tuber Lung Dis* 1994; 75(1):54-7.
- Godfrey-Faussett P, Githui W, Batchelor B et al. Recurrence of HIV-related tuberculosis in an endemic area may be due to relapse or reinfection. *Tuber Lung Dis* 1994; 75(3):199-202.

- Godfrey-Faussett P, Mortimer PR, Jenkins PA, Stoker NG. Evidence of transmission of tuberculosis by DNA fingerprinting. *BMJ* 1992; 305:221-3.
- Godfrey-Faussett P, Stoker NG. Aspects of tuberculosis in Africa. 3. Genetic 'fingerprinting' for clues to the pathogenesis of tuberculosis. *Trans R Soc Trop Med Hyg* 1992; 86(5):472-5.
- Goff DC, Tsai G, Levitt J et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. *Arch Gen Psychiatry* 1999; 56(1):21-7.
- Gokce C, Gokce O, Erdogmus Z et al. Problems in running a tuberculosis dispensary in a developing country: Turkey. *Tubercle* 1991; 72(4):268-76.
- Gold HS, Moellering RC. Antimicrobial-drug resistance. *N Engl J Med* 1996; 335(19):1445-53.
- Goldfarb A, Healing T, Kimerling ME. PHRI/MERLIN/WHO Tomsk TB project. New York: Public Health Research Institute, 1999.
- Goldfarb A, Kimerling ME. PHRI/Soros Russian TB program: an initiative of the International Center for Public Health. Submitted to the Gore-Primakov Commission edition. New York: Public Health Research Institute, 1999.
- Goldman A, Braman S. Isoniazid: a review with emphasis on adverse effects. *Chest* 1972; 62(1):71-7.
- Goldman DP, Clarke AE, Garber AM. Creating the costliest orphan: the Orphan Drug Act in the development of cefedase. *Int J Technol Assess Health Care* 1992; 8(4):583-97.
- Golovin IA, Charykova GP. [Certain problems of epidemiology of tuberculosis among children]. [Russian]. *Probl Tuberk* 1973; 51(12):9-12.
- Gómez Marín JE, Rigouts L, Villegas Londono LE, Portaels F. [Analysis of restriction fragment length polymorphism (RFLP) in epidemiology of tuberculosis]. [Spanish]. *Bol Oficina Sanit Panam* 1995; 119(1):1-10.
- González Montaner LJ, Dambrosi A, Manassero M, Dambrosi VML. Adverse effects of antituberculosis drugs causing changes in treatment. *Tubercle* 1982; 63(4):291-4.
- Good RC, Mastro TD. The modern mycobacteriology laboratory: how it can help the clinician. *Clin Chest Med* 1989; 10(3):315-22.
- Goodman RM, Speers MA, McLeroy K et al. Identifying and defining the dimensions of community capacity to provide a basis for measurement. *Health Educ Behav* 1998; 25(3):258-78.
- Gordin FM, Slutkin G, Schechter G, Goodman PC, Hopewell PC. Presumptive diagnosis and treatment of pulmonary tuberculosis based on radiographic findings. *Am Rev Respir Dis* 1989; 139(5):1090-3.
- Gothi GD, Narayan R, Nair SS, Chakraborty AK, Srikantharamu N. Estimation of prevalence of bacillary tuberculosis on the basis of chest X-ray and/or symptomatic screening. *Indian J Med Res* 1976; 64(8):1150-9.
- Govindaraj M. Multiple-drug reactions to tuberculosis: an illustrative case. *Tubercle* 1968; 49(4):416-8.
- Goyal M, Ormerod LP, Shaw RJ. Epidemiology of an outbreak of drug-resistant tuberculosis in the U.K. using restriction fragment length polymorphism. *Clin Sci* 1994; 86(6):749-51.
- Gradon J. Antituberculous therapy. In: Lutwick L, ed. *Tuberculosis: A Clinical Handbook*. New York: Chapman and Hall Medical, 1995: 295-316.
- Graham NM, Chaisson RE. Tuberculosis and HIV infection: epidemiology, pathogenesis, and clinical aspects. *Ann Allergy* 1993; 71(5):421-8.
- Grandes G, López-de-Munain J, Díaz T, Rullán JV. Drug-resistant tuberculosis in Puerto Rico, 1987-1990. *Am Rev Respir Dis* 1993; 148(1):6-9.
- Grange JM, Festenstein F. The human dimension of tuberculosis control. *Tuber Lung Dis* 1993; 74(4):219-22.
- Grange JM, Stanford JL. Current trends in the management of tuberculosis. *J R Soc Med* 1994; 87(12):733-6.
- Grange JM, Zumla A. Paradox of the global emergency of tuberculosis. *Lancet* 1999; 353:996.
- Grassi C, Peona V. New drugs for tuberculosis. *Eur Respir J* 1995; 8(Suppl. 20):714s-8s.
- Greenberg PD, Lax KG, Schechter CB. Tuberculosis in house staff: A decision analysis comparing the tuberculin screening strategy with the BCG vaccination. *Am Rev Respir Dis* 1991; 143(3):490-5.
- Greenberger PA. Drug challenge and desensitization protocols. *Immunology and Allergy Clinics of North America* 1998; 18(4):759-72.
- Greifinger RB, Heywood NJ, Glaser JB. Tuberculosis in prison: balancing justice and public health. *J Law Med Ethics* 1993; 21(3-4):332-41.
- Griffiths A. Cost-effectiveness and cost-benefit analysis of health services: the methodology and its application. *Health Policy* 1988; 9:251-65.
- Grinspun MS, Goldenberg R. Evaluation of Chile's national tuberculosis program. *Bull Pan Am Health Organ* 1974; 8(4):318-24.
- Grishko AN. [Medical and social aspects of tuberculosis prevention in multi-million urban areas]. [Russian]. *Probl Tuberk* 1994; 13-6.
- Grosset J. Survey of primary and secondary drug resistance of *M. tuberculosis* in France. *Tuber Lung Dis* 1996; 77(Suppl. 2):63.
- Grosset J. Systematic drug susceptibility testing: a necessary component of the 'DOTS Plus' strategy? *Int J Tuberc Lung Dis* 1999; 3(7):549-50.
- Grosset J, Leventis S. Adverse effects of rifampin. *Rev Infect Dis* 1983; 5(S3):S440-S450.
- Grosset J, Mouton Y. Is PCR a useful tool for the diagnosis of tuberculosis in 1995? *Tuber Lung Dis* 1995; 76(3):183-4.
- Gruchalla RS. Drug allergies. *Prim Care* 1998; 25(4):791-807.
- Gruft H, Johnson R, Claflin R, Loder A. Phage-typing and drug-resistance patterns as tools in mycobacterial epidemiology. *Am Rev Respir Dis* 1984; 130(1):96-7.
- Grzybowski S. Drugs are not enough: failure of short-course chemotherapy in a district in India. *Tuber Lung Dis* 1993; 74(3):145-6.
- Grzybowski S. Epidemiology of tuberculosis and the role of BCG. *Clin Chest Med* 1980; 1(2):175-87.
- Grzybowski S. The impact of treatment programmes on the epidemiology of tuberculosis. *Tubercle* 1985; 66(1):69-72.

- Grzybowski S. Natural history of tuberculosis. *Epidemiology. Bull Int Union Tuberc Lung Dis* 1991; 66(4):193-4.
- Grzybowski S, Barnett GD, Styblo K. Contacts of cases of active pulmonary tuberculosis. *Bull Int Union Tuberc* 1975; 50(1):90-106.
- Guillemot L, Chakraborty M, Mitra PK, Dey DK. Integration of leprosy and tuberculosis control – a field experiment. *Lepr India* 1980; 52(4):491-500.
- Gupta DK, Mital OP, Agarwal MC, Kansal HM, Nath S. A comparison of therapeutic efficacy and toxicity of ethionamide and prothionamide in Indian patients. *J Indian Med Assoc* 1977; 68(2):25-9.
- Gupta DK, Mital OP, Agarwala MC. Hepatic injury due to ethionamide (1314-TH) and prothionamide (1321-TH). *J Assoc Physicians India* 1975; 23(2):147-51.
- Gupta PR, Singhal B, Sharma TN, Gupta RB. Prevalence of initial drug resistance in tuberculosis patients attending a chest hospital. *Indian J Med Res* 1993; 97(A):102-3.
- Gupta R, Brenner JG, Henry CL et al. Procurement of second-line anti-tuberculosis drugs for DOTS-Plus pilot projects. WHO Working Group on DOTS-Plus for MDR-TB. Proceedings of a meeting, Cambridge, MA 5-6 July 1999. Geneva: World Health Organization, 2000.
- Gupta R, Kim JY, Espinal MA et al. Public health: responding to market failures in tuberculosis control. *Science* 2001; 293(5532):1049-51.
- Gusset T, Rieder HL, Salfinger M. [Incidence or resistance of tuberculosis bacteria in Switzerland]. [German]. *Schweiz Rundsch Med Prax* 1993; 82(40):1101-4.
- Guzmán AM, García P, Valenzuela MT et al. [Acquired resistance of *M. tuberculosis* to the antitubercular drugs in Chile from 1988 to 1991]. [Spanish]. *Rev Med Chil* 1993; 121(11):1269-73.
- Guzmán AM, Valenzuela P. [Do previously treated tuberculosis patients require a special treatment regimen?]. [Spanish]. *Rev Chil Enf Respir* 1991; 7:164-7.
- Haas DW, Des Prez RM. *Mycobacterium tuberculosis*. In: Mandell GL, Bennett JE, Dolin R, eds. *Principles and Practice of Infectious Diseases*. 4th edition. New York: Churchill Livingstone, 1995: 2213-43.
- Haas DW, Des Prez RM. Tuberculosis and acquired immunodeficiency syndrome: a historical perspective on recent developments. *Am J Med* 1994; 96(5):439-50.
- Habouzit M. Drug resistance study inside the Georgian penitentiary system-I. *Int J Tuberc Lung Dis* 1998; 2(11 Suppl. 2):S327.
- Hadiarto M. Present situation of multidrug-resistant tuberculosis in Asian countries and the possibility of MDR-TB treatment by new quinolones. *Chemotherapy* 1996; 42(S3).
- Hadiarto M, Tjandra YA, Hudoyo A. Treatment of multidrug-resistant tuberculosis in Indonesia. *Chemotherapy* 1996; 42(Suppl. 3):24-9.
- Hadlock FP, Park SK, Wallace RJ. Routine radiographic screening of the chest in pregnant women: is it indicated? *Obstet Gynecol* 1979; 54(4):433-6.
- Haffner ME. Orphan products: ten years later and then some. *Food Drug Law J* 1994; 49:593-601.
- Haffner ME, Kelsey JV. Evaluation of orphan products by the U.S. Food and Drug Administration. *Int J Technol Assess Health Care* 1992; 8(4):647-57.
- Hamadeh MA, Glassroth J. Tuberculosis and pregnancy. *Chest* 1992; 101(4):1114-20.
- Hampel B, Hullmann R, Schmidt H. Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use – safety report. *Pediatr Infect Dis J* 1997; 16(1):127-9; discussion 160-2.
- Harding S, Bailey W. Chemotherapy of tuberculosis. In: Schlossberg D, ed. *Tuberculosis*. New York: Springer-Verlag, 1994: 69-88.
- Hardy MA, Schmidek HH. Epidemiology of tuberculosis aboard a ship. *JAMA* 1968; 203(3):175-9.
- Harkin TJ, Harris HW. Treatment of multidrug-resistant tuberculosis. In: Rom WN, Garay SM, eds. *Tuberculosis*. Boston: Little, Brown and Co., 1996: 843-50.
- Harper I, Fryatt R, White A. Tuberculosis case finding in remote mountainous areas – are microscopy camps of any value? Experience from Nepal. *Tuber Lung Dis* 1996; 77(4):384-8.
- Harries AD, Kamenya A, Subramanyam VR, Salaniponi FM, Nyangulu DS. Sputum smears for diagnosis of smear-positive pulmonary tuberculosis. *Lancet* 1996; 347:834-5.
- Harries AD, Mbewe LN, Salaniponi FML et al. Tuberculosis programme changes and treatment outcomes in patients with smear-positive pulmonary tuberculosis in Blantyre, Malawi. *Lancet* 1996; 347:807-9.
- Harries AD, Salanipont FM, Kwanjana JH. Directly observed treatment for tuberculosis. *Lancet* 1999; 353:146-7.
- Harrigan RA, Kauffman FH, Love MB. Tuberculous psoas abscess. *J Emerg Med* 1995; 13(4):493-8.
- Harrow EM, Rangel JM, Arriaga JM et al. Epidemiology and clinical consequences of drug resistant tuberculosis in a Guatemalan hospital. *Chest* 1998; 113(6):1452-8.
- Hassine E, Hadoussa J, Hamzaoui A et al. Multidrug resistant tuberculosis (MDR) in Tunisia. *Int J Tuberc Lung Dis* 1998; 2(11 Suppl. 2):S328.
- Hattingh ME. Tuberculosis management – some aspects of the role of the nurse manager. *Curationis* 1981; 4(3):26-8.
- Hatvany T. [Development, present situation and perspectives of care of women with genital tuberculosis in Slovakia]. [Slovak]. *Cesk Gynekol* 1969; 34(3):174-7.
- Haverkos HW. Infectious diseases and drug abuse. Prevention and treatment in the drug abuse treatment system. *J Subst Abuse Treat* 1991; 8(4):269-75.
- Hawkins JE. Nonweekend schedule for BACTEC drug susceptibility testing of *Mycobacterium tuberculosis*. *J Clin Microbiol* 1986; 23(5):934-7.
- Hayes EB, Talbot SB, Matheson ES, Pressler HM, Hanna AB, McCarthy CA. Health status of pediatric refugees in Portland, ME. *Arch Pediatr Adolesc Med* 1998; 152(6):564-8.
- Haygood TM, Briggs JE. World War II military led the way in screening chest radiography. *Mil Med* 1992; 157(3):113-6.

- Haynes RB. A critical review of the 'determinants' of patient compliance with therapeutic regimens. In: Haynes B, Taylor DW, Sackett D, eds. *Compliance in Health Care*. Baltimore: Johns Hopkins University Press, 1979: 26-39.
- Haynes RB, McKibbin KA, Kanani R. Systematic review of randomized trials of interventions to assist patients to follow prescriptions for medications. *Lancet* 1996; 348:383-6.
- Hayward AC, Herbert J, Bennett DE, Watson JM. A case-control study of risk factors for drug resistance in *Mycobacterium tuberculosis* isolates in England and Wales: 1993-1994. *Tuber Lung Dis* 1996; 77(Suppl. 2):62.
- Hayward AC, Watson JM. Typing of mycobacteria using spoligotyping. *Thorax* 1998; 53(5):329-30.
- Hayward CM, Herrman JL, Griffin GE. Drug resistant tuberculosis: mechanisms and management. *Br J Hosp Med* 1995; 54(9):494-500.
- Heggenhougen K, Vaughan P, Muhondwa E et al. *Community Health Workers: The Tanzanian Experience*. New York: Oxford University Press, 1987.
- Heifets LB. Antimycobacterial drugs. *Semin Respir Infect* 1994; 9(2):84-103.
- Heifets LB. Drug susceptibility testing. *Clin Lab Med* 1996; 16(3):641-56.
- Heifets LB. Drug susceptibility tests in the management of chemotherapy of tuberculosis. In: Heifets LB, ed. *Drug Susceptibility in the Chemotherapy of Mycobacterial Infections*. Boca Raton: CRC Press, 1991: 89-121.
- Heifets LB, Cangelosi GA. Drug susceptibility testing of *Mycobacterium tuberculosis*: a neglected problem at the turn of the century. *Int J Tuberc Lung Dis* 1999; 3(7):564-81.
- Heifets LB, Cynamon MH. *Drug Susceptibility in the Chemotherapy of Mycobacterial Infections*. Boca Raton: CRC Press, 1991.
- Heifets LB, Good R. Current laboratory methods for the diagnosis of tuberculosis. In: Bloom B, ed. *Tuberculosis: Pathogenesis, Protection, and Control*. Washington DC: American Society of Microbiology Press, 1994: 85-110.
- Heifets LB, Lindholm-Levy P. Comparison of bactericidal activities of streptomycin, amikacin, kanamycin, and capreomycin against *Mycobacterium avium* and *M. tuberculosis*. *Antimicrob Agents Chemother* 1989; 33(8):1298-301.
- Heldal E, Cruz JR, Arnadottir T, Tardencilla A, Enarson DA. Successful management of a National Tuberculosis Programme under conditions of war. *Int J Tuberc Lung Dis* 1997; 1(1):16-24.
- Hellberg H. Tuberculosis programmes: fragmentation or integration? *Tuber Lung Dis* 1995; 76(1):1-3.
- Hellyer TJ, DesJardin LE, Teixeira L, Perkins MD, Cave MD, Eisenach KD. Detection of viable *Mycobacterium tuberculosis* by reverse transcriptase-strand displacement amplification of mRNA. *J Clin Microbiol* 1999; 37(3):518-23.
- Helmy B. Side effects of cycloserine. *Scand J Respir Dis* 1970; 71(Suppl.):200-5.
- Henderson DA. The challenge of eradication: lessons from past eradication campaigns. *Int J Tuberc Lung Dis* 1998; 2(9 Suppl.):S4-S8.
- Henderson JM. *Gastrointestinal Pathophysiology*. Philadelphia: Lippincott-Raven, 1996.
- Henderson RH. The expanded programme on immunization of the World Health Organization. *Rev Infect Dis* 1984; 6(Suppl. 2):S475-9.
- Herrera M, Blancarte QF, Anzaldo QF, Campos PQ, Senties R. [Primary resistance in 126 cases of pulmonary tuberculosis]. [Spanish]. *Salud Publica Mex* 1976; 18(1):111-4.
- Hershfield ES. Drug resistance – response to Dr. Shima. *Tubercle* 1987; 68(Suppl.):17-8.
- Hessel PA, Hnizdo E, Goldstein B, Sluis-Cremer GK. Pathological findings in mine workers: II. Quality of the Pathaut data. *Am J Ind Med* 1987; 12(1):81-9.
- Heym B, Alzari PM, Honoré N, Cole ST. Missense mutations in the catalase-peroxidase gene, *katG*, are associated with isoniazid resistance in *Mycobacterium tuberculosis*. *Mol Microbiol* 1995; 15(2):235-45.
- Heym B, Honoré N, Truffot-Pernot C et al. Implications of multidrug resistance for the future of short course chemotherapy of tuberculosis: a molecular study. *Lancet* 1994; 344:293-8.
- Heymann SJ. Modelling the efficacy of prophylactic and curative therapies for preventing the spread of tuberculosis in Africa. *Trans R Soc Trop Med Hyg* 1993; 87(4):406-11.
- Heymann SJ, Brewer TF, Wilson ME, Fineberg HV. The need for global action against multidrug-resistant tuberculosis. *JAMA* 1999; 281(22):2138-40.
- Heywood S, Amoa AB, Mola GL, Klufio CA. A survey of pregnant women with tuberculosis at the Port Moresby General Hospital. *P N G Med J* 1999; 42(3-4):63-70.
- Hill CE. *Community Health Systems in the Rural American South: Linking People and Policy*. Boulder: Westview Press, 1988.
- Hilty DM, Lim RF, Hales RE. The psychotic patient. *Prim Care* 1999; 26(2):327-48.
- Hirano K, Kazumi Y, Abe C, Mori T, Aoki M, Aoyagi T. Resistance to antituberculosis drugs in Japan. *Tuber Lung Dis* 1996; 77(2):130-5.
- Hirata T, Saito H, Tomioka H et al. In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 1995; 39(10):2295-303.
- Hirota Y. [Tuberculosis control in Nepal – BCG vaccination and case-finding programme using the door-to-door visit method in an anti-tuberculosis campaign]. [Japanese]. *Kekkaku* 1979; 54(5):277-80.
- Hoffner SE. Drug-resistant *Mycobacterium tuberculosis*: some data from Sweden, Estonia and Ethiopia. *Scand J Infect Dis* 1995; 98(Suppl.):17-8.
- Hoffner SE, Gezelius L, Olsson-Liljequist B. In-vitro activity of fluorinated quinolones and macrolides against drug-resistant *Mycobacterium tuberculosis*. *J Antimicrob Chemother* 1997; 40(6):885-8.
- Holdiness MR. Adverse cutaneous reactions to antituberculosis drugs. *Int J Dermatol* 1985; 24(5):280-5.

- Holdiness MR. Clinical pharmacokinetics of the antituberculosis drugs. *Clin Pharmacokinet* 1984; 9(6):511-44.
- Holdiness MR. Neurological manifestations and toxicities of the antituberculosis drugs: a review. *Med Toxicol* 1987; 2(1):33-51.
- Holmberg SD, Solomon SL, Blake PA. Health and economic impacts of antimicrobial resistance. *Rev Infect Dis* 1987; 9(6):1065-78.
- Hong Kong Chest Service, British Medical Research Council. A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin, and rifampin. *Tuber Lung Dis* 1992; 73(1):59-67.
- Hong Kong Chest Service, British Medical Research Council. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. *Am Rev Respir Dis* 1991; 143:700-6.
- Hong Kong Chest Service, British Medical Research Council. Controlled trial of 4 three-times weekly regimens and a daily regimen all give for 6 months for pulmonary tuberculosis. Second report: the results up to 24 months. *Tubercle* 1982; 63(2):89-98.
- Hong Kong Chest Service, British Medical Research Council. Controlled trial of four thrice weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. *Lancet* 1981; 1:171-74.
- Hong Kong Chest Service, British Medical Research Council. Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. *Am Rev Respir Dis* 1987; 136:1339-42.
- Hong Kong Chest Service, British Medical Research Council. Survey of patients presenting to the government chest service in Hong Kong and the effects of active tuberculosis case-finding by publicity campaigns. *Tubercle* 1984; 65(3):173-84.
- Hong YP, Kim SJ, Lew WJ, Lee SH, Lee EK. Cohort analyses of the treatment of smear-positive pulmonary tuberculosis patients under programme conditions in Korea, 1983-1994. *Int J Tuberc Lung Dis* 1998b; 2(5):365-71.
- Hong YP, Kwon DW, Kim SJ et al. Survey of knowledge, attitudes and practices for tuberculosis among general practitioners. *Tuber Lung Dis* 1995; 76(5):431-5.
- Hooi LN. Case-finding for pulmonary tuberculosis in Penang. *Med J Malaysia* 1994; 49(3):223-30.
- Hopewell PC. Global tuberculosis control: an optimist's perspective. *Int J Tuberc Lung Dis* 1999; 3(4):270-2.
- Hopewell PC. Impact of human immunodeficiency virus infection on the epidemiology, clinical features, management, and control of tuberculosis. *Clin Infect Dis* 1992; 15(3):540-7.
- Hopewell PC, Ganter B, Baron RB, Sánchez-Hernández M. Operational evaluation of treatment for tuberculosis. Results of 8- and 12-month regimens in Peru. *Am Rev Respir Dis* 1985; 132(4):737-41.
- Hopewell PC, Sánchez-Hernández M, Baron RB, Ganter B. Operational evaluation of treatment for tuberculosis: results of a "standard" 12-month regimen in Peru. *Am Rev Respir Dis* 1984; 129(3):439-43.
- Horsburgh CR Jr, Pozniak A. Epidemiology of tuberculosis in the era of HIV. *AIDS* 1993; 7 (Suppl. 1):S109-14.
- Horton R. Towards the elimination of tuberculosis. *Lancet* 1995; 346:790.
- Hsing CT. Chest microfilm versus direct microscopic sputum examination in tuberculosis control in the developing country. *Dis Chest* 1967; 52(5):648-51.
- Hua CC, Chang LC, Yu TJ, Lee N, Shieh WB. Antituberculosis drug resistance in Keelung area – 1993 to 1994. *Changeng Yi Xue Za Zhi* 1996; 19(2):107-14.
- Hudelson P. Gender differentials in tuberculosis: the role of socio-economic and cultural factors. *Tuber Lung Dis* 1996; 77(5):391-400.
- Hudson LD, Sbarbaro JA. Twice weekly tuberculosis chemotherapy. *JAMA* 1973; 223(2):139-43.
- Humma LM. Prevention and treatment of drug-resistant tuberculosis. *Am J Health Syst Pharm* 1996; 53(19):2291-8.
- Humphries M. Tuberculosis: history of directly observed therapy. *Lancet* 1995; 346:380.
- Hussels H, Matthiessen W, Kind A, Gobel D. Frequency and epidemiology of primary drug-resistance in tuberculosis in the Federal Republic of Germany including Berlin (West). Partial result of a study of the W.A.T.L. *Scand J Respir Dis Suppl* 1978; 102(Suppl.):65-7.
- Hussey G, Kibel M, Parker N. Ciprofloxacin treatment of multiply drug-resistant extrapulmonary tuberculosis in a child. *Pediatr Infect Dis J* 1992; 11(5):408-9.
- Hyman CL. Tuberculosis: a survey and review of current literature. *Curr Opin Pulm Med* 1995; 1(3):234-42.
- Hyppolite PR, Pape JW. [HIV infections and tuberculosis in Haiti]. [Spanish]. *Bol Oficina Sanit Panam* 1995; 118(2):161-9.
- Iagafarova RK. [Current methodologic approaches to the study of epidemiology extrapulmonary tuberculosis in the Russian Federation]. [Russian]. *Probl Tuberk* 1994; (3):8-10.
- Idanpaan-Heikkilä JE. Essential drugs. *Ann Med* 1993; 25(1):19-23.
- Idigbe EO, Sofola T, Odiah F. Initial and acquired drug resistant tuberculosis among prison inmates in Lagos, Nigeria. *Int J Tuberc Lung Dis* 1999; 2(11 Suppl. 2):S330.
- Ijsselmuiden CB, Kustner HG, Barron PM, Steinberg WJ. Notification of five of the EPI target diseases in South Africa. An assessment of disease and vaccination reporting. *S Afr Med J* 1987; 72(5):311-6.
- Ikeda RM, Birkhead GS, DiFerdinando GT Jr et al. Nosocomial tuberculosis: An outbreak of a strain resistant to seven drugs. *Infect Control Hosp Epidemiol* 1995; 16(3):152-9.
- Inamoto H. [Tuberculosis in dialysis patients. 10. Epidemiology of kidney and urinary tract tuberculosis]. [Japanese]. *Kekkaku* 1983; 58(5):287-91.
- Inamoto H. [Tuberculosis in dialysis patients. 5. Epidemiology of miliary tuberculosis in patients receiving dialysis]. [Japanese]. *Kekkaku* 1982; 57(11):579-83.
- Indyk D, Belleville R. Linking frontline work and state-of-the-art knowledge: a community exchange system. *J Case Manag* 1995; 4(2):48-53.

- Ingham B, Brentnall DW, Dale EA, McFadzean JA. Arthropathy induced by antibacterial fused N-alkyl-4-pyridone-3-carboxylic acids. *Toxicol Lett* 1977; 1:21-6.
- Ingle RF. Modern doctors, the community and old-fashioned tuberculosis. *S Afr Med J* 1980; 57(17):714-6.
- Ingram M. Russia is on the brink of AIDS epidemic. *BMJ* 1996; 313:252.
- Instituto Nacional de Estadística e Informática. Peru: *Compendio Estadístico 1993-94* [Peru: *Statistical Compendium 1993-94*]. Lima: Instituto Nacional de Estadística e Informática: Dirección Técnica de Indicadores Económicos, 1994.
- International Union Against Tuberculosis and Lung Disease. *Management of Tuberculosis: A Guide for Low Income Countries*. Paris: IUATLD, 2000.
- Ipuge YA, Rieder HL, Becx-Bleumink M, Kimerling ME. Evaluation and planning in national tuberculosis control programmes: the usefulness of the standardised patient treatment card. *East Afr Med J* 1997; 74(12):816-8.
- Ipuge YA, Rieder HL, Enarson DA. The yield of acid-fast bacilli from serial smears in routine microscopy laboratories in rural Tanzania. *Trans R Soc Trop Med Hyg* 1996; 90(3):258-61.
- Iseman MD. *A Clinician's Guide to Tuberculosis*. Philadelphia: Lippincott Williams and Wilkins, 2000.
- Iseman MD. Directly-observed therapy, patient education and combined drug formulations: complementary, not alternative, strategies in tuberculosis control. *Tuber Lung Dis* 1996; 77(2):101.
- Iseman MD. Evolution of drug-resistant tuberculosis: a tale of two species. *Proc Natl Acad Sci U S A* 1994; 91(7):2428-9.
- Iseman MD. A leap of faith. What can we do to curtail intrainstitutional transmission of tuberculosis? *Ann Intern Med* 1992; 117(3):251-3.
- Iseman MD. Management of multidrug-resistant tuberculosis. *Chemotherapy* 1999; 45 Suppl 2:3-11.
- Iseman MD. MDR-TB and the developing world – a problem no longer to be ignored: the WHO announces 'DOTS Plus' strategy. *Int J Tuberc Lung Dis* 1998; 2(11):867.
- Iseman MD. Tailoring a time bomb: inadvertent genetic engineering. *Am Rev Respir Dis* 1985; 132(4):735-6.
- Iseman MD. Treatment of multidrug-resistant tuberculosis. *N Engl J Med* 1993; 329(11):784-91.
- Iseman MD. An unholy trinity – three negative sputum smears and release from tuberculosis isolation. *Clin Infect Dis* 1997; 25:671-2.
- Iseman MD, Cohn DL, Sbarbaro JA. Directly observed treatment of tuberculosis: we can't afford not to try it. *N Engl J Med* 1993; 328(8):576-8.
- Iseman MD, Madsen LA. Drug-resistant tuberculosis. *Clin Chest Med* 1989; 10(3):341-53.
- Iseman MD, Madsen LA, Goble M, Pomerantz M. Surgical intervention in the treatment of pulmonary disease caused by drug-resistant *Mycobacterium tuberculosis*. *Am Rev Respir Dis* 1990; 141(3):623-5.
- Iseman MD, Sbarbaro JA. Short-course chemotherapy of tuberculosis: Hail Britannia (and friends)! *Am Rev Respir Dis* 1991; 143(4 Pt. 1):697-8.
- Iturbe P. Personnel requirements in an integrated tuberculosis program in developing countries. *Bull Int Union Tuberc* 1970; 43:149-61.
- Iversen E. Epidemiological basis of tuberculosis eradication. 8. Some factors of significance for the prognosis for a tuberculosis patient. *Bull World Health Organ* 1967; 37(6):893-906.
- Iwaki Chávez R, Bussalleu Rivera A. [Gastrointestinal and peritoneal tuberculosis]. [Spanish]. *Rev Gastroenterol Peru* 1994; 14(2):99-113.
- Jacobs RF, Eisenach KD. Childhood tuberculosis. *Adv Pediatr Infect Dis* 1993; 8:23-51.
- Jacobson ML, Mercer MA, Miller LK, Simpson TW. Tuberculosis risk among migrant farm workers on the Delmarva Peninsula. *Am J Public Health* 1987; 77(1):29-32.
- Jacobson R, Krahenbuhl JL, Patout C, Axelrod C. Public health applications of Hansen's disease research and treatment. *Public Health Rep* 1994; 109(6):818-20.
- Jacoby GA. Antimicrobial-resistant pathogens in the 1990s. *Annu Rev Med* 1996; 47:169-79.
- Jagannath C, Reddy MV, Kailasam S, O'Sullivan JF, Gangadharam PR. Chemotherapeutic activity of clofazimine and its analogues against *Mycobacterium tuberculosis*: in vitro, intracellular, and in vivo studies. *Am J Respir Crit Care Med* 1995; 151:1083-6.
- Jagirdar J, Zagzag D. Pathology and insights into pathogenesis of tuberculosis. In: Rom WN, Garay SM, eds. *Tuberculosis*. Boston: Little, Brown and Co., 1996: 467-82.
- Jave O. [Differential tuberculosis treatment regimens]. [Spanish]. *La Salud* 1996; 29-34.
- Jeanes CW. The program of the Canadian Tuberculosis Association. *Med Serv J Can* 1966; 22(10):890-3.
- Jin BW, Kim SC, Mori T, Shima T. The impact of intensified supervisory activities on tuberculosis treatment. *Tuber Lung Dis* 1993; 74:267-72.
- Joesoef MR, Remington PL, Jiptoherijanto PT. Epidemiological model and cost-effectiveness analysis of tuberculosis treatment programmes in Indonesia. *Int J Epidemiol* 1989; 18(1):174-9.
- Johansson E, Diwan VK, Huong ND, Ahlberg BM. Staff and patient attitudes to tuberculosis and compliance with treatment: an exploratory study in a district in Vietnam. *Tuber Lung Dis* 1996; 77(2):178-83.
- Johnson H, Lee B, Doherty E, Kelly E, McDonnell T. Tuberculin sensitivity and the BCG scar in tuberculosis contacts. *Tuber Lung Dis* 1995; 76(2):122-5.
- Johnson L, Sepkowitz K. Treatment of multidrug-resistant tuberculosis. In: Lutwick L, ed. *Tuberculosis: A Clinical Handbook*. New York: Chapman and Hall Medical, 1995: 315-30.
- Jones DS, Malecki JM, Bigler WJ, Witte JJ, Oxtoby MJ. Pediatric tuberculosis and human immunodeficiency virus infection in Palm Beach County, Florida. *Am J Dis Child* 1992; 146(10):1166-70.

- Jordan TJ, Sunderam G, Thomas L, Reichman LB. Tuberculin reaction size measurement by the pen method compared to traditional palpation. *Chest* 1987; 92(2):234-6.
- Jovanovic A. [Effect of chronic patients on the epidemiology of tuberculosis]. [Serbo-Croatian]. *Tuberkuloza* 1967; 19(5):633-5.
- Jung HD, Merkel S. [Epidemiology of peripheral lymph node tuberculosis]. [German]. *Dermatol Monatsschr* 1984; 170(4):232-6.
- Kahlmeter G, Dahlager JJ. Aminoglycoside toxicity – a review of clinical studies published between 1975 and 1982. *J Antimicrob Chemother* 1984; 13(Suppl. A):9-22.
- Kalweit H. [Problems of early detection and care of urogenital tuberculosis]. [German]. *Z Tuberk Erkr Thoraxorg* 1966; 125(3):388-92.
- Kamat SR, Dawson JJ, Devadatta S, et al. A controlled study of the influence of segregation of tuberculous patients for one year on the attack rate of tuberculosis in a 5-year period in close family contacts in South India. *Bull World Health Organ* 1966; 34(4):517-32.
- Kamolratanakul P, Sawert H, Kongsin S et al. Economic impact of tuberculosis at the household level. *Int J Tuberc Lung Dis* 1999; 3(7):596-602.
- Kanai K. Acquired resistance to tuberculous infection in experimental model. *Jpn J Med Sci Biol* 1967; 20(1):21-72.
- Kaplan H, Sadock B. *Comprehensive Textbook of Psychiatry*. 6th edition. Baltimore: Williams and Wilkins, 1995.
- Kaplan JA, Krieff DM. Quinolones for the treatment and prophylaxis of tuberculosis. *Ann Pharmacother* 1996; 30(9):1020-2.
- Kapur V, Li LL, Iordanescu S et al. Characterization by automated DNA sequencing of mutations in the gene (*rpoB*) encoding the RNA polymerase b subunit in rifampin-resistant *Mycobacterium tuberculosis* strains from New York City and Texas. *J Clin Microbiol* 1994; 32(4):1095-8.
- Karmon G, Savir H, Zevin D, Levi J. Bilateral optic neuropathy due to combined ethambutol and isoniazid treatment. *Ann Ophthalmol* 1979; 11(7):1013-7.
- Karonga Prevention Trial Group. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed *Mycobacterium leprae* vaccine for prevention of leprosy and tuberculosis in Malawi. *Lancet* 1996; 348:17-24.
- Karstaedt AS, Jones N, Khoosal M, Crewe-Brown HH. The bacteriology of pulmonary tuberculosis in a population with high human immunodeficiency virus seroprevalence. *Int J Tuberc Lung Dis* 1998; 2(4):312-6.
- Kaseje DC, Sempebwa EK, Spencer HC. Community leadership and participation in the Saradidi, Kenya, rural health development programme. *Ann Trop Med Parasitol* 1987; 81 Suppl. 1:46-55.
- Kaseje MA, Kaseje DC, Spencer HC. The training process in community-based health care in Saradidi, Kenya. *Ann Trop Med Parasitol* 1987; 81 Suppl. 1:67-76.
- Kauffmann GW. [Community care of the so-called inactive primary tuberculosis]. [German]. *Z Tuberk Erkr Thoraxorg* 1966; 125(3):181-92.
- Kaupova N, Nukusheva S, Biktasheva H, Goyaux N, Thonneau P. Trends and causes of maternal mortality in Kazakhstan. *Int J Gynaecol Obstet* 1998; 63(1):175-81.
- Kaye K, Frieden TR. Tuberculosis control: the relevance of classic principles in an era of acquired immunodeficiency syndrome and multidrug resistance. *Epidemiol Rev* 1996; 18(1):52-63.
- Keane VP, de Klerk N, Krieng T, Hammond G, Musk AW. Risk factors for the development of non-response to first-line treatment for tuberculosis in southern Vietnam. *Int J Epidemiol* 1997; 26(5):1115-20.
- Kearney MT, Warklyn PD, Teale C, Goldman JM, Pearson SB. Tuberculosis and poverty. *BMJ* 1993; 307:1143.
- Kendig N. Tuberculosis control in prisons. *Int J Tuberc Lung Dis* 1998; 2(9 Suppl. 1):S57-S63.
- Kennedy N, Ramsey A, Viso L, et al. Nutritional status and weight gain in patients with pulmonary tuberculosis in Tanzania. *Trans R Soc Trop Med Hyg* 1996; 90(2):162-6.
- Kent JA, Smith CH. Involving the urban poor in health services through accommodation – the employment of neighborhood representatives. *Am J Public Health Nations Health* 1967; 57(6):997-1003.
- Kent JH. The epidemiology of multidrug-resistant tuberculosis in the United States. *Med Clin N Am* 1993; 77(6):1391-409.
- Kent PT, Kubica G. *Public Health Mycobacteriology: A Guide for the Level III Laboratory*. Atlanta: DHHS, Centers for Disease Control, 1985.
- Kenyon TA, Mwasekaga MJ, Huebner R, Rumisha D, Binkin N, Maganu E. Low-levels of drug resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus co-epidemics in Botswana. *Int J Tuberc Lung Dis* 1999; 3(1):4-11.
- Kenyon TA, Ridzon R, Luskin-Hawk R et al. A nosocomial outbreak of multidrug-resistant tuberculosis. *Ann Intern Med* 1997; 127(1):32-6.
- Kenyon TA, Valway SE, Ihle WW, Oronato IM, Castro KG. Transmission of multidrug-resistant *Mycobacterium tuberculosis* during a long airplane flight. *N Engl J Med* 1996; 334(15):933-8.
- Kessler C, Connolly M, Levy M, Porter JD, Rieder HL. Tuberculosis control in refugee populations: a challenge to both relief agencies and national programs. *Int J Tuberc Lung Dis* 1998; 2(2):105-10.
- Khan EA, Starke JR. Diagnosis of tuberculosis in children: increased need for better methods. *Emerg Infect Dis* 1995; 1(4):115-23.
- Khan J, Ajanee N, Islam N, Jafri W. Drug resistance of *Mycobacterium tuberculosis* in Karachi, Pakistan. *Trop Doct* 1993; 23(1):13-4.
- Khan M, Pillay T, Moodley J, Connolly C. Maternal mortality associated with tuberculosis-HIV coinfection in Durban, South Africa. *Ann NY Acad Sci* 2000; 918:367-9.
- Khan MA, Kovnat DM, Bachus B, Whitcomb ME, Broody JS, Snider GL. Clinical and roentgenographic spectrum of pulmonary tuberculosis in the adult. *Am J Med* 1977; 62:31-8.
- Khanna BK, Gupta VP, Singh MP. Ethambutol-induced hyperuricaemia. *Tubercle* 1984; 65(3):195-9.

- Kim BJ, Kim SY, Park BH et al. Mutations in the *rpoB* of *Mycobacterium tuberculosis* can interfere with PCR-single-strand conformation polymorphism analysis for rifampin susceptibility testing. *J Clin Microbiol* 1997; 35(2):492-4.
- Kim J. Community health practitioners in the Republic of Korea. *World Health Forum* 1987; 8:197-9.
- Kim JH, Langston AA, Gallis HA. Miliary tuberculosis: epidemiology, clinical manifestations, diagnosis, and outcome. *Rev Infect Dis* 1990; 12(4):583-90.
- Kim JY, Furin JJ, Shakow AD et al. Treatment of multidrug-resistant tuberculosis (MDR-TB): new strategies for procuring second- and third-line drugs. *Int J Tuberc Lung Dis* 1999; 3(9 Suppl. 1):S81.
- Kim SJ, Bai SH, Hong YP. Drug-resistant tuberculosis in Korea, 1994. *Int J Tuberc Lung Dis* 1997; 1(4):302-8.
- Kim SJ, Hong YP, Lew WJ, Yang SC, Lee EG. Incidence of pulmonary tuberculosis among diabetics. *Tuber Lung Dis* 1995; 76(6):529-33.
- Kimerling ME, Benjamin WH, Lok KH, Curtis G, Dunlap NE. Restriction fragment length polymorphism screening of *Mycobacterium tuberculosis* isolates: population surveillance for targeting disease transmission in a community. *Int J Tuberc Lung Dis* 1998; 2(8):655-62.
- Kimerling ME, Kluge H, Vezhnina N et al. Inadequacy of the current WHO re-treatment regimen in a central Siberian prison: treatment failure and MDRTB. *Int J Tuberc Lung Dis* 1999; 3(5):451-3.
- Kimerling ME, Vaughn ES, Dunlap NE. Childhood tuberculosis in Alabama: epidemiology of disease and indicators of program effectiveness, 1983 to 1993. *Pediatr Infect Dis J* 1995; 14(8):678-84.
- Kirk J, Miller M. *Reliability and Validity in Qualitative Research*. London: Sage Publications, 1984.
- Kirkland LR. Preventive therapy for multidrug-resistant tuberculosis. *JAMA* 1996; 276(1):27-8.
- Kitagawa EM, Hauser PM. *Differential Mortality in the United States: A Study in Socioeconomic Epidemiology*. Cambridge: Harvard University Press, 1973.
- Kleeberg HH. The dynamics of tuberculosis in South Africa and the impact of the control programme. *S Afr Med J* 1982; Spec No:22-3.
- Klein DN, Kocsis JH, McCullough JP, Holzer CE 3rd, Hirschfeld RM, Keller MB. Symptomatology in dysthymic and major depressive disorder. *Psychiatr Clin North Am* 1996; 19(1):41-53.
- Klein SJ, DiFerdinando GT, Naizby BE. Directly observed therapy for tuberculosis in New York City. *JAMA* 1994; 272(6):435-6.
- Kleinman A. *Patients and Healers in the Context of Culture: An Exploration of the Borderland between Anthropology, Medicine, and Psychiatry*. Berkeley: University of California Press, 1980.
- Klemens SP, DeStefano MS, Cynamon MH. Therapy of multidrug-resistant tuberculosis: lessons from studies with mice. *Antimicrob Agents Chemother* 1993; 37(11):2344-7.
- Kline SE, Hedemark LL, Davies SF. Outbreak of tuberculosis among regular patrons of a neighborhood bar. *N Engl J Med* 1995; 333(4):222-7.
- Klotz SA, Penn RL. Acid-fast staining of urine and gastric contents is an excellent indicator of mycobacterial disease. *Am Rev Respir Dis* 1987; 136(5):1197-8.
- Kochi A. Directly observed treatment for tuberculosis. *Lancet* 1999; 353:147-8.
- Kochi A. The global tuberculosis situation and the new control strategy of the World Health Organization. *Tubercle* 1991; 72(1):1-6.
- Kochi A. Government intervention programs in HIV/tuberculous infection. Outline of guidelines for National Tuberculosis Control Programs in view of the HIV epidemic. *Bull Int Union Tuberc Lung Dis* 1991; 66(1):33-6.
- Kochi A. WHO's role for tuberculosis control in the world. *Bull Int Union Tuberc Lung Dis* 1990; 65(2-3):94.
- Kochi A, Nunn P, Dye C, Tayler E. Global burden of disease. *Lancet* 1997; 350:142.
- Kochi A, Vareldzis B, Styblo K. Multidrug resistant tuberculosis and its control. *Res Microbiol* 1994; 144(2):104-10.
- Kolassa EM. *Elements of Pharmaceutical Pricing*. New York: Haworth Press, Inc, 1997.
- Konig K, Haubensak K. [Epidemiology of urogenital tuberculosis]. [German]. *Urologe A* 1972; 11(1):22-6.
- Koo D, Royce S, Rutherford GW. Drug-resistant *Mycobacterium tuberculosis* in California, 1991 to 1992. *West J Med* 1995; 163(5):441-5.
- Kopano DE, Snider DE Jr, Johnson M. Recurrent tuberculosis: why do patients develop disease again? *Am J Public Health* 1988; 78(1):30-3.
- Korzeniowski OM. Antibacterial agents in pregnancy. *Infect Dis Clin North Am* 1995; 9(3):639-51.
- Kovaleva SI, Bryzgalova OK, Bobriakova AG. [Epidemiology of tuberculosis in patients with diabetes mellitus]. [Russian]. *Probl Tuberk* 1971; 49(6):11-4.
- Kraan JK. Results of the fight against tuberculosis in the Netherlands. *Scand J Respir Dis* 1968; 65(Suppl.):63-7.
- Krause RM. The origin of plagues: old and new. *Science* 1992; 257:1073-8.
- Krause VL, Britton WJ. Tuberculosis in the tropics. *Med J Aust* 1993; 159(6):412-5.
- Krebs A. The fight against tuberculosis in the German Democratic Republic, with special reference to prophylaxis and mass miniature radiography. *Scand J Respir Dis* 1972; 80(Suppl.):51-60.
- Kritski AL, Ozorio-Marques MJ, Rabahi MF et al. Transmission of tuberculosis to close contacts of patients with multidrug-resistant tuberculosis. *Am J Respir Crit Care Med* 1996; 153(1):331-5.
- Kritski AL, Rodrigues de Jesus LS, Andrade MK, Werneck-Barroso E, Haffner A, Riley IW. Retreatment tuberculosis cases: factors associated with drug resistance and adverse outcomes. *Chest* 1997; 111(5):1162-7.
- Kroeger A. Health interview surveys in developing countries: a review of the methods and results. *Int J Epidemiol* 1983; 12:465-81.
- Kropp R, Jungbluth H, Radenbach KL. Influence of capreomycin on renal function (preliminary results). *Antibiot Chemother* 1970; 16:59-68.

- Krüüner A, Sillastu H, Danilovitsh M et al. Drug resistant tuberculosis in Estonia. *Int J Tuberc Lung Dis* 1998; 2(2):130-3.
- Kuaban C, Bercion R, Jifon G, Cunin P. Acquired antituberculosis drug resistance in Yaoundé, Cameroon. *Int J Tuberc Lung Dis* 1999; 2(11 Suppl. 2):S325.
- Kubica GP. Correlation of acid-fast staining methods with culture results for mycobacteria. *Bull Int Union Tuberc* 1980; 55:117-24.
- Kucherov AL. [Resection of the lungs in patients with pulmonary tuberculosis hospitalized at a district antituberculous center]. [Russian]. *Probl Tuberc* 1966; 44(6):46-50.
- Kumaresan JA, de Colombani P, Smith I. Review of national tuberculosis programmes: the experience in Bangladesh. *Int J Tuberc Lung Dis* 1999; 3(12):1140-2.
- Kurita T, Tanase F, Miura M, Hirano Y, Matsuki T. [Public health planning and the plan for tuberculosis prevention at Hajima Public Health Clinic]. [Japanese]. *Hokenfu Zasshi* 1983; 39(2):144-52.
- Labonte R. Social capital and community development: practitioner emptor. *Aust N Z J Public Health* 1999; 23(4):430-3.
- Lacey L, Tukes S, Manfredi C, Warnecke RB. Use of lay health educators for smoking cessation in a hard-to-reach urban community. *J Community Health* 1991; 16(5):269-82.
- Lafontaine A. [The laboratory viewpoint in tuberculosis epidemiology]. [French]. *Arch Belg Med Soc* 1970; 28(1):17-25.
- Laing R. The world health and drug situation. *International Dispensary Association Symposium, Amsterdam*. 1997.
- Lambregts-van Weezenbeek CS, Jansen HM, Nagelkerke NJ, van Klingeren B, Veen J. Nationwide surveillance of drug-resistant tuberculosis in The Netherlands: rates, risk factors and treatment outcomes. *Int J Tuberc Lung Dis* 1998; 2(4):288-95.
- Lambregts-van Weezenbeek CS, Jansen HM, Veen J, Nagelkerke NJ, Sebek MM, van Soolingen D. Origin and management of primary and acquired drug-resistant tuberculosis in The Netherlands: the truth behind the rates. *Int J Tuberc Lung Dis* 1998; 2(4):296-302.
- Lambregts-van Weezenbeek CS, Veen J. Control of drug-resistant tuberculosis. *Tuber Lung Dis* 1995; 76(5):455-9.
- Lancaster E. Tuberculosis comeback: impact on long-term care facilities. *J Gerontol Nurs* 1993; 19(7):16-21.
- Lanckriet C, Levy-Bruhl D, Bingono E, Siopathis RM, Guerin N. Efficacy of BCG vaccination of the newborn: evaluation by a follow-up study of contacts in Bangui. *Int J Epidemiol* 1995; 24(5):1042-9.
- Landesman SH. Commentary: tuberculosis in New York City – the consequences and lessons of failure. *Am J Public Health* 1993; 83(5):766-8.
- Lange F. [Electronic data processing in tuberculosis health services]. [German]. *Beitr Klin Erforsch Tuberk Lungenkr* 1969; 140(1):80-7.
- Lansdown FS, Beran M, Litwak T. Psychotoxic reaction during ethionamide therapy. *Am Rev Respir Dis* 1967; 95(6):1053-5.
- Laserson K, Osorio LE, Hernández H et al. Risk factors for chronic, drug-resistant tuberculosis, Buenaventura, Colombia, 1998. *Int J Tuberc Lung Dis* 1998; 2(11 Suppl. 2):S311.
- Laserson K, Thorpe L, Leimane V et al. Speaking the same language: proposed treatment outcome definitions for multidrug-resistant tuberculosis (manuscript submitted to the *Lancet*). 2002.
- Laszlo A. Tuberculosis bacteriology laboratory services and incremental protocols for developing countries. *Clin Lab Med* 1996; 16(3):697-716.
- Laszlo A, de Kantor IN. A random sample survey of initial drug resistance among tuberculosis cases in Latin America. *Bull World Health Organ* 1994; 72(4):603-10.
- Lavy A, Mates A. A 10 year survey of *Mycobacterium tuberculosis* isolates in Israel and their drug resistance. *Is J Med Sci* 1994; 30(11):805-10.
- Lawrence RM, Lawrence RA. Given the benefits of breastfeeding, what contraindications exist? *Pediatr Clin North Am* 2001; 48(1):235-51.
- Laycock JF, Wise PH. *Essential Endocrinology*. 3rd edition. New York: Oxford University Press, 1996.
- Layton MC, Henning KJ, Alexander TZ et al. Universal radiographic screening for tuberculosis among inmates upon admission to jail. *Am J Public Health* 1997; 87(8):1335-7.
- Le H, Davidson P. Reactivation and exogenous reinfection: their relative roles in the pathogenesis of tuberculosis. *Curr Clin Top Infect Dis* 1996; 16:260-76.
- Lederberg J, Shope RE, Oaks SC. *Emerging Infections: Microbial Threats to Health in the United States*. Washington DC: National Academy Press, 1992.
- Ledru S, Cauchoux B, Yaméogo M et al. Impact of short-course therapy on tuberculosis drug resistance in South-West Burkina Faso. *Tuber Lung Dis* 1996; 77(5):429-36.
- Lee CN, Lin TP, Chang MF, Jimenez MV, Dolfi L, Oliario P. Rifabutin as salvage therapy for cases of chronic multidrug-resistant pulmonary tuberculosis in Taiwan. *J Chemother* 1996; 8(2):137-43.
- Lee JH, Park SS, Lee DH, Shin DH, Yang SC, Yoo BM. Endobronchial tuberculosis: clinical and bronchoscopic features in 121 cases. *Chest* 1992; 102(4):990-4.
- Lee MW, Adebonojo FO. Tuberculosis among urban black children: failure of comprehensive health care services to influence incidence rates. *Clin Pediatr (Phila)* 1976; 15(11):1055-9.
- Lee SS, Tan KK, Chew SK, Snodgrass I. Multidrug-resistant tuberculosis. *Ann Acad Med Singapore* 1995; 24(3):442-6.
- Lee T, Price M. Indicators and research methods for rapid assessment of a tuberculosis control programme: case study of a rural area in South Africa. *Tuber Lung Dis* 1995; 76(5):441-9.
- Lee TY, Brown HW. Tuberculous meningitis patients as index cases in the epidemiology of tuberculosis. *Am J Public Health Nations Health* 1968; 58(19):1901-9.
- Leff A, Geppert EF. Public health and preventive aspects of pulmonary tuberculosis. Infectiousness, epidemiology, risk factors, classification, and preventive therapy. *Arch Intern Med* 1979; 139(12):1405-10.
- Leggat PO. Ethionamide neuropathy. *Tubercle* 1962; 43:95-6.

- Leitch AG. Setting up and running a local tuberculosis service. *Br J Dis Chest* 1987; 81(1):6-13.
- Lemaître N, Sougakoff W, Truffot-Pernot C et al. Use of DNA fingerprinting for primary surveillance of nosocomial tuberculosis in a large urban hospital: detection of outbreaks in homeless people and migrant workers. *Int J Tuberc Lung Dis* 1998; 2(5):390-6.
- Leowski J, Miller M. Tuberculosis and AIDS: European and worldwide perspectives. *Soz Präventivmed* 1992; 37(5):199-206.
- Lerner BH. Can stress cause disease? Revisiting the tuberculosis research of Thomas Holmes, 1949-1961. *Ann Intern Med* 1996; 124(7):673-80.
- Lesprit P, Zagdanski AM, de La Blanchardière A et al. Cerebral tuberculosis in patients with the acquired immunodeficiency syndrome (AIDS). Report of 6 cases and review. *Medicine (Baltimore)* 1997; 76(6):423-31.
- Lester W. Treatment of drug-resistant tuberculosis. *Dis Mon* 1971; 1-43.
- Leston JM, Rey JC, Gonzalez Montaner LJ, Grondona A, Zavalla PN. Psychosomatic reactions to cycloserine in the treatment of tuberculosis. *Scand J Respir Dis Suppl* 1970; 71:231-4.
- Levine DM, Becker DM, Bone LR. Narrowing the gap in health status of minority populations: a community-academic medical center partnership. *Am J Prev Med* 1992; 8(5):319-23.
- Levine RA. Steatorrhea induced by para-aminosalicylic acid. *Ann Intern Med* 1968; 68(6):1265-70.
- Levins R, Awerbuch T, Brinkmann U et al. The emergence of new diseases: lessons learned from the emergence of new diseases and the resurgence of old ones may help us prepare for future epidemics. *Am Sci* 1994; 82(1):52-60.
- Levy H, Feldman C, Sacho H, van der Meulen H, Kallenbach J, Koornhof H. A re-evaluation of sputum microscopy and culture in diagnosis of primary tuberculosis. *Chest* 1989; 95:1193-7.
- Levy SB. Confronting multidrug resistance: a role for each of us. *JAMA* 1993; 269(14):1840-2.
- Liard R, Harf R, Korobaëff M, Schwoebel V, Neukirch F. HIV infection and tuberculosis: an epidemiological study from a French register. *Tuber Lung Dis* 1994; 75(4):291-6.
- Lichtenstein MR. Chicago tuberculosis prophylaxis program for children. *Tuberculosis and Thoracic Diseases* 1967; 24(1):4-6.
- Lienhardt C, Manneh K, Bouchier V, Lahai G, Milligan PJM, McAdam KPWJ. Factors determining the outcome of treatment of adult smear-positive tuberculosis cases in the Gambia. *Int J Tuberc Lung Dis* 1998; 2(9):712-8.
- Lienhardt C, Rowley J, Manneh K. Directly observed treatment for tuberculosis. *Lancet* 1999; 353:145-6.
- Lietman PS. Fluoroquinolone toxicities. An update. *Drugs* 1995; 49(Suppl. 2):159-63.
- Lin TM, Li SF, Chen CY. Evaluation of domiciliary chemotherapy of pulmonary tuberculosis in a health center in Taiwan. *Taiwan I Hsueh Hui Tsu Chih* 1968; 67(11):435-48.
- Linton CJ, Jalal H, Leeming JP, Millar MR. Rapid discrimination of *Mycobacterium tuberculosis* strains by random amplified polymorphic DNA analysis. *J Clin Microbiol* 1994; 32(9):2169-74.
- Lisella RS, Comer RD. The photofluorograph as a tuberculosis case finding tool: an evaluation. *Mil Med* 1971; 136(3):258-60.
- Livengood JR, Sigler TG, Foster LR, Bobst JG, Snider DE. Isoniazid-resistant tuberculosis. A community outbreak and report of a rifampin prophylaxis failure. *JAMA* 1985; 253(19):2847-9.
- Lockgart B, Sharp V, Squires K et al. Improved outcome of MDR-TB in patients receiving a five or more drug initial therapy. IX International Conference on AIDS. 1993.
- Loebstein R, Koren G. Clinical pharmacology and therapeutic drug monitoring in neonates and children. *Pediatr Rev* 1998; 19(12):423-8.
- Long R, Manfreda J, Mendella L, Wolfe J, Parker S, Hershfield E. Antituberculosis drug resistance in Manitoba from 1980 to 1989. *Can Med Assoc J* 1993; 148(9):1489-95.
- Long R, Scalcini M, Manfreda J et al. Impact of human immunodeficiency virus type 1 on tuberculosis in rural Haiti. *Am Rev Respir Dis* 1991a; 143(1):69-73.
- Long R, Scalcini M, Manfreda J, Jean-Baptiste M, Hershfeld E. The impact of HIV on the usefulness of sputum smears for the diagnosis of tuberculosis. *Am J Public Health* 1991b; 81:1326-8.
- Lortholary O, Tod M, Cohen Y, Petitjean O. Aminoglycosides. *Med Clin N Am* 1995; 79(4):761-87.
- Lotte A, Perdrizet S. [Value and limits of radiophotographic examinations of the thorax in the field of tuberculosis epidemiology]. [French]. *Bull Inst Natl Sante Rech Med* 1966; 21(4):781-803.
- Lounis N, Ji B, Truffot-Pernot C, Grosset J. Which aminoglycoside or fluoroquinolone is more active against *Mycobacterium tuberculosis* in mice? *Antimicrob Agents Chemother* 1997; 41(3):607-10.
- Löytönen M, Maasilta P. Multi-drug resistant tuberculosis in Finland – a forecast. *Soc Sci Med* 1998; 46(6):695-702.
- Lugosi L. Quantitative methods in the tuberculosis epidemiology and in the evaluation of BCG vaccination programs. *Dev Biol Stand* 1986; 58(Pt. A):299-306.
- Lukas W. [Epidemiology of extrapulmonary tuberculosis]. [German]. *Prax Klin Pneumol* 1977; 31(8):695-701.
- Luna-Herrera J, Reddy VM, Daneluzzi D, Gangadharam PR. Antituberculosis activity of clarithromycin. *Antimicrob Agents Chemother* 1995; 39(12):2692-5.
- Lundgren RI, Lang R. 'There is no sea, only fish': effects of United States policy on the health of the displaced in El Salvador. *Soc Sci Med* 1989; 28(7):697-706.
- Maartens G, Willcox PA, Benatar SR. Miliary tuberculosis: rapid diagnosis, hematologic abnormalities, and outcome in 109 treated adults. *Am J Med* 1990; 89(3):291-6.

- Macgregor A, Somner A. The anti-thyroid action of para-aminosalicylic acid. *Lancet* 1954; 2:931-6.
- Mackay L. Evaluation is the key to success. A nurse-led tuberculosis contact tracing service. *Prof Nurse* 1993; 9(3):176-80.
- Madsen LA, Iseman MD. Management of drug-resistant tuberculosis. *Chest Surg Clin N Am* 1993; 3(4):715-21.
- Maher D, Hausler HP, Raviglione MC et al. Tuberculosis care in community care organizations in sub-Saharan Africa: practice and potential. *Int J Tuberc Lung Dis* 1997; 1(3):276-83.
- Mahler HT. Tuberculosis in the world today. *Bull Int Union Tuberc* 1970; 43:19-25.
- Mahmoudi A, Iseman MD. Pitfalls in the care of patients with tuberculosis: common errors and their association with the acquisition of drug resistance. *JAMA* 1993; 270(1):65-8.
- Makarevich NM, Mkrtchian SV, Afanas'eva IP. [Cross resistance of *Mycobacterium tuberculosis* to streptomycin, kanamycin and viomycin]. [Russian]. *Antibiotiki* 1970; 15(4):345-51.
- Malone JL, Paparello SF, Malone JD et al. Drug susceptibility of *Mycobacterium tuberculosis* from recent Haitian migrants: correlation with clinical response. *Clin Infect Dis* 1994; 19(5):938-40.
- Malone JL, Paparello SF, Malone JD, Hill HE, Myers JW, Weiss P. Tuberculosis and HIV infection. *Lancet* 1993; 342:677.
- Maloney SA, Pearson ML, Gordon MT, Del Castillo R, Boyle JF, Jarvis WR. Efficacy of control measures in preventing nosocomial transmission of multidrug-resistant tuberculosis to patients and health care workers. *Ann Intern Med* 1995; 122(5):90-5.
- Manalo F, Tan F, Sbarbaro JA, Iseman MD. Community-based short-course treatment of pulmonary tuberculosis in a developing nation. Initial report of an eight-month, largely intermittent regimen in a population with a high prevalence of drug resistance. *Am Rev Respir Dis* 1990; 142(6 Pt. 1):1301-5.
- Mandell GL, Bennett JE, Dolin R, eds. *Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases*. 5th edition. Philadelphia: Churchill Livingstone, 2000.
- Mandell GL, Sande MA. Antimicrobial agents use in the chemotherapy of tuberculosis and leprosy. In: Gilman AG, Goodman LS, Gilman A, eds. *The Pharmacological Basis of Therapeutics*. 6th edition. New York: Macmillan, 1980: 1200-21.
- Mangelsdorf KR. The selection and training of primary health care workers in Ecuador: issues and alternatives for public policy. *Int J Health Serv* 1988; 18(3):471-93.
- Mangtani P, Jolley DJ, Watson JM, Rodrigues LC. Socioeconomic deprivation and notification rates for tuberculosis in London during 1982-91. *BMJ* 1995; 310:963-9.
- Mangunegoro H, Tulak AD, Hudoyo A. The efficacy of low-dose ofloxacin in the treatment of MDR-TB in Indonesia. *Int J Tuberc Lung Dis* 1999; 2(11):S178.
- Mann J, Tarantola D, eds. *AIDS in the World II: The Global AIDS Policy Coalition*. New York: Oxford University Press, 1996.
- Manolidis S, Frenkiel S, Yskovitch A, Black M. Mycobacterial infections of the head and neck. *Otolaryngol Head Neck Surg* 1993; 109(3 Pt. 1):427-33.
- Mantzoros CS, Brown PD, Dembry L. Extraosseous epidural tuberculoma: case report and review. *Clin Infect Dis* 1993; 17(6):1032-6.
- Maranetra KN. Treatment of multidrug-resistant tuberculosis in Thailand. *Chemotherapy* 1996; 42(Suppl. 3):10-5.
- Markowitz N, Hansen NI, Wilcosky TC et al. Tuberculin and anergy testing in HIV-seropositive and HIV-seronegative persons. Pulmonary complications of HIV infection study group. *Ann Intern Med* 1993; 119(3):185-93.
- Markowitz SB. Epidemiology of tuberculosis among health care workers. *Occup Med* 1994; 9(4):589-608.
- Marmorstein B, Scheinhorn D. Effect of ethionamide on thyroid function. *Curr Ther Res Clin Exp* 1976; 19(4):483-86.
- Marrero A, Caminero JA, Rodríguez R, Billo NE. Towards elimination of tuberculosis in a low income country: the experience of Cuba, 1962-97. *Thorax* 2000; 55(1):39-45.
- Marsh D, Hashim R, Hassany F et al. Front-line management of pulmonary tuberculosis: an analysis of tuberculosis and treatment practices in urban Sindh, Pakistan. *Tuberc Lung Dis* 1996; 77(1):86-92.
- Martin DJ, Schoub BD, Miller GB, Sim JG. AIDS and tuberculosis. *S Afr Med J* 1990; 78(9):533-5.
- Martin P, Widgren J. International migration: a global challenge. *Population Bulletin* 1996; 51(1):2-47.
- Martín V, González P, Cayla JA et al. Case-finding of pulmonary tuberculosis on admission to a penitentiary centre. *Tuberc Lung Dis* 1994; 75(1):49-53.
- Martiny O. A tuberculosis programme for South Africa, the mines and voluntary agencies. *Proc Mine Med Off Assoc* 1970; 49(407):162-9.
- Martoy J. The tuberculosis campaign in Uruguay. *World Med J* 1967; 14(3):91-3.
- Masdjedi M, Hastaie P, Ghazisaidi S, Salek S, Velayati A. Study of drug resistance in 106 patients with pulmonary tuberculosis during 18 months. *Int J Tuberc Lung Dis* 1999; 2(11):S327.
- Masobe P, Lee T, Price M. Isoniazid prophylactic therapy for tuberculosis in HIV-seropositive patients – a least-cost analysis. *S Afr Med J* 1995; 85(2):75-81.
- Massachusetts State Laboratory Institute. *Mycobacteriology Guide to Laboratory Services*. Boston: Massachusetts Department of Public Health, 1993.
- Massey DS. International migration at the dawn of the twenty-first century: the role of the state. *Population and Development Review* 1999; 25(2):303-22.
- Mastro TD, Coninx R. The management of tuberculosis in refugees along the Thai-Kampuchean border. *Tubercle* 1988; 69:95-103.
- Mata JI. Integrating the client's perspective in planning a tuberculosis education and treatment program in Honduras. *Med Anthropol* 1985; 9(1):57-64.
- Matas M. Tuberculosis programs of the medical services, Department of National Health and Welfare. *Med Serv J Can* 1966; 22(10):878-83.
- Matthews C, van der Walt H, Barron P. A shotgun marriage – community health workers and government health services. *S Afr Med J* 1994; 84(10):659-63.

- Mattie H, Craig WA, Pechere JC. Determinants of efficacy and toxicity of aminoglycosides. *J Antimicrob Chemother* 1989; 24(3):281-93.
- May RM. The rise and fall and rise of tuberculosis. *Nat Med* 1995; 1(8):752.
- Mazouni L, Zidouni N, Boulahbal F, Chaulet P. Treatment of failure and relapse cases of pulmonary TBC within a national programme based on short course chemotherapy. Preliminary report. *Tuberculosis surveillance research unit of the IUATLD, Progress Report* vol 1.
- Mburu FM. Whither community health workers in the age of structural adjustment? *Soc Sci Med* 1994; 39(7):883-5.
- McAulliffe W, Breer P, Doering S. An evaluation of policy using ex-addict outreach workers to educate intravenous drug users about AIDS. *AIDS Public Policy Journal* 1989; 4:218-23.
- McClathy J, Kanes W, Davidson P, Moulding T. Cross-resistance in *M. tuberculosis* to kanamycin, capreomycin, and viomycin. *Tubercle* 1977; 58:29-34.
- McCord C, Kielmann AA. A successful programme for medical auxiliaries treating childhood diarrhoea and pneumonia. *Trop Doct* 1978; 8(4):220-5.
- McCue M, Afifi LA. Using peer helpers for tuberculosis prevention. *J Am Coll Health* 1996; 44(4):173-6.
- McDonald PJ, Murray CJ, McDonald HM. Antibiotics, antiseptics and tubercle bacilli. *Med J Aust* 1974; 2(2):41-5.
- McDonald RJ, Memon AM, Reichman LB. Successful supervised ambulatory management of tuberculosis treatment failures. *Ann Intern Med* 1982; 96(3):297-302.
- McFadyen JE, ed. *International Drug Price Indicator Guide*. Boston: Management Sciences for Health, 2000.
- McFarland JW, Hickman C, Osterholm MT, MacDonald KL. Exposure to *Mycobacterium tuberculosis* during air travel. *Lancet* 1993; 342:112-3.
- McKenna MT, McCray E, Onorato I. The epidemiology of tuberculosis among foreign-born persons in the United States, 1986 to 1993. *N Engl J Med* 1995; 332(16):1071-6.
- McSherry G, Connor E. Current epidemiology of tuberculosis. *Pediatr Ann* 1993; 22(10):600-4.
- Meeran K. Prevalence of HIV infection among patients with leprosy and tuberculosis in rural Zambia. *BMJ* 1989; 298:364-85.
- Mehrotra ML, Gautam KD, Chaube CK. Short course chemotherapy of pulmonary tuberculosis and its possible impact on epidemiology of disease. *Indian J Chest Dis Allied Sci* 1982; 24(2-3):195-202.
- Mehta JB, Dutt A, Harvill L, Mathews KM. Epidemiology of extrapulmonary tuberculosis. A comparative analysis with pre-AIDS era. *Chest* 1991; 99(5):1134-8.
- Meier JL. Mycobacterial and fungal infections of bone and joints. *Curr Opin Rheumatol* 1994; 6(4):408-14.
- Meister JS, Warrick LH, de Zapien JG, Wood AH. Using lay health workers: case study of a community-based prenatal intervention. *J Community Health* 1992; 17(1):37-51.
- Mendoza MT, Gonzaga AJ, Roa C et al. Nature of drug resistance and predictors of multidrug-resistant tuberculosis among patients seen at the Philippine General Hospital, Manila, Philippines. *Int J Tuberc Lung Dis* 1997; 1(1):59-63.
- Menegoni L. Conceptions of tuberculosis and therapeutic choices in Highland Chiapas, Mexico. *Med Anthropol Q* 1996; 10(3):381-401.
- Menzies D, Adhikari N, Tannenbaum T. Patient characteristics associated with failure of tuberculosis prevention. *Tuber Lung Dis* 1996; 77(4):308-14.
- Menzies D, Fanning A, Yuan L, FitzGerald JM et al. Tuberculosis in health care workers: a multicentre Canadian prevalence survey: preliminary results. *Int J Tuberc Lung Dis* 1998; 2(9 Suppl.):S98-S102.
- Menzies R, Rocher I, Vissandjee B. Factors associated with compliance in treatment of tuberculosis. *Tuber Lung Dis* 1993; 74(1):32-7.
- Messner RP. Arthritis due to tuberculosis, fungal infections, and parasites. *Curr Opin Rheumatol* 1991; 3(4):617-20.
- Metcalf CA, Bradshaw D, Stindt WW. Knowledge and beliefs about tuberculosis among non-working women in Ravensmead, Cape Town. *S Afr Med J* 1990; 77(8):408-11.
- Meux C. Tuberculosis in prisons. *Lancet* 1995; 346:1239.
- Michalowska-Mitczuk D, Kus J, Wedzicha S, Zwolska Z. Retrospective analysis of drug resistance in 100 patients with chronic pulmonary tuberculosis (CPTB) treated in the Institute of Tuberculosis and Lung Disease in Warsaw. *Int J Tuberc Lung Dis* 1999; 2(11 Suppl. 2):S333.
- Michaud C, Murray CJ. External assistance to the health sector in developing countries: a detailed analysis, 1972-90. *Bull World Health Organ* 1994; 72(4):639-51.
- Middlebrook G, Cohn ML. Some observations on the pathogenicity of isoniazid-resistant variants of tubercle bacilli. *Science* 1953; 118:297-9.
- Migliori GB, Khomenko AG, Punga VV et al. Cost-effectiveness analysis of tuberculosis control policies in Ivanovo Oblast, Russian Federation. Ivanovo Tuberculosis Project Study Group. *Bull World Health Organ* 1998; 76(5):475-83.
- Migliori GB, Borghesi A, Rossanigo P et al. Proposal of an improved score method for the diagnosis of pulmonary tuberculosis in childhood in developing countries. *Tuber Lung Dis* 1992; 73(3):145-9.
- Miles SH, Maat RB. A successful supervised outpatient short-course tuberculosis treatment programme in an open refugee camp on the Thai-Cambodian border. *Am Rev Respir Dis* 1984; 130(5):827-30.
- Miller K, Miller J. Tuberculosis in pregnancy: interactions, diagnosis, and management. *Clin Obstet Gynecol* 1996; 39(1):120-42.
- Miller MA, Valway SE, Oronato IM. Tuberculosis risk after exposure on airplanes. *Tuber Lung Dis* 1996; 77(5):414-9.
- Ministerio de Salud. *El control de la tuberculosis en el Perú y sus logros 1990-1997 [TB Control in Peru and Achievements 1990-1997]*. Lima: Ministerio de Salud, 1998.

- Ministerio de Salud. Programa Nacional de Control de la Tuberculosis en el Perú: Año 1994 [National Tuberculosis Control Program of Peru: 1994]. Lima: Ministerio de Salud, 1995.
- Ministerio de Salud. Tuberculosis en el Perú: Informe 1996 [National Tuberculosis Control Program of Peru: 1996]. Lima: Ministerio de Salud, 1997.
- Ministerio de Salud. Tuberculosis en el Perú: Informe 1997 [National Tuberculosis Control Program of Peru: 1997]. Lima: Ministerio de Salud, 1998.
- Ministerio de Salud. Tuberculosis en el Perú: Informe 1999 [National Tuberculosis Control Program of Peru: 1999]. Lima: Ministerio de Salud, 2000.
- Ministerio de Salud, Programa Nacional de Control de Enfermedades Transmisibles – Control de la Tuberculosis. Vigilancia de la resistencia a los medicamentos antituberculosos en el Perú, 1995-1996 [Surveillance of antituberculous drug-resistance in Peru, 1995-1996]. Lima: Ministerio de Salud, 1996.
- Ministerio de Salud, Reunión Regional de Directores Nacionales de Programas de Control de la Tuberculosis. Informe Final [Final Report]. Lima: Ministerio de Salud, 1997.
- Mintz AA. Tuberculous meningitis in children before and since isoniazid. *South Med J* 1976; 69(8):1061-2.
- Miörner H, Sjöbring U, Nayak P, Chandramuki A. Diagnosis of tuberculous meningitis: a comparative analysis of 3 immunoassays, an immune complex assay and the polymerase chain reaction. *Tuber Lung Dis* 1995; 76(5):381-6.
- Mirzoyev F, LeClerc A. Modification of resistance profiles to first line drugs among patients under standard, DOTS based treatment protocol. *Int J Tuberc Lung Dis* 1999; 3(9 Suppl. 1):S123.
- Mishkinis K, Kaminskaite A, Purvanetskene B. [Treatment of multidrug resistant tuberculosis in Santakiskes tuberculosis hospital]. [Russian]. *Probl Tuberk* 2000; (3):9-11.
- Mishkinis K, Purvanetskene B. Drug resistant tuberculosis in Lithuania. *Tuber Lung Dis* 1996; 77(Suppl. 2):63.
- Mitchison DA. Drug resistance in mycobacteria. *Br Med Bull* 1984; 40(1):84-90.
- Mitchison DA. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. *Int J Tuberc Lung Dis* 1998; 2(1):10-5.
- Mitchison DA. Tubercle bacilli resistant to isoniazid: virulence and response to treatment with isoniazid in guinea-pigs. *BMJ* 1954; 4:128-30.
- Mitchison DA, Dickinson JM. Laboratory aspects of intermittent drug therapy. *Postgrad Med* 1971; 47:737-41.
- Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. *Am Rev Respir Dis* 1986; 133(3):423-30.
- Mitike G, Kebede D, Yeneneh H. Prevalence of antituberculosis drug resistance in Harar Tuberculosis Centre, Ethiopia. *East Afr Med J* 1997; 74(3):158-61.
- Mitnick CD. Outcomes of directly observed, individualized, community-based therapy for multidrug-resistant tuberculosis in a shantytown in northern Lima, Peru [Sc.D. thesis]. Boston: Harvard University, 2001.
- Mitnick CD, Furin JJ, Henry CL, Ross J. Tuberculosis among the foreign born in Massachusetts, 1982-1984: a reflection of social and economic disadvantage. *Int J Tuberc Lung Dis* 1998; 2(9 Suppl. 1):S32-40.
- Mitnick CD, Palacios E, Shin S et al. Treatment outcomes in 75 patients with chronic multidrug-resistant tuberculosis enrolled in aggressive community-based therapy in urban Peru. *Int J Tuberc Lung Dis* 2001; 5(11 Suppl. 1):S156-7.
- Moghazeh SL, Pan X, Arain T, Stover CK, Musser JM, Kreiswirth BN. Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant *Mycobacterium tuberculosis* isolates with known rpoB mutations. *Antimicrob Agents Chemother* 1996; 40(11):2655-7.
- Mohar A, Romo J, Salido F et al. The spectrum of clinical and pathological manifestations of AIDS in a consecutive series of autopsied patients in Mexico. *AIDS* 1992; 6(5):467-73.
- Monatova LN, Nikiforenko NS, Kovaleva TE, Dubinets AV. [Prevalence and clinical aspects of tuberculosis in children and adolescents in the Primorsk region]. [Russian]. *Probl Tuberk* 1995; (6):10-2.
- Monno L, Agarano G, Carbonara S et al. Emergence of drug-resistant *Mycobacterium tuberculosis* in HIV-infected patients. *Lancet* 1991; 337:852.
- Moore AV, Kirk SM, Callister SM, Mazurek GH, Shell RF. Safe determination of susceptibility of *Mycobacterium tuberculosis* to antimycobacterial agents by flow cytometry. *J Clin Microbiol* 1999; 37(3):479-83.
- Moore M, Fleming KS, Sands L. A passenger with pulmonary/laryngeal tuberculosis: no evidence of transmission of two short flights. *Aviat Space Environ Med* 1996; 67(11):1097-100.
- Moore M, Onorato IM, McCray E, Castro KG. Trends in drug-resistant tuberculosis in the United States, 1993-1996. *JAMA* 1997; 278(10):833-7.
- Moore RD, Chaulk CP, Griffiths R, Cavalcante S, Chaisson RE. Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis. *Am J Respir Crit Care Med* 1996; 154(4 Pt. 1):1013-9.
- Moore VJ. A review of side-effects experienced by patients taking clofazimine. *Leprosy* 1983; 54(4):327-35.
- Mor N, Esfandiari A. Synergistic activities of clarithromycin and pyrazinamide against *Mycobacterium tuberculosis* in human macrophages. *Antimicrob Agents Chemother* 1997; 41(9):2035-6.
- Morcillo N, Alito A, Romano MI et al. Multidrug resistant tuberculosis outbreak in Buenos Aires: DNA fingerprinting analysis of isolates. *Medicina (B Aires)* 1996; 56(1):45-7.
- Mori T. [The decision making process in tuberculosis control programme]. [Japanese]. *Kekkaku* 1993; 68(10):657-66.
- Mori T. [Problems of HIV infection and tuberculosis (TB) in Asia – an epidemiologic model analysis of the impact of HIV infection on TB control]. [Japanese]. *Nippon Kyobu Shikkan Gakkai Zasshi* 1994; 32(Suppl.):216-22.
- Moro ML, Gori A, Errante I et al. An outbreak of multidrug-resistant tuberculosis involving HIV-infected patients of two hospitals in Milan, Italy. *AIDS* 1998; 12(9):1095-102.

- Morrison G, Hark L. *Medical Nutrition and Disease*. 2nd edition. Malden: Blackwell Science, 1999.
- Morse DI. Directly observed therapy for tuberculosis. *BMJ* 1996; 312:719-20.
- Moss AR, Alland D, Telzak E et al. A city-wide outbreak of a multiple-drug-resistant strain of *Mycobacterium tuberculosis* in New York. *Int J Tuberc Lung Dis* 1997; 1(2):115-21.
- Moulding TS, Sbarbaro JA. Case finding to prevent tuberculosis: is it justified? *Chest* 1974; 66(4):344-5.
- Mshana RN, Tadesse G, Abate G, Miörner H. Use of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide for rapid detection of rifampin-resistant *Mycobacterium tuberculosis*. *J Clin Microbiol* 1998; 36(5):1214-9.
- Munkner T. Studies on goitre due to para-aminosalicylic acid. *Scand J Respir Dis* 1969; 50(3):212-26.
- Murkehar MV, Kulkarni HR, Zodpey SP, Dehankar AG. Effectiveness of mass neonatal BCG vaccination in the prevention of pulmonary tuberculosis: a case-control study in Nagpur, India. *Tuber Lung Dis* 1995; 76(6):545-9.
- Murphy P. Satellite clinics for tuberculosis care. *Nurs Outlook* 1972; 20(3):186-7.
- Murphy PR. Tuberculosis control in San Francisco's Chinatown. *Am J Nurs* 1970; 70(5):1044-6.
- Murray CJ. Issues in operational, social, and economic research on tuberculosis. In: Bloom B, ed. *Tuberculosis: Pathogenesis, Protection, and Control*. Washington DC: American Society for Microbiology, 1994: 583-622.
- Murray CJ. Social, economic and operational research on tuberculosis: recent studies and some priority questions. *Bull Int Union Tuberc Lung Dis* 1991; 66(4):149-56.
- Murray CJ, DeJonghe E, Chum HJ, Nyangulu DS, Salomao A, Styblo K. Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries. *Lancet* 1991; 338:1305-8.
- Murray CJ, López AD, eds. *The Global Burden of Disease*. Cambridge: Harvard University Press, 1996.
- Murray CJ, López AD. *Global Health Statistics: A Compendium of Incidence, Prevalence and Mortality Estimates for over 200 Conditions*. Cambridge: Harvard University Press, 1996.
- Murray CJ, López AD. Global mortality, disability, and the contribution of risk factors: global burden of disease study. *Lancet* 1997; 349:1436-42.
- Murray CJ, López AD. Quantifying disability: data, methods and results. *Bull World Health Organ* 1994; 72(3):481-94.
- Murray CJ, López AD, Jamison DT. The global burden of disease in 1990: summary results, sensitivity analysis and future directions. *Bull World Health Organ* 1994; 72(3):495-509.
- Murray CJ, Salomon JA. Expanding the WHO tuberculosis control strategy: rethinking the role of active case-finding. *Int J Tuberc Lung Dis* 1998; 2(9 Suppl. 1):S9-S15.
- Murray CJ, Styblo K, Rouillon A. Tuberculosis. In: Jamison DT, Mosley WH, Measham AR, Bobadilla JL, eds. *Disease Control Priorities in Developing Countries*. New York: Oxford University Press, Inc, 1991: 233-59.
- Murray CJ, Styblo K, Rouillon A. Tuberculosis in developing countries: burden, intervention and cost. *Bull Int Union Tuberc Lung Dis* 1990; 65(1):6-24.
- Murray JF. Tuberculosis and human immunodeficiency virus infection during the 1990's. *Bull Int Union Tuberc Lung Dis* 1991; 66(1):21-5.
- Murtagh K. Unreliability of the Mantoux test using 1 TU PPD in excluding childhood tuberculosis in Papua New Guinea. *Arch Dis Child* 1980; 55(10):795-9.
- Mushtaque A, Chowdhury R. Success with DOTS strategy. *Lancet* 1999; 353:1003-4.
- Musser JM, Kapur V, Williams DL, Kreiswirth BN, van Soolingen D, van Embden JD. Characterization of the catalase-peroxidase gene (*katG*) and *inhA* locus isoniazid-resistant and -susceptible strains of *Mycobacterium tuberculosis* by automated DNA sequencing: restricted array of mutations associated with drug resistance. *J Infect Dis* 1996; 173(1):196-202.
- Nagpaul DR, Vishwanath MK, Dwarakanath G. A socio-epidemiological study of out-patients attending a city tuberculosis clinic in India to judge the place of specialized centres in a tuberculosis control programme. *Bull World Health Organ* 1970; 43(1):17-34.
- Nair SS. A simple model for planning and assessment of programmes for tuberculosis control. *Indian J Public Health* 1977; 21(3):111-31.
- Narain JP, Raviglione MC, Kochi A. HIV-associated tuberculosis in developing countries: epidemiology and strategies for prevention. *Tuber Lung Dis* 1992; 73(6):311-21.
- Narayan R, Prabhakar S, Thomas S, Kumari SP, Suresh T, Srikantharamu N. A sociological study of awareness of symptoms and action taking of persons with pulmonary tuberculosis (a resurvey). *Indian J Tuberc* 1979; 26(3):136-46.
- Nardell EA. Dodging droplet nuclei: Reducing the probability of nosocomial tuberculosis transmission in the AIDS era. *Am Rev Respir Dis* 1990; 142(3):501-3.
- Nardell EA, Brickner PW. Tuberculosis in New York City: focal transmission of an often fatal disease. *JAMA* 1996; 276(15):1259-60.
- Nardell EA, McInnis B, Thomas B, Weidhaas S. Exogenous reinfection with tuberculosis in a shelter for the homeless. *N Engl J Med* 1986; 315(25):1570-5.
- Nardini S, Schiavon F, Zuin R, Romani S. [Has the role of radiology changed in the fight against pulmonary tuberculosis?]. [Italian]. *Radiol Med (Torino)* 1995; 89(1-2):49-56.
- Nariman S. Adverse reactions to the drugs used in the treatment of tuberculosis. *Adverse Drug React Acute Poisoning Rev* 1988; 7(4):207-27.
- Naroditskaya V, Werner BG, Farmer P, Becerra M, Sloutsky A. Limited mutation pattern found by DNA sequence analysis of rifampin-resistant (rif-R) clinical *Mycobacterium tuberculosis* isolates from Peru. *Abstracts of the Annual Meeting of the American Society of Microbiology* 1999; Session #27/U-11:635.
- Nash KA, Gaytan A, Inderlied CB. Detection of rifampin resistance in *Mycobacterium tuberculosis* by use of a rapid, simple, and specific RNA/RNA mismatch assay. *J Infect Dis* 1997; 176(2):533-6.
- Needham DM, Godfrey-Faussett P, Foster SD. Barriers to tuberculosis control in urban Zambia: the economic impact and burden on patients prior to diagnosis. *Int J Tuberc Lung Dis* 1998; 2(10):811-7.

- Neher A, Breyer G, Shrestha B, Feldmann K. Directly observed intermittent short-course chemotherapy in the Kathmandu valley. *Tuber Lung Dis* 1996; 77(4):302-7.
- Nelson SM, Deike MA, Cartwright CP. Value of examining multiple sputum specimens in the diagnosis of pulmonary tuberculosis. *J Clin Microbiol* 1998; 36(2):467-9.
- Netto EM, Dye C, Raviglione MC. Progress in global tuberculosis control 1995-1996, with emphasis on 22 high-incidence countries. *Int J Tuberc Lung Dis* 1999; 3(4):310-20.
- Neu HC. The crisis in antibiotic resistance. *Science* 1992; 257:1064-73.
- Neumann G. [Causes of failures in the clinical treatment of open pulmonary tuberculosis. Possibilities of their removal from the standpoint of the tuberculosis community health service physician]. [German]. *Beitr Klin Erforsch Tuberk Lungenkr* 1969; 140(1):157-76.
- Neumann G. [Reorganization of tuberculosis dispensaries. Guiding principles]. [German]. *Offentl Gesundheitswes* 1977; 39(7):379-82.
- Neumann G, Lichtenfeld A. [HIV infection and tuberculosis – result of a survey]. [German]. *Pneumologie* 1991; 45(7):565-9.
- Neville K, Bromberg A, Bromberg R, Bonk S, Hanna BA, Rom WN. The third epidemic – multidrug-resistant tuberculosis. *Chest* 1994; 105(1):45-8.
- Newell KW. *Health by the People*. Geneva: World Health Organization, 1975.
- Newton RW. Side effects of drugs used to treat tuberculosis. *Scott Med J* 1975; 20(2):47-9.
- Ngoc Van L, Thi Luong D. Situation of drug resistance of *M. tuberculosis* isolated from extra-pulmonary TB patients at the Nat. Inst. of TB and Resp. Diseases (1985-1995). *Int J Tuberc Lung Dis* 1999; 2(11 Suppl. 2):S325.
- Nicas M. Modeling respirator penetration values with the beta distribution: an application to occupational tuberculosis transmission. *Am Ind Hyg Assoc J* 1994; 55(6):515-24.
- Nichter MA. The primary health center as a social system: PHC, social status, and the issue of team-work in South Asia. *Soc Sci Med* 1986; 23(4):347-55.
- Niemann S, Rusch-Gerdes S, Richter E. IS6110 fingerprinting of drug-resistant *Mycobacterium tuberculosis* strains isolated in Germany during 1995. *J Clin Microbiol* 1997; 35(12):3015-20.
- Nikodemowicz E, Sawicki F, Janczy S, Czajka-Kropaczek L, Pawlikowska L, Piotrowska B. [Epidemiology of chronic non-specific respiratory diseases in Poland. Pulmonary tuberculosis and cough and expectoration symptoms among Cracow inhabitants]. [French]. *Lille Med* 1974; 19(7):756-60.
- Nitta AT, Davidson PT, de Koning ML, Kilman RJ. Misdiagnosis of multidrug-resistant tuberculosis possibly due to laboratory-related errors. *JAMA* 1996; 276(24):1980-3.
- Nivin B, Nicholas P, Gayer M, Frieden TR, Fujiwara PI. A continuing outbreak of multidrug resistant tuberculosis, with transmission in a hospital nursery. *Clin Infect Dis* 1998; 26(2):303-7.
- Noble RC. Infectiousness of pulmonary tuberculosis after starting chemotherapy: review of the available data on an unresolved question. *Am J Infect Control* 1981; 9(1):6-10.
- Noguchi H, Ogushi Y. Computer-assisted system for a mycobacteria tuberculosis laboratory using MUMPS. *Med Inform (Lond)* 1978; 3(4):305-15.
- Nolan CM. Incorporation of pyrazinamide into community-wide treatment of tuberculosis. *Am J Public Health* 1990; 80(12):1525-6.
- Nolan CM. Multidrug-resistant tuberculosis in the USA: the end of the beginning. *Tuber Lung Dis* 1996; 77(4):293-4.
- Nolan CM. Nosocomial multidrug-resistant tuberculosis: global spread of the third epidemic. *J Infect Dis* 1997; 176(3):748-51.
- Nolan CM, Aitken ML, Elarth AM, Anderson KM, Miller WT. Active tuberculosis after isoniazid chemoprophylaxis of southeast Asian refugees. *Am Rev Respir Dis* 1986; 133(3):431-6.
- Nolan CM, Elarth AM. Tuberculosis in a cohort of Southeast Asian refugees: a five-year surveillance study. *Am Rev Respir Dis* 1988; 137(4):805-9.
- Nolan RJ. Childhood tuberculosis in North Carolina: a study of the opportunities for intervention in the transmission of tuberculosis to children. *Am J Public Health* 1986; 76(1):26-30.
- Nsanzumuhire H, Aluoch JA, Karuga WK et al. A third study of case-finding methods for pulmonary tuberculosis in Kenya, including the use of community leaders. *Tubercle* 1981; 62(2):79-94.
- Nsanzumuhire H, Lukwago EW, Edwards EA, Stott H, Fox W, Sutherland I. A study of the use of community leaders in case-finding for pulmonary tuberculosis in the Machakos district of Kenya. *Tubercle* 1977; 58(3):117-28.
- Nunn P, Brindle R, Carpenter L et al. Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya: analysis of early (6 month) mortality. *Am Rev Respir Dis* 1992; 146:849-54.
- Nunn P, Felten M. Surveillance of resistance to antituberculosis drugs in developing countries. *Tuber Lung Dis* 1994; 75(3):163-7.
- Nunn P, Mungai M, Nyamwaya J et al. The effect of immunodeficiency virus type-1 on the infectiousness of tuberculosis. *Tuber Lung Dis* 1994; 75(1):25-32.
- Nunn P, Odhiambo J, Elliott A. Tuberculosis and HIV infection. *Lancet* 1990; 335:1044.
- Nyirenda TE, Mundy CJ, Harries AD, Banerjee A, Salaniponi FM. Safety in laboratories carrying out sputum smear microscopy: a dilemma for resource-poor countries. *Int J Tuberc Lung Dis* 1998; 2(8):690-3.
- O'Brien KL, Ruff AJ, Louis MA et al. *Bacillus Calmette-Guérin* complications in children born to HIV-1-infected women with a review of the literature. *Pediatrics* 1995; 95(3):414-8.
- O'Brien RJ. Drug-resistant tuberculosis: etiology, management and prevention. *Semin Respir Infect* 1994; 9(2):104-12.
- O'Brien RJ. The epidemiology of nontuberculous mycobacterial disease. *Clin Chest Med* 1989; 10(3):407-18.

- O'Brien RJ, Geiter IJ, Snider DE. The epidemiology of nontuberculous mycobacterial diseases in the United States. Results from a national survey. *Am Rev Respir Dis* 1987; 135(5):1007-14.
- O'Brien TF, Pla MP, Mayer KH et al. Intercontinental spread of a new antibiotic resistance gene on an epidemic plasmid. *Science* 1985; 230:87-8.
- O'Donnell B. The epidemiology and control of tuberculosis. *Ir J Med Sci* 1985; 154(5 Suppl. 1):24-8.
- Okwera A, Whalen C, Byekwaso F et al. Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. *Lancet* 1994; 344:1323-8.
- Oliveira E, Oliveira A, Costa A, Sa L, Vieira A, Oliveira A. [Gastric tuberculosis]. [Portuguese]. *Acta Med Port* 1994; 7(12):687-90.
- Olivier C. [Tuberculosis and children. I – epidemiology]. [French]. *Rev Infirm* 1991; 41(4):33-5.
- Olshansky SJ, Carnes B, Rogers RG, Smith L. Infectious diseases – new and ancient threats to world health. *Population Bulletin* 1997; 52(2):2-47.
- Omodei Zorini A, L'Eltore G, Spadoni M. Results of the first nine courses on epidemiology and tuberculosis control held at the Carlo Forlanini Institute in Rome, for doctors from the developing countries. *Bull Int Union Tuberc* 1970; 44:144-6.
- Onozaki I, Shakya TM. Feasibility study of a district tuberculosis control programme with an 8-month short-course chemotherapy regimen utilizing the integrated health service network under field conditions in Nepal. *Tuber Lung Dis* 1995; 76(1):65-71.
- Opl G. [Epidemiology, diagnosis, and treatment of renal tuberculosis. A report of 213 cases]. [German]. *Wiener Med Wochenschr* 1980; 130(12):417-20.
- Ordway DJ, Sonnenberg MG, Donahu SA, Belisle JT, Orme IM. Drug-resistant strains of *Mycobacterium tuberculosis* exhibit a range of virulence for mice. *Infection Immun* 1995; 63(2):741-3.
- Ormerod LP, Horsfield N. Frequency and type of reactions to antituberculosis drugs: observations in routine treatment. *Tuber Lung Dis* 1996; 77(1):37-42.
- Ormerod P, Skinner C. Reinfection tuberculosis: two cases in the family of a patient with drug-resistant disease. *Thorax* 1980; 35(1):56-9.
- Osborne CM. The challenge of diagnosis childhood tuberculosis in a developing country. *Arch Dis Child* 1995; 72(4):369-74.
- Ou Z, Xi-fu W, Jie Y. Initial drug resistance to anti-tuberculosis drugs among inpatients of a provincial chest hospital in China 1980-1991. *Tuber Lung Dis* 1996; 77(Suppl. 2):62.
- Ouattara SA, Diallo D, Meite M et al. [Epidemiology of infections caused by human immunodeficiency viruses HIV-1 and HIV-2 in the Ivory Coast]. [French]. *Med Trop (Mars)* 1988; 48(4):375-9.
- Oviawe O, Ojemudia E. The problem of non-attendance at a paediatric tuberculosis outpatient clinic. *Ann Trop Paediatr* 1993; 13(3):243-7.
- Owens RC, Ambrose PG. Clinical use of the fluoroquinolones. *Med Clin N Am* 2000; 84(6):1447-69.
- Paaby P, Norvin E. The absorption of vitamin B12 during treatment with para-aminosalicylic acid. *Acta Med Scand* 1966; 180(5):561-4.
- Pablos-Méndez A, Blustein J, Knirsch CA. The role of diabetes mellitus in the higher prevalence of tuberculosis among diabetics. *Am J Public Health* 1997; 87(4):574-9.
- Pablos-Méndez A, Knirsch CA, Barr RG, Lerner BH, Frieden TR. Nonadherence in tuberculosis treatment: predictors and consequences in New York City. *Am J Med* 1997; 102(2):164-70.
- Pablos-Méndez A, Raviglione M, Battan R, Ramos-Zuniga R. Drug resistant tuberculosis among the homeless in New York City. *New York State Journal of Medicine* 1990; 90(7):351-5.
- Pablos-Méndez A, Raviglione MC, Laszlo A et al. Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. *N Engl J Med* 1998; 338(23):1641-9.
- Pablos-Méndez A, Sterling TR, Frieden TR. The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis. *JAMA* 1996; 276(15):1223-8.
- Pan American Health Organization-Perú, World Health Organization, Ministerio de Salud-Perú. *Report of a Review of the National Tuberculosis Control Programme: Perú*. Washington DC: PAHO, 1994.
- Pangon B, Michon C, Bizet C et al. [Retrospective bacteriological study of mycobacterial infections in patients with acquired immunodeficiency syndrome]. [French]. *Presse Med* 1988; 17(19):945-8.
- Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD Jr. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. *Lancet* 1993; 342:268-72.
- Paramasivan CN, Kubendiran G, Herbert D. Action of metronidazole in combination with isoniazid & rifampicin on persisting organisms in experimental murine tuberculosis. *Indian J Med Res* 1998; 108:115-9.
- Paramasivan CN, Narayana ASL, Prabhakar R, Rajagopal MS, Somasundaram PR, Tripathy SP. Effect of storage of sputum specimens at room temperature on smear and culture results. *Tubercle* 1983; 64(2):119-24.
- Park MM, Davis AL, Schluger NW, Cohen H, Rom WN. Outcome of MDR-TB patients, 1983-1993. Prolonged survival with appropriate therapy. *Am J Respir Crit Care Med* 1996; 153(1):317-24.
- Park SK, Kim CT, Song SD. Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. *Int J Tuberc Lung Dis* 1998; 2(11):877-84.
- Parry CM, Kamoto O, Harries AD et al. The use of sputum induction for establishing a diagnosis in patients with suspected pulmonary tuberculosis in Malawi. *Tuber Lung Dis* 1995; 76(1):72-6.
- Pasargiklian M, Biondi L. Neurologic and behavioural reactions of tuberculous patients treated with cycloserine. *Scand J Respir Dis Suppl* 1970; 71:201-8.

- Passanante MR, Gallagher CT, Reichman LB. Preventive therapy for contacts of multidrug-resistant tuberculosis. A Delphi survey. *Chest* 1994; 106(2):431-4.
- Patel A, Schofield F, Siskind V, Abrahams E, Parker J. Case-control evaluation of a school-age BCG vaccination programme in subtropical Australia. *Bull World Health Organ* 1991; 69(4):425-33.
- Patel AM, McKeon J. Avoidance and management of adverse reactions to antituberculosis drugs. *Drug Saf* 1995; 12(1):1-25.
- Pearson ML, Jereb JA, Frieden TR et al. Nosocomial transmission of multidrug-resistant *Mycobacterium tuberculosis*: a risk to patients and health care workers. *Ann Intern Med* 1992; 117(3):191-6.
- Pécoul B, Chirac P, Trouiller P, Pinel J. Access to essential drugs in poor countries: a lost battle? *JAMA* 1999; 281(4):361-7.
- Peirce TH, York GK, Parsons GH, Spannagel V, Lillington GA, Cross CE. A combined health department-medical school rural outpatient tuberculosis program. *Am J Public Health* 1977; 67(3):257-9.
- Peloquin CA. Pharmacology of the antimycobacterial drugs. *Med Clin N Am* 1993; 77(6):1253-62.
- Peloquin CA. Using therapeutic drug monitoring to dose the antimycobacterial drugs. *Clin Chest Med* 1997; 18(1):79-87.
- Pelto PJ, Pelto GH. *Anthropological Research: The Structure of Inquiry*. 2nd edition. New York: Cambridge University Press, 1978.
- Pelto H, Nur Mohamed ON, Kataja M et al. Risk of infection with *Mycobacterium tuberculosis* among children and mothers in Somalia. *Clin Infect Dis* 1994; 18(1):106-11.
- Peñarrieta I. *Informe preliminar de la encuesta aplicada por Socios En Salud, Carabayllo*. Lima: 1996.
- Perera HW. The integrated National Tuberculosis Programme of Sri Lanka. *Bull Int Union Tuberc* 1976; 51(1):369-79.
- Pérez-Stable EJ, Hopewell PC. Current tuberculosis treatment regimens: choosing the right one for your patient. *Clin Chest Med* 1989; 10(3):323-39.
- Pérez-Stable EJ, Slutkin G, Paz EA, Hopewell PC. Tuberculin reactivity in United States and foreign-born Latinos: results of a community-based screening program. *Am J Public Health* 1986; 76(6):643-6.
- Perino SS. Nike-footed health workers deal with the problems of adolescent pregnancy. *Public Health Rep* 1992; 107(2):208-12.
- Perneger TV, Sudre P, Lundgren JD, Hirschel B. Does the onset of tuberculosis in AIDS predict shorter survival? Results of a cohort study in 17 European countries over 13 years. *BMJ* 1995; 311:1468-71.
- Perriens JH, St. Louis ME, Mukadi YB et al. Pulmonary tuberculosis in HIV-infected patients in Zaïre. *N Engl J Med* 1995; 332(12):779-84.
- Perronne C. Multiple-drug-resistant tuberculosis: current aspects in industrialized countries and future strategies. *Microbiol Res* 1993; 144(2):129-33.
- Perronne C, de Truchis P. [Multidrug-resistant tuberculosis. Epidemiology, treatment, prevention and diagnostic research]. [French]. *Rev Med Interne* 1995; 16(7):547-52.
- Perronne C, Zahraoui M, Lepout C et al. [Tuberculosis in patients infected with the human immunodeficiency virus. 30 cases]. [French]. *Presse Med* 1988; 17(29):1479-83.
- Petersen KF. [Significance of bacteriological examination for the epidemiology and therapy of pulmonary tuberculosis]. [German]. *Offentl Gesundheitswes* 1974; 36(5):345-9.
- Petrenko VM, Cherenko SA, Vengerov BB. Does mycobacterial resistance affect outcomes of tuberculosis treatment? *Tuber Lung Dis* 1996; 77(Suppl. 2):59.
- Phillips M, Feachem RG, Murray CJ, Over M, Kjellstrom T. Adult health: a legitimate concern for developing countries. *Am J Public Health* 1993; 83(11):1527-30.
- Piatek AS, Tyagi S, Pol AC et al. Molecular beacon sequence analysis for detecting drug resistance in *Mycobacterium tuberculosis*. *Nature Biotechnol* 1998; 16(4):359-63.
- Pilheu JA. Tuberculosis 2000: problems and solutions. *Int J Tuberc Lung Dis* 1998; 2(9):696-703.
- Pilheu JA, De Salvo MC, Koch O. Liver alterations in antituberculosis regimens containing pyrazinamide. *Chest* 1981; 80(6):720-2.
- Pio A. Epidemiology of tuberculosis. *Minerva Med* 1984; 75(11):507-17.
- Pio A, Luelmo F, Kumaresan J, Spinaci S. National tuberculosis programme review: experience over the period 1990-1995. *Bull World Health Organ* 1997; 75(6):569-81.
- Pirkis JE, Speed BR, Yung AP, Dunt DR, MacIntyre CR, Plant AJ. Time to initiation of anti-tuberculosis treatment. *Tuber Lung Dis* 1996; 77(5):401-6.
- Pitchenik AE, Burr J, Laufer M et al. Outbreaks of drug-resistant tuberculosis at AIDS Centre. *Lancet* 1990; 336:440-1.
- Pitchenik AE, Russell BW, Cleary T, Pejovic I, Cole C, Snider DE Jr. The prevalence of tuberculosis and drug resistance among Haitians. *N Engl J Med* 1982; 307(3):162-5.
- Pitts F. Tuberculosis prevention and therapy. Hook E, Gwaltney J et al, eds. *Current Concepts in Infectious Diseases*. New York: John Wiley and Sons, 1977: 181-94.
- Plum G, Wenzel RP. [Epidemiology of multidrug-resistant tuberculosis in the United States of America]. [German]. *Internist* 1995; 36(10):980-6.
- Pocock D, Khare A, Harries AD. Case holding for tuberculosis in Africa: the patient's perspective. *Lancet* 1996; 347:1258.
- Polansky F. The cost of tuberculosis control in Czechoslovakia. *Tubercle* 1968; 49(Suppl. 1):9-11.
- Polkey MI, Rees PJ. Tuberculosis: current issues in diagnosis and treatment. *Br J Clin Pract* 1994; 48(5):251-5.
- Pomerantz BJ, Cleveland JC, Olson HK, Pomerantz M. Pulmonary resection for multi-drug resistant tuberculosis. *J Thorac Cardiovasc Surg* 2001; 121(3):448-53.
- Pomerantz M, Denton JR, Huitt GA, Brown JM, Powell LA, Iseman MD. Resection of the right middle lobe and lingula for mycobacterial infection. *Ann Thorac Surg* 1996; 62(4):990-3.

- Pomerantz M, Madsen LA, Goble M, Iseman MD. Surgical management of resistant mycobacterial tuberculosis and other mycobacterial pulmonary infections. *Ann Thorac Surg* 1991; 52(5):1108-12.
- Poole DL. Building community capacity to promote social and public health: challenges for universities. *Health SocWork* 1997; 22(3):163-70.
- Poole GW, Schneeweiss J. Peripheral neuropathy due to ethionamide. *Am Rev Respir Dis* 1961; 84:890-2.
- Porav I, Lutai G, Pitrop L, Szatmari Z. [Dynamics of the participation of different health departments in the detection of tuberculosis]. [Romanian]. *Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumofiziol Pneumofiziol* 1981; 30(1):59-63.
- Portaels F, Rigouts L, Bastian I. Addressing multidrug-resistant tuberculosis in penitentiary hospitals and in the general population of the former Soviet Union. *Int J Tuberc Lung Dis* 1999; 3(7):582-8.
- Porter J, Jick H. Drug-induced anaphylaxis, convulsions, deafness, and extrapyramidal symptoms. *Lancet* 1977; 1(8011):587-8.
- Porter JD. Geographical information systems (GIS) and the tuberculosis DOTS strategy. *Trop Med Int Health* 1999; 4(10):631-3.
- Porter JD. Tuberculosis in developing countries. *CDR (Lond Engl Rev)* 1991; 1(12):R136-R139.
- Porter JD, McAdam KP. Aspects of tuberculosis in Africa. 1. Tuberculosis in Africa in the AIDS era – the role of chemoprophylaxis. *Trans R Soc Trop Med Hyg* 1992; 86(5):467-9.
- Porter JD, McAdam KP. The re-emergence of tuberculosis. *Annu Rev Public Health* 1994; 15:303-23.
- Post FA, Wood R, Pillay GP. Pulmonary tuberculosis in HIV infection: radiographic appearance is related to CD4+ t-lymphocyte count. *Tuber Lung Dis* 1995; 76(6):518-21.
- Pottenger FM. Public health significance of rare tubercle bacilli in sputum. *Am Rev Tuberc* 1948; 58:314-21.
- Pouchot J, Grasland A, Collet C, Coste J, Esdaile JM, Vinceneux P. Reliability of tuberculin skin test measurement. *Ann Intern Med* 1997; 126(3):210-4.
- Powell KE, Brown ED, Seggerson JJ, Farer LS. Evaluation of tuberculosis control programs: some national trends. *Am J Public Health* 1984; 74(4):344-8.
- Pretorius GS, Sirgel FA, Schaaf HS, van Helden PD, Victor TC. Rifampicin resistance in *Mycobacterium tuberculosis* – rapid detection and implications in chemotherapy. *S Afr Med J* 1996; 86(1):50-5.
- Program in Infectious Disease and Social Change. *The Global Impact of Drug-Resistant Tuberculosis*. Boston: Harvard Medical School and the Open Society Institute, 1999.
- Public Health Service Cooperation Investigation. Prevalence of drug resistance in previously untreated patients. *Am Rev Respir Dis* 1964; 89:327-36.
- Pym AS, Cole ST. Post DOTS, post genomics: the next century of tuberculosis control. *Lancet* 1999; 353:1004-5.
- Qian YF. [Evaluation of BCG vaccination programme based on results of the third nationwide tuberculosis survey]. [Chinese]. *Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih* 1994; 17(5):281-5, 318.
- Quigley P, Ebrahim GJ. Women and community health workers promoting community health and development. *J Trop Pediatr* 1994; 40(2):66-71.
- Quillian JP. Community health workers and primary health care in Honduras. *J Am Acad Nurse Pract* 1993; 5(5):219-25.
- Quinn M. A study of services in a tuberculosis control program. *Nurs Outlook* 1965; 13(12):35-7.
- Raad I, Hachem R, Leeds N, Sawaya R, Salem Z, Atweh S. Use of adjunctive treatment with interferon-alpha in an immunocompromised patient who had refractory multidrug-resistant tuberculosis of the brain. *Clin Infect Dis* 1996; 22(3):572-4.
- Raffalli J, Sepkowitz KA, Armstrong D. Community-based outbreaks of tuberculosis. *Arch Intern Med* 1996; 156(10):1053-60.
- Rajeswari R, Chandrasekaran K, Thiruvalluvan E et al. Study of the feasibility of involving male student volunteers in case holding in an urban tuberculosis programme. *Int J Tuberc Lung Dis* 1997; 1(5):573-5.
- Raleigh JW, Wichelhausen RH, Rado TA, Bates JH. Evidence for infection by two distinct strains of *Mycobacterium tuberculosis* in pulmonary tuberculosis: report of 9 cases. *Am Rev Respir Dis* 1975; 112(4):497-503.
- Ramakrishnan CV, Andrews RH, Devadatta S et al. Influence of segregation of tuberculous patients for one year on the attack rate of tuberculosis in a 2-year period in close family contacts in South India. *Bull World Health Organ* 1961; 24(1):129-48.
- Ramachandran P, Prabhakar R. Defaults, defaulter action and retrieval of patients during studies on tuberculous meningitis in children. *Tuber Lung Dis* 1992; 73:170-3.
- Ramprasad V. Community health workers – an evolving force. *World Health Forum* 1988; 9(2):229-34.
- Rao KP, Nair SS, Naganathan N, Rajalakshmi R. Assessment of diagnosis of pulmonary tuberculosis by sputum microscopy in a district tuberculosis programme. *Indian J Tuberc* 1971; 18(1):10-21.
- Rastogi N. Emergence of multiple-drug-resistant tuberculosis: fundamental and applied research aspects, global issues and current strategies. *Res Microbiol* 1993; 144(2):103.
- Rastogi N, David HL. Mode of action of antituberculous drugs and mechanisms of drug resistance in *Mycobacterium tuberculosis*. *Res Microbiol* 1993; 144(2):133-43.
- Rastogi N, Goh KS. *In vitro* activity of the new difluorinated quinolone sparfloxacin (AT-4140) against *Mycobacterium tuberculosis* compared with activities of ofloxacin and ciprofloxacin. *Antimicrob Agents Chemother* 1991; 35(9):1993-36.
- Rastogi N, Labrousse V, Goh K. *In vitro* activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of *Mycobacterium tuberculosis* and comparative intracellular activities against the virulent H37Rv strain in human macrophages. *Curr Microbiol* 1996; 33(3):167-75.
- Rastogi N, Ross BC, Dwyer B et al. Emergence during unsuccessful chemotherapy of multiple drug resistance in a strain of *Mycobacterium tuberculosis*. *Eur J Clin Microbiol Infect Dis* 1992; 11(10):901-7.

- Raviglione MC, Dye C, Schmidt S, Kochi A. Assessment of worldwide tuberculosis control. WHO Global Surveillance and Monitoring Project. *Lancet* 1997; 350(9078):624-9.
- Raviglione MC, Rieder HL, Styblo K, Khomenko AG, Esteves K, Kochi A. Tuberculosis trends in eastern Europe and the former USSR. *Tuber Lung Dis* 1994; 75(6):400-16.
- Raviglione MC, Harries AD, Msiska R, Wilkinson D, Nunn P. Tuberculosis and HIV: current status in Africa. *AIDS* 1997; 11(Suppl. B):S115-S23.
- Raviglione MC, Luelmo F. Update on the global epidemiology of tuberculosis. *Current Issues in Public Health* 1996; 2:192-7.
- Raviglione MC, Narain JP, Kochi A. HIV-associated tuberculosis in developing countries: clinical features, diagnosis, and treatment. *Bull World Health Organ* 1992; 70(4):515-26.
- Raviglione MC, Nunn PP, Kochi A, O'Brien RJ. The pandemic of HIV-associated tuberculosis. In: Mann J, Tarantola D, eds. *AIDS in the World II: The Global AIDS Policy Coalition*. New York: Oxford University Press, 1996: 87-96.
- Raviglione MC, Nunn PP, Kochi A, Snider DE Jr. Tuberculosis treatment in developing nations. *JAMA* 1995; 274(2):125-6.
- Raviglione MC, Snider DE Jr, Kochi A. Global epidemiology of tuberculosis: morbidity and mortality of a worldwide epidemic. *JAMA* 1995; 273(3):220-6.
- Reeves SA, Noble RC. Ineffectiveness of annual chest roentgenograms in tuberculin skin test-positive hospital employees. *Am J Infect Control* 1983; 11(6):212-6.
- Reich MR. Essential drugs: economics and politics in international health. *Health Policy* 1987; 8:39-57.
- Reich MR. The politics of health sector reform in developing countries: three cases of pharmaceutical policy. *Health Policy* 1995; 32:47-77.
- Reichman LB. Defending the public's health against tuberculosis. *JAMA* 1997; 278(10):865-7.
- Reichman LB. How to ensure the continued resurgence of tuberculosis. *Lancet* 1996; 347:175-7.
- Reichman LB. Multidrug resistance in the world: the present situation. *Chemotherapy* 1996; 42(Suppl. 3):2-9.
- Reichman LB. Multidrug-resistant tuberculosis: meeting the challenge. *Hosp Pract* 1994; 29(5):85-96.
- Reichman LB. Tuberculosis case finding. *Chest* 1975; 68(4):611-2.
- Reichman LB. Tuberculosis elimination – what's to stop us? *Int J Tuberc Lung Dis* 1997; 1(1):3-11.
- Reichman LB. Tuberculosis screening and chest X-ray films. *Chest* 1975; 68(3 Suppl.):448-51.
- Reichman LB. The U-shaped curve of concern. *Am Rev Respir Dis* 1991; 144(4):741-2.
- Reichman LB, Hershfield ES. *Tuberculosis: A Comprehensive International Approach*. 2nd edition. New York: Marcel Dekker Inc., 2000.
- Reisner BS, Gatson AM, Woods GL. Use of Gen-Prob AccuProbes to identify *Mycobacterium avium* complex, *Mycobacterium tuberculosis* complex, *Mycobacterium kansasii*, and *Mycobacterium goodii* directly from BACTEC TB broth cultures. *J Clin Microbiol* 1994; 32(12):2995-8.
- Revis ME, Mofenson LM et al. for the Women and Infants Transmission Study Group. *Mycobacterium tuberculosis* infection in pregnant and non-pregnant women infected with HIV in the Women and Infants Transmission Study. (*Arch Intern Med*. 1995; 155:1066-72). *Pediatr AIDS HIV Infect* 1995; 6(5):304-5.
- Reves R, Blakey D, Snider DE Jr, Farer LS. Transmission of multiple drug resistant tuberculosis: report of a school and community outbreak. *Am J Epidemiol* 1981; 113(4):423-35.
- Reyes H, Coninx R. Pitfalls of tuberculosis programmes in prisons. *BMJ* 1997; 315:1447-50.
- Rhee JT, Piatek AS, Small PM et al. Molecular epidemiologic evaluation of transmissibility and virulence of *Mycobacterium tuberculosis*. *J Clin Microbiol* 1999; 37(6):1764-70.
- Riantawan P, Punnotok J, Chaisuksuwan R, Pransujarit V. Resistance of *Mycobacterium tuberculosis* to antituberculosis drugs in the Central Region of Thailand, 1996. *Int J Tuberc Lung Dis* 1998; 2(8):616-20.
- Richardson V, Zickler CF, Wheat LJ. Tuberculosis screening and treatment in children. *J Pediatr Health Care* 1991; 5(1):11-7.
- Richner SM, Meiring J, Kirby R. A study of the genetic diversity of *Mycobacterium tuberculosis* isolated from patients in the Eastern Province of South Africa using random amplified polymorphic DNA profiling. *Electrophoresis* 1997; 18(9):1570-6.
- Richter ED. Tuberculosis control in the inner city. Model for community health programs. *NY State J Med* 1972; 72(5):625-9.
- Richter RW, Bengen B, Alsup PA, Bruun B, Kilcoyne MM, Challenor BD. The community health worker. A resource for improved health care delivery. *Am J Public Health* 1974; 64(11):1056-61.
- Ridzon R, Kent JH, Shefer A et al. Outbreak of drug resistant tuberculosis at a high school, California, 1993. *Program and Abstracts of the Epidemic Intelligence Service 43rd Annual Conference*. Abstract 15.
- Ridzon R, Kent JH, Valway S et al. Outbreak of drug-resistant tuberculosis with second-generation transmission in a high school in California. *J Pediatr* 1997; 131(6):863-8.
- Ridzon R, Kenyon T, Luskin-Hawk R, Schultz C, Valway S, Oronato IM. Nosocomial transmission of human immunodeficiency virus and subsequent transmission of multidrug-resistant tuberculosis in a healthcare worker. *Infect Control Hosp Epidemiol* 1997; 18(6):422-3.
- Ridzon R, Whitney CG, McKenna MT et al. Risk factors for rifampin mono-resistant tuberculosis. *Am J Respir Crit Care Med* 1998; 157(6 Pt. 1):1881-4.
- Rieder HL. Case finding in high- and low-prevalence countries. In: Reichman LB, Hershfield ES, eds. *Tuberculosis: A Comprehensive International Approach*. New York: Marcel Dekker Inc., 2000: 167-82.
- Rieder HL. Drug-resistant tuberculosis: issues in epidemiology and challenges for public health. *Tuber Lung Dis* 1994; 75(5):321-3.

- Rieder HL. Methodological issues in the estimation of the tuberculosis program from tuberculin surveys. *Tuber Lung Dis* 1995; 76(2):114-21.
- Rieder HL. Socialization patterns are key to transmission dynamics of tuberculosis. *Int J Tuberc Lung Dis* 1999; 3(3):177-8.
- Rieder HL. Sputum smear conversion during directly observed treatment for tuberculosis. *Tuber Lung Dis* 1996; 77(2):124-9.
- Rieder HL. Tuberculosis in an Indochinese refugee camp: epidemiology, management and therapeutic results. *Tubercle* 1985; 66(3):179-86.
- Rieder HL, Enarson DA. A computer-based ordering system for supplies in National Tuberculosis Programs. *Tuber Lung Dis* 1995; 76(5):450-4.
- Rieder HL, Watson JM, Ravighione MC et al. Surveillance of tuberculosis in Europe. *Eur Respir J* 1996; 9(5):1097-104.
- Rifkin SB. Paradigms lost: toward a new understanding of community participation in health programmes. *Acta Trop* 1996; 61(2):79-92.
- Rigouts L, Portaels F. DNA fingerprints of *Mycobacterium tuberculosis* do not change during the development of resistance to various antituberculous drugs. *Tuber Lung Dis* 1994; 75(2):160.
- Riley LW. Drug-resistant tuberculosis. *Clin Infect Dis* 1993; 17(Suppl. 2):S442-6.
- Riley LW, Arathoon E, Loverde VD. The epidemiologic patterns of drug-resistant *Mycobacterium tuberculosis* infections: a community-based study. *Am Rev Respir Dis* 1989; 139(5):1282-5.
- Riley R, Mills CO, Grady F, Sultan L, Wittstadt F, Shivpuri DN. Infectiousness of air from a tuberculosis ward. *Am Rev Respir Dis* 1962; 85:511-25.
- Riska PF, Su Y, Bardarov S, Freundlich L, Sarkis G et al. Rapid film-based determination of antibiotic susceptibilities of *Mycobacterium tuberculosis* strains by using a Luciferase Reporter Phage and the Bronx Box. *J Clin Microbiol* 1999; 37(4).
- Ritacco V, Di Leonardo M, Reniero A et al. Nosocomial spread of human immunodeficiency virus – related multidrug-resistant tuberculosis in Buenos Aires. *J Infect Dis* 1997; 176(3):637-42.
- Ritacco V, Reniero A, Ambroggi M et al. Inter-hospital spread of multidrug-resistant tuberculosis in Buenos Aires, Argentina. *Tuber Lung Dis* 1996; 77(Suppl. 2):64.
- Rivera Medina J, Almendras M, Devoto G et al. [Abdominal tuberculosis in childhood: the clinical manifestations]. [Spanish]. *Rev Gastroenterol Peru* 1993; 13(2):90-5.
- Roberts GD, Thompson GP. Bacteriology and bacteriologic diagnosis of tuberculosis. In: Schlossberg D, ed. *Tuberculosis*. New York: Springer-Verlag, 1994.
- Robinson SA, Larsen DE. The relative influence of the community and the health system on work performance: a case study of community health workers in Colombia. *Soc Sci Med* 1990; 30(10):1041-8.
- Robinson TD, Barnes DJ. A role for surgery in the management of multi-drug-resistant tuberculosis (MDRTB). *Aust N Z J Med* 1998; 28(4):473-4.
- Roderick PJ, Connelly JB. The problems of monitoring tuberculosis in an inner-city health district: Integrated information is required. *Public Health* 1992; 106(3):193-201.
- Rodier G, Gravier P, Sèvre J-P, Binson G, Omar CS. Multidrug-resistant tuberculosis in the Horn of Africa. *J Infect Dis* 1993; 168(2):523-4.
- Rodrigues LC. BCG revaccination against tuberculosis. *Lancet* 1996; 348:4.
- Rodrigues LC, Smith PG. Tuberculosis in developing countries and methods for its control. *Trans R Soc Trop Med Hyg* 1990; 84(5):739-44.
- Rom WN, Kinney D. Potential new therapies for tuberculosis. In: Rom WN, Garay SM, eds. *Tuberculosis*. Boston: Little, Brown and Co., 1995: 851-62.
- Rom WN, O'Brien R, Spinaci S. Design and support for national tuberculosis programs. In: Rom WN, Garay SM, eds. *Tuberculosis*. Boston: Little, Brown and Co., 1995: 953-63.
- Romero W, Pamo O, Cordero L. [Morbidity and mortality in tuberculous meningoencephalitis]. [Spanish]. *Rev Med Hered* 1992; 3:157-66.
- Romulo R. Epidemiology of tuberculosis in Rhode Island. *R I Med* 1992; 75(9):437-8.
- Ronaghy HA, Najarzadeh E, Schwartz TA, Russel SS, Solter S, Zeighami B. The front line health worker: selection, training, and performance. *Am J Public Health* 1976; 66(3):273-7.
- Ronsmans C, Bennis ML, Wierza T. Diagnosis and management of dysentery by community health workers. *Lancet* 1988; 2(8610):552-5.
- Roos BR, van Cleeff MRA, Bithui WA et al. Cost-effectiveness of the polymerase chain reaction versus smear examination for the diagnosis of tuberculosis in Kenya: a theoretical model. *Int J Tuberc Lung Dis* 1998; 2(3):235-41.
- Rose DN. The relationship between TB and HIV infections. *Occup Med* 1994; 9(4):575-87.
- Rose DN, Schechter CB, Fahs MC, Silver AL. Tuberculosis prevention: cost-effectiveness analysis of isoniazid chemoprophylaxis. *Am J Prev Med* 1988; 4(2):102-9.
- Rosenblum LS, Castro KG, Dooley S, Morgan M. Effect of HIV infection and tuberculosis on hospitalizations and cost of care for young adults in the United States, 1985 to 1990. *Ann Intern Med* 1994; 121(10):786-92.
- Ross C. New drug approval process under scrutiny. *Lancet* 1994; 344:1075-6.
- Ross JD. Use of card system in community control of tuberculosis. *Community Health (Bristol)* 1975; 6(4):205-16.
- Rossi PH, Freeman HE. *Evaluation: A Systematic Approach*. 5th edition. Newbury Park CA: Sage Publications, 1993.
- Rothe TB, Karrer W. Short-course therapy of pulmonary tuberculosis: doctor's compliance. *Tuber Lung Dis* 1996; 77(1):93-7.
- Rouillon A. The mutual assistance programme of the IUATLD. Development, contribution and significance. *Bull Int Union Tuberc Lung Dis* 1991; 66(4):159-72.
- Rouillon A. Tuberculosis: a model for approaching disease control. *Chest* 1979; 76(6 Suppl.):739-40.
- Rouillon A, Perdrizet S, Parrot R. Transmission of tubercle bacilli: the effects of chemotherapy. *Tubercle* 1976; 57(4):275-99.

- Rubel AJ, Garro LC. Social and cultural factors in the successful control of tuberculosis. *Public Health Rep* 1992; 107(6):626-35.
- Rubin G, Chen C, de Herrera Y, de Aparicio V, Massey J, Morris L. Primary health care workers: the rural health aide program in El Salvador. *Bull Pan Am Health Organ* 1983; 17(1):42-50.
- Ruckenstein MJ. Vertigo and dysequilibrium with associated hearing loss. *Otolaryngol Clin North Am* 2000; 33(3):535-62.
- Rullán JV, Herrera D, Cano R et al. Nosocomial transmission of multidrug-resistant *Mycobacterium tuberculosis* in Spain. *Emerg Infect Dis* 1996; 2(2):125-9.
- Rusnak J, Sartin JS, Pace E et al. Drug susceptibility of *Mycobacterium tuberculosis* isolates from a cohort of Haitian migrants evaluated in 1994. *Clin Infect Dis* 1995; 21(4):1066.
- Russell LB, Gold MR, Siegel JE, Daniels D, Weinstein M. The role of cost-effectiveness analysis in health and medicine. *JAMA* 1996; 276(14):1172-7.
- Safi H, Aznar J, Palomares JC. Molecular epidemiology of *Mycobacterium tuberculosis* strains isolated during a 3-year period (1993 to 1995) in Seville, Spain. *J Clin Microbiol* 1997; 35(10):2472-6.
- Sahn SA, Neff TA. Miliary tuberculosis. *Am J Med* 1974; 56:495-505.
- Saidi KG, Stanford JL, Stanford CA et al. Vaccination and skin test studies on children living in villages with differing endemicity for leprosy and tuberculosis. *Int J Leprosy* 1989; 57(1):45-53.
- Saks AM, Posner R. Tuberculosis in HIV positive patients in South Africa: a comparative radiological study with HIV negative patients. *Clin Radiol* 1992; 46(6):387-90.
- Salber EJ. The lay advisor as a community health resource. *J Health Polit Policy Law* 1979; 3(4):469-78.
- Salfinger M. [Multiresistant tuberculosis in New York]. [German]. *Schweiz Rundsch Med Prax* 1993; 82(40):1105-7.
- Salfinger M. Role of the laboratory in evaluating patients with mycobacterial disease. *Clinical Microbiology Newsletter* 1995; 17(14):108-10.
- Salfinger M, Pfyffer GE. The new diagnostic mycobacteriology laboratory. *Eur J Clin Microbiol Infect Dis* 1994; 13(11):961-79.
- Salleras Sanmarti L, Alcaide Megias J, Altet Gómez MN et al. Evaluation of the efficacy of health education on the compliance with antituberculosis chemoprophylaxis in school children. A randomized clinical trial. *Tuber Lung Dis* 1993; 74(1):28-31.
- Salo WL, Aufderheide AC, Buikstra J, Holcomb TA. Identification of *Mycobacterium tuberculosis* DNA in a pre-Columbian Peruvian mummy. *Proc Natl Acad Sci U S A* 1994; 91(6):2091-4.
- Salomon N, Perlman DC, Friedmann P, Buchstein S, Kreiswirth BN, Mildvan D. Predictors and outcome of multidrug-resistant tuberculosis. *Clin Infect Dis* 1995; 21(5):1245-52.
- Samb B, Henzel D, Daley CL et al. Methods for diagnosing tuberculosis among in-patients in Eastern Africa whose sputum smears are negative. *Int J Tuberc Lung Dis* 1997; 1(1):25-30.
- Samper S, Iglesias MJ, Rabanaque MJ et al. The molecular epidemiology of tuberculosis in Zaragoza, Spain: a retrospective epidemiological study in 1993. *Int J Tuberc Lung Dis* 1998; 2(4):281-7.
- Sanches O. [Classification of subjects in the tuberculin test: application of a statistical model when the frequency distribution of the induration is a mixture of normal components]. [Spanish]. *Rev Saude Publica* 1976; 10(4):285-9.
- Sande MA, Mandell GL. Effect of rifampin on nasal carriage of *Staphylococcus aureus*. *Antimicrob Agents Chemother* 1975; 7(3):294-7.
- Sanders WE Jr, Hartwig C, Schneider N, Cacciatore R, Valdez H. Activity of amikacin against mycobacteria in vitro and in murine tuberculosis. *Tuberle* 1982; 63(3):201-8.
- Sane SV, Sane NS, Thakker SV. Alternatives to INH chemoprophylaxis. *Indian Pediatr* 1995; 32(8):935-7.
- Sanghavi DM, Gilman RH, Lescano-Guevara AG, Checkley W, Cabrera LZ, Cardenas V. Hyperendemic pulmonary tuberculosis in a Peruvian shantytown. *Am J Epidemiol* 1998; 148(4):384-9.
- Satagopan MC, Radhakrishna S, Krishnaswami KV, Somasundaram PR, Tripathy SP, Fox W. A novel system to obtain addresses of out-patients – assessment in routine clinic practice in Madras, S. India. *Tuberle* 1984; 65(1):41-5.
- Satcher D. Emerging infections: getting ahead of the curve. *Emerg Infect Dis* 1995; 1(1):1-6.
- Saunders LD, Irwig LM, Wilson TD, Kahn A, Groeneveld H. Tuberculosis management in Soweto. *S Afr Med J* 1984; 66(9):330-3.
- Saunders NA. State of the art: typing *Mycobacterium tuberculosis*. *J Hosp Infect* 1995; 29(3):169-76.
- Saunders PR. An economic evaluation of alternative programme designs for tuberculosis control in rural Uganda. *Soc Sci Med* 1995; 40(9):1203-12.
- Sawert H, Girardi E, Antonucci G, Raviglione MC, Viale P, Ippolito G. Preventative therapy for tuberculosis in HIV-infected persons: analysis of policy options based on tuberculin status and CD4+ cell count. *Arch Intern Med* 1998; 158(19):2112-21.
- Sbarbaro JA. Compliance: inducements and enforcements. *Chest* 1979; 76(Suppl.):750S-6S.
- Sbarbaro JA. "Elimination": of tuberculosis or of Tuberculosis Control Programs. *Bull Int Union Tuberc Lung Dis* 1990; 65(2-3):47-8.
- Sbarbaro JA. 'Multidrug'-resistant tuberculosis – it is time to focus on the private sector of medicine. *Chest* 1997; 111(5):1149-51.
- Sbarbaro JA. The patient-physician relationship: compliance revisited. *Ann Allergy* 1990; 64(4):325-31.
- Sbarbaro JA. Public health aspects of tuberculosis: supervision of therapy. *Clin Chest Med* 1980; 1(2):253-63.
- Sbarbaro JA. Skin testing in the diagnosis of tuberculosis. *Semin Respir Infect* 1986; 1(4):234-8.

- Sbarbaro JA. Tuberculin test: a re-emphasis on clinical judgement. *Am Rev Respir Dis* 1985; 132:177-8.
- Sbarbaro JA. Tuberculosis in the 1990s. Epidemiology and therapeutic challenge. *Chest* 1995; 108(2 Suppl.):58S-62S.
- Sbarbaro JA, Catlin BJ, Iseman MD. Long-term effectiveness of intermittent therapy for tuberculosis: final report of three Denver studies. *Am Rev Respir Dis* 1980; 121:172-4.
- Sbarbaro JA, Iseman MD. "Koch's lymph" 107 years later – an oldie but not a goldie. *Clin Infect Dis* 1997; 25:664-5.
- SBS Comas, SBS Sergio Bernales-Canta, Socios En Salud, Partners In Health. Reporte Preliminar: Tratamiento Alternativo en Pacientes con TBC Multidrogó-Resistente [Preliminary Report: Alternative Treatment in Multidrug-resistant Tuberculosis Patients]. 1997.
- Scalcini M, Carré G, Jean-Baptiste M et al. Antituberculous drug resistance in central Haiti. *Am Rev Respir Dis* 1990; 142:508-11.
- Scalcini M, Occenac R, Manfreda J, Long R. Pulmonary tuberculosis, human immunodeficiency virus type-1 and malnutrition. *Bull Int Union Tuberc Lung Dis* 1991; 66(1):37-41.
- Schaaf HS, Botha P, Beyers N et al. The 5-year outcome of multidrug resistant tuberculosis patients in the Cape Province of South Africa. *Trop Med Int Health* 1996; 1(5):718-22.
- Schaaf HS, Gie RP, van Ris A, Seifart HI, van Helden PD, Cotton MF. Second episode of tuberculosis in an HIV-infected child: relapse or reinfection? *J Infect* 2000; 41(1):100-3.
- Schaaf HS, Vermeulen HAS, Gie RP, Beyers B, Donald PR. Evaluation of young children in household contact with adult multidrug-resistant pulmonary tuberculosis cases. *Pediatr Infect Dis J* 1999; 18(6):494-500.
- Schaberg T, Gloger G, Reichert B, Mauch H, Lode H. Drug-resistant pulmonary tuberculosis in Berlin, Germany, 1987-1993. *Eur Respir J* 1995; 8(2):278-84.
- Schiffman PL, Ashkar B, Bishop M, Cleary MG. Drug resistant tuberculosis in a large southern California hospital. *Am Rev Respir Dis* 1977; 116(5):821-5.
- Schluger N, Ciotoli C, Cohen D, Johnson H, Rom WN. Comprehensive tuberculosis control for patients at high risk for noncompliance. *Am J Respir Crit Care Med* 1995; 151(5):1486-90.
- Schluger NW, Huberman R, Wolinsky N, Dooley R, Rom WN, Holzman RS. Tuberculosis infection and disease among persons seeking social services in New York City. *Int J Tuberc Lung Dis* 1997; 1(1):31-7.
- Schluger NW, Rom WN. Current approaches to the diagnosis of active pulmonary tuberculosis. *Am J Respir Crit Care Med* 1994; 149(1):264-7.
- Schoeman JH, Westaway MS, Neethling A. The relationship between socioeconomic factors and pulmonary tuberculosis. *Int J Epidemiol* 1991; 20(2):435-40.
- Schulzer M, Fitzgerald JM, Enarson DA, Grzybowski S. An estimate of the future size of the tuberculosis problem in sub-Saharan Africa resulting from HIV infection. *Tuber Lung Dis* 1992; 73(1):52-8.
- Schweinin JE. Evolving concepts of the epidemiology, diagnosis, and therapy of *Mycobacterium tuberculosis* infection. *Yale J Biol Med* 1990; 63(6):565-79.
- Schweitzer SO. *Pharmaceutical Economics and Policy*. New York: Oxford University Press, 1997.
- Scolari C, El-Hamad I, Matteelli A et al. Incidence of tuberculosis in a community of Senegalese immigrants in Northern Italy. *Int J Tuberc Lung Dis* 1999; 3(1):18-22.
- Scrimshaw S. Combining quantitative and qualitative methods in the study of intra-household resource allocation. In: Rogers B, Schlossman N, eds. *Intra-Household Resource Allocation: Issues and Methods for Developing Policy and Planning*. Tokyo: United Nations University Press, 1990.
- Seager JR. Is active case-finding an effective TB control measure? *South Afr J Med Sci* 1986; 82:389.
- Sechi LA, Zanetti S, Delogu G, Montinaro B, Sanna A, Fadda G. Molecular epidemiology of *Mycobacterium tuberculosis* strains isolated from different regions of Italy and Pakistan. *J Clin Microbiol* 1996; 34(7):1825-8.
- Seetha MA, Srikantaramu N, Aneja KS, Singh H. Influence of motivation of patients and their family members on the drug collection by patients. *Indian J Tuberc* 1988; 28(4):182-90.
- Selwyn PA, Hartel D, Lewis VA et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. *N Engl J Med* 1989; 320(9):545-50.
- Selwyn PA, Sckell BM, Alcabes P, Friedland GH, Klein RS, Schoenbaum EE. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. *JAMA* 1992; 268(4):504-9.
- Senderovitz T, Viskum K. Corticosteroids and tuberculosis. *Respir Med* 1994; 88:561-5.
- Sepkowitz KA. How contagious is tuberculosis? *Clin Infect Dis* 1996; 23(1):954-62.
- Sepkowitz KA. Tuberculin skin testing and the health care worker: lessons of the Proplit Survey. *Tuber Lung Dis* 1996; 77(1):81-5.
- Sepkowitz KA. Tuberculosis and the health care worker: a historical perspective. *Ann Intern Med* 1994; 120(1):71-9.
- Sepkowitz KA, Raffalli J. Tuberculosis at the end of the twentieth century. *Eur J Clin Microbiol Infect Dis* 1994; 13(11):902-7.
- Sepkowitz KA, Raffalli J, Riley L, Kiehn TE, Armstrong D. Tuberculosis in the AIDS era. *Clin Microbiol Rev* 1995; 8(2):180-99.
- Serkey JM. Multidrug-resistant tuberculosis: a new era in prevention and control. *Dimens Crit Care Nurs* 1995; 14(5):236-44.
- Shafer RW, Chirgwin KD, Glatt AE, Dahdouh MA, Landesman SH, Suster B. HIV prevalence, immunosuppression, and drug resistance in patients with tuberculosis in an area endemic for AIDS. *AIDS* 1991; 5(4):399-405.
- Shafer RW, Singh SP, Larkin C, Small PM. Exogenous reinfection with multidrug-resistant *Mycobacterium tuberculosis* in an immunocompetent patient. *Tuber Lung Dis* 1995; 76(6):575-7.

- Shafer RW, Small PM, Larkin C et al. Temporal trends and transmission patterns during the emergence of multidrug-resistant tuberculosis in New York City: a molecular epidemiological assessment. *J Infect Dis* 1995; 171(1):170-6.
- Shah A, Bhagat R, Panchal N. Resistant tuberculosis: successful treatment with amikacin, ofloxacin, clofazimine, and PAS. *Tuber Lung Dis* 1993; 74(1):64-5.
- Shah PR, Ramakrishna B, Mehta DK, Shah RC. Pulmonary tuberculosis in Ahmedabad: epidemiology, diagnosis and short course chemotherapy. *Indian J Pediatr* 1992; 59(4):435-42.
- Sharer L, Smith J. Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid. *Ann Intern Med* 1969; 71:1113.
- Sharlai NK. [Activities of a district nurse of the regional tuberculosis clinic]. [Russian]. *Med Sestr* 1972; 31(2):49-50.
- Shaw JB, Wynn-Williams N. Infectivity of pulmonary tuberculosis in relation to sputum status. *Am Rev Tuberc* 1954; 69:724-32.
- Shears P. Tuberculosis control in Somali refugee camps. *Tubercle* 1984; 65(2):111-6.
- Shears P. *Tuberculosis Control Programmes in Developing Countries*. OXFAM Practical Health Guide No. 4. Second edition. Oxford: OXFAM, 1988.
- Sherer JL. Neighbor-to-neighbor: community health workers educate their own. *Hosp Health Netw* 1994; 68(20):52-6.
- Shimao T. Drug resistance in tuberculosis control. *Tubercle* 1987; 68(2 Suppl.):5-18.
- Shinnick TM, Good RC. Diagnostic mycobacteriology laboratory practices. *Clin Infect Dis* 1995; 21(2):291-9.
- Siddiqi SH, Hawkins JE, Laszlo A. Interlaboratory drug susceptibility testing of *Mycobacterium tuberculosis* by a radiometric procedure and two conventional methods. *J Clin Microbiol* 1985; 22(6):919-23.
- Siddiqi SH, Stauffer JC, Ali MA, Middlebrook G. Some bacteriologic aspects of the epidemiology of pulmonary and extrapulmonary tuberculosis. *Am J Epidemiol* 1976; 103(1):101-11.
- Sifuentes-Osorio J, Ponce-de-León L, Camacho-Mezquita F et al. [Resistance of *Mycobacterium tuberculosis* in Mexican patients: clinical features and risk factors]. [Spanish]. *Rev Invest Clin* 1995; 47(4):273-81.
- Silverman M, Lee PR, Lydecker M. Drug promotion: the third world revisited. *Int J Health Serv* 1986; 16(4):659-67.
- Simpson D, Walker J. Hypersensitivity to para-aminosalicylic acid. *Am J Med* 1960; 29:297-306.
- Singapore Tuberculosis Service, British Medical Research Council. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. *Am Rev Respir Dis* 1991; 143:707-12.
- Singapore Tuberculosis Service, British Medical Research Council. Five-year follow-up of a clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. *Am Rev Respir Dis* 1988; 137:1147-50.
- Singleton L, Turner M, Haskal R, Etkind SC, Tricarico M, Nardell E. Long-term hospitalization for tuberculosis control: experience with a medical-psychosocial inpatient unit. *JAMA* 1997; 278(10):838-42.
- Slutkin G. Management of tuberculosis in urban homeless indigents. *Public Health Rep* 1986; 101(5):481-5.
- Slutkin G, Leowski J, Mann J. Tuberculosis and AIDS: the effects of the AIDS epidemic on the tuberculosis problem and tuberculosis programmes. *Bull Int Union Tuberc Lung Dis* 1988; 63(2):21-4.
- Slutkin G, Schecter FG, Hopewell PC. The results of 9-month isoniazid-rifampin therapy for pulmonary tuberculosis under program conditions in San Francisco. *Am Rev Respir Dis* 1988; 138(6):1622-4.
- Small PM, Hopewell PC, Singh SP et al. The epidemiology of tuberculosis in San Francisco. A population-based study using conventional and molecular methods. *N Engl J Med* 1994; 330(24):1703-9.
- Small PM, Moss A. Molecular epidemiology and the new tuberculosis. *Infect Agents Dis* 1993; 2(3):132-8.
- Small PM, Schecter GF, Goodman PC, Sande MA, Chaisson RE, Hopewell PC. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. *N Engl J Med* 1991; 324(5):289-94.
- Small PM, Shafer RW, Hopewell PC et al. Exogenous reinfection with multidrug-resistant *Mycobacterium tuberculosis* in patients with advanced HIV infection. *N Engl J Med* 1993; 328(16):1137-44.
- Smith I, Bam DS, Malla P, Shrestha B, Yamakami K. Methods and results of a sentinel site survey of primary drug resistance in Nepal. *Tuber Lung Dis* 1996; 77(Suppl. 2):64.
- Smith KC. Tuberculosis in children. *Curr Probl Pediatr* 2001; 31(1):1-30.
- Smith MH. Tuberculosis in children and adolescents. *Clin Chest Med* 1989; 10(3):381-95.
- Smithwick RW. *Laboratory manual for acid-fast microscopy*. 2nd edition. Atlanta: CDC, 1976.
- Smithwick RW. The working mycobacteriology laboratory. In: Friedman LN, ed. *Tuberculosis: Current Concepts and Treatment*. Boca Raton: CRC Press, 2001: 77-90.
- Snell NJ. Pediatric tuberculosis in immigrants to the United Kingdom from the Indian sub-continent. *Indian J Pediatr* 1990; 57(5):645-50.
- Snider DE Jr. The tuberculin skin test. *Am Rev Respir Dis* 1982; 125(3 Pt. 2):108-18.
- Snider DE Jr, Caras G. Isoniazid-associated hepatitis deaths: a review of available information. *Am Rev Respir Dis* 1992; 145(2 Pt 1):494-97.
- Snider DE Jr, Castro KG. The global threat of drug-resistant tuberculosis. *N Engl J Med* 1998; 338(23):1689-90.
- Snider DE Jr, Graczyk J, Bek E, Rogowski J. Supervised six-months treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampin, and pyrazinamide with and without streptomycin. *Am Rev Respir Dis* 1984; 130:1091-4.

- Snider DE Jr, Kelly GD, Caughen GM, Thompson NJ, Kilburn JO. Infection and disease among contacts of tuberculosis cases with drug-resistant and drug-susceptible bacilli. *Am Rev Respir Dis* 1985; 132(1):125-32.
- Snider DE Jr, Roper WL. The new tuberculosis. *N Engl J Med* 1992; 326(10):703-5.
- Snodgrass I, Chew SK. A national computer-based surveillance system for tuberculosis notification in Singapore. *Tuber Lung Dis* 1995; 76(3):264-70.
- Sodhy JS. Priorities in a modern tuberculosis program in developing countries. *Med J Malaysia* 1970; 24(3):171-5.
- Sola C, Devallois A, Horgen L et al. Tuberculosis in the Caribbean: using spacer oligonucleotide typing to understand strain origin and transmission. *Emerg Infect Dis* 1999; 5(3):404-14.
- Sola C, Horgen L, Maisetti J, Devallois A, Goh KS, Rastogi N. Spoligotyping followed by double-repetitive-element PCR as rapid alternative to IS6110 fingerprinting for epidemiological studies of tuberculosis. *J Clin Microbiol* 1998; 36(4):1122-4.
- Solorzano Moguel JJ, Alvarez Cuevas ME. [Care of tuberculosis patients at the community level in the state of Chiapas, Mexico]. [Spanish]. *Bol Oficina Sanit Panam* 1991; 111(5):432-8.
- Somner AR, Brace AA. Late results of treatment of chronic drug-resistant pulmonary tuberculosis. *BMJ* 1966; 26:775-8.
- Sosna J, Shulimzon T, Roznman J et al. Drug-resistant pulmonary tuberculosis in Israel, a society of immigrants: 1985-1994. *Int J Tuberc Lung Dis* 1999; 3(8):689-94.
- Spence DP, Hotchkiss J, Williams CS, Davies PD. Tuberculosis and poverty. *BMJ* 1993; 307:759-61.
- Spencer DC. Human immunodeficiency virus type-1 and tuberculosis in an urbanized, hospitalised community in Johannesburg, South Africa. *Nurs RSA* 1992; 7(5):39.
- Spilker B. *Multinational Pharmaceutical Companies: Principles and Practices*. 2nd edition. New York: Raven Press, 1994.
- Spinaci S, De Virgilio G, Bugiani M, Linari D, Bertolaso G, Elo O. Tuberculin survey among Afghan refugee children. Tuberculosis control programme among Afghan refugees in North West Frontier Province (NWFP) Pakistan. *Tubercle* 1989; 70(2):83-92.
- Spradley JP. *The Ethnographic Interview*. New York: Holt, Rinehart and Winston, 1979.
- Springett VH. Epidemiology of tuberculosis in Britain and the effects of BCG vaccination. *Scott Med J* 1978; 23(2):178-81.
- Springett VH. The treatment of tuberculosis. *Practitioner* 1975; 215:480-6.
- Squire SB, Harries AD. Lessons to be learned from tuberculosis control in China. *Lancet* 1996; 347:835-6.
- Sritharan V, Barker RH Jr. A simple method for diagnosing *M. tuberculosis* infection in clinical samples using PCR. *Mol Cell Probes* 1991; 5(5):385-95.
- Stamos JK, Rowley AH. Pediatric tuberculosis: an update. *Curr Probl Pediatr* 1995; 25(4):131-6.
- Stanford JL, Grange JM, Pozniak A. Is Africa lost? *Lancet* 1991; 338:557-8.
- Stanford JL, Stanford CA, Grange JM, Lan NN, Etemadi A. Does immunotherapy with heat-killed *Mycobacterium vaccae* offer hope for the treatment of multi-drug-resistant pulmonary tuberculosis? *Respir Med* 2001; 95(6):444-7.
- Stark R. Lay workers in primary health care: victims in the process of social transformation. *Soc Sci Med* 1985; 20(3):269-75.
- Starke JR. Tuberculosis in childhood and pregnancy. In: Friedman LN, ed. *Tuberculosis: Current Concepts and Treatment*. Boca Raton: CRC Press, 2001: 191-229.
- Starke JR. Tuberculosis in children. *Curr Opin Pediatr* 1995; 7(3):268-77.
- Starr C. Orphan Drug Act: celebration a decade and 87 drugs later. *Drug Topics* 1993; 137(7):26.
- Stead WW. Management of health care workers after inadvertent exposure to tuberculosis: a guide for the use of preventive therapy. *Ann Intern Med* 1995; 122(12):906-12.
- Steiner M, Zimmerman R, Park BH, Shirall, Schmidt H. Primary tuberculosis in children. 2. Correlation of susceptibility patterns of *M. tuberculosis* isolated from children with those isolated from source cases as an index of drug-resistant infection in a community. *Am Rev Respir Dis* 1968; 98:201-9.
- Steiner P, Rao M, Mitchell M, Steiner M. Primary drug-resistant tuberculosis in children. Correlation of drug-susceptibility patterns of matched patient and source case strains of *Mycobacterium tuberculosis*. *Am J Dis Child* 1985; 139(8):780-2.
- Stepanishina VN, Panfertsev EA, Korobova OV et al. Drug-resistant strains of *Mycobacterium tuberculosis* isolated in Russia. *Int J Tuberc Lung Dis* 1999; 3(2):149-52.
- Stevens DJ. Evolution of x-ray equipment for tuberculosis case-finding programmes in Australia. *Med J Aust* 1968; 2(21):931-5.
- Stevens JP, Daniel TM. Bacille Calmette Guérin immunization of health care workers exposed to multidrug-resistant tuberculosis: a decision analysis. *Tuber Lung Dis* 1996; 77(4):315-21.
- Steyn M, Viljoen M. The combating of tuberculosis: health perceptions, intentions and vaccination of children. *Curatiosis* 1990; 13(1-2):2-5.
- Sticht-Groh V, Rüsck-Gerdes, Boillot F, Remillieux M. Multidrug-resistant strains of tubercle bacilli isolated from pulmonary tuberculosis retreatment patients in Sierra Leone, West Africa. *Tuber Lung Dis* 1993; 74(6):411-2.
- Stoeckle MY, Guan L, Riegler N et al. Catalase-peroxidase gene sequences in isoniazid-sensitive and -resistant strains of *Mycobacterium tuberculosis* from New York City. *J Infect Dis* 1993; 168(4):1063-5.
- Stone L. Cultural influences in community participation in health. *Soc Sci Med* 1992; 35(4):409-17.
- Stop TB Partnership. *The Global Plan to Stop Tuberculosis*. New York: Open Society Institute, Partners In Health, USAID, World Bank, World Health Organization, 2002.
- Stoudemire A, Fogel BS, Greenberg DB. *Psychiatric Care of the Medical Patient*. 2nd edition. New York: Oxford University Press, 2000.

- Stricker BH. *Drug-Induced Hepatic Injury*. 2nd edition. Amsterdam: Elsevier, 1992.
- Strong BE, Kubica G. *Isolation and Identification of Mycobacterium tuberculosis: A Guide for the Level II Laboratory*. Atlanta: Centers for Disease Control, 1981.
- Stroud LA, Tokars JI, Grieco MH et al. Evaluation of infection control measures in preventing the nosocomial transmission of multidrug-resistant *Mycobacterium tuberculosis* in a New York City hospital. *Infect Control Hosp Epidemiol* 1995; 16(3):141-7.
- Stur D, Thiel W. [Evaluation criteria of antitubercular drugs from microbiological view]. [German]. *Adv Clin Pharmacol* 1977; 14:59-65.
- Styblo K. The impact of HIV infection on the global epidemiology of tuberculosis. *Bull Int Union Tuberc Lung Dis* 1991; 66(1):27-32.
- Styblo K. The relationship between the risk of tuberculous infection and the risk of developing infectious tuberculosis. *Bull Int Union Tuberc* 1985; 60:117-9.
- Styblo K. Tuberculosis and its control: lessons to be learned from past experience and implications for leprosy control programmes. *Ethiop Med J* 1983; 21(2):101-22.
- Styblo K. Tuberculosis control and surveillance. In: Flenley DC, Petty TL, eds. *Recent Advances in Respiratory Medicine*. New York: Churchill Livingstone, 1983: 77-108.
- Styblo K, Bumgarner R. Tuberculosis can be controlled with existing technologies: evidence. Tuberculosis surveillance research unit of the IUATLD, Progress Report. 1991; vol 2).
- Styblo K, Meijer J. [Recent advances in tuberculosis epidemiology with regard to formulation or adaptation of tuberculosis control programs]. [French]. *Bull Int Union Tuberc* 1978; 53(4):301-12.
- Styblo K, van Geuns HA, Meijer J. The yield of active case-finding in persons with inactive pulmonary tuberculosis or fibrotic lesions. A 5-year study in tuberculosis clinics in Amsterdam, Rotterdam and Utrecht. *Tubercle* 1984; 65(4):237-51.
- Suárez PG, Jave O, Canales R, Portocarrero J, Alarcon E. Who, when, where and why tuberculosis patients die during short course treatment. *Tuber Lung Dis* 1996; 77 (Suppl. 2):73.
- Suárez PG, Jave OC, Sabogal IT et al. Cohorts of treatment of positive smear pulmonary tuberculosis with short course 2RHZE/4R2H2 scheme in operational conditions in Peru. *Tuber Lung Dis* 1995; 76 (Suppl. 2):80.
- Sudre P, ten Dam G, Chan C, Kochi A. *Tuberculosis in the Present Time: A Global Overview of the Tuberculosis Situation*. Geneva: World Health Organization, 1991.
- Sullivan EA, Kreiswirth BN, Palumbo L et al. Emergence of fluoroquinolone-resistant tuberculosis in New York City. *Lancet* 1995; 345:1148-50.
- Sumartojo E. When tuberculosis treatment fails: a social behavioral account of patient adherence. *Am Rev Respir Dis* 1993; 147(5):1311-20.
- Sung SW, Kang CH, Kim YT, Han SK, Shim YS, Kim JH. Surgery increased the chance of cure in multi-drug resistant pulmonary tuberculosis. *Eur J Cardiothorac Surg* 1999; 16(2):187-93.
- Suo J, Yu MC, Lee CN, Chiang CY, Lin TP. Treatment of multidrug-resistant tuberculosis in Taiwan. *Chemotherapy* 1996; 42(Suppl. 3):20-3.
- Sutherland I. Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli. *Adv Tuberc Res* 1976; 19:1-63.
- Sutherland I. Research into the control of tuberculosis and leprosy in the community. *Br Med Bull* 1988; 44(3):665-78.
- Sutton FM, Graham DY, Goodgame RW. Infectious esophagitis. *Gastrointest Endosc Clin N Am* 1994; 4(4):713-29.
- Swanson DS, Starke JR. Drug-resistant tuberculosis in pediatrics. *Pediatr Clin North Am* 1995; 42(3):553-81.
- Syabbalo N. Hemoptysis: the third-world perspective. *Chest* 1991; 99(5):1316-7.
- Tabet SR, Goldbaum GM, Hooton TM, Eisenach KD, Cave MD, Nolan CM. Restriction fragment length polymorphism analysis detecting a community-based tuberculosis outbreak among persons infected with human immunodeficiency virus. *J Infect Dis* 1994; 169(1):189-92.
- Tabilo F, Casasepere MD, Guzmán A. [Pulmonary TB: intervals between consult, diagnosis, and treatment – Servicio de Salud Metropolitano Sur-Oriente]. [Spanish]. *Boletín Epidemiológico De Chile* 1987; 14(2):33-40.
- Tack KJ, Smith JA. The safety profile of ofloxacin. *Am J Med* 1989; 87(6C):78S-81S.
- Takahashi M. [Tuberculosis in Nepal: case-finding and quality control of sputum-smear examination]. [Japanese]. *Kekkaku* 1994; 69(7):475-82.
- Takahashi M, Kazumi Y, Fukasawa Y et al. Restriction fragment length polymorphism analysis of epidemiologically related *Mycobacterium tuberculosis* isolates. *Microbiol Immunol* 1993; 37(4):289-94.
- Takai R. [Statistics and epidemiology of tuberculosis]. [Japanese]. *Kango Gijutsu* 1973; 19(11):98-110.
- Takizawa T, Hashimoto K, Minami T, Yamashita S, Owen K. The comparative arthropathy of fluoroquinolones in dogs. *Hum Exp Toxicol* 1999; 18(6):392-9.
- Tala EO, Tala-Heikkilä MM. Pros and cons of BCG vaccination in countries with low incidence of tuberculosis. *Infect Control Hosp Epidemiol* 1994; 15(7):497-9.
- Tala-Heikkilä M, Nurmela T, Tala E, Tuominen J. Evaluation of the BCG revaccination programme of schoolchildren in Finland. *Bull Int Union Tuberc Lung Dis* 1991; 66(1):57-9.
- Talavera W, Miranda R, Lessnau KD, Klapholtz A. Extrapulmonary tuberculosis. In: Friedman LN, ed. *Tuberculosis: Current Concepts and Treatment*. Boca Raton: CRC Press, 2001: 139-90.
- Tamas F. Use of amikacin and amoxicillin-clavulanic acid against *Mycobacterium tuberculosis*. *Chest* 1993; 104(1):328.
- Tan K, Sin Fai K, Chew L. Mortality of patients while on treatment for active tuberculosis. *Singapore Med J* 1996; 37(3):258-60.
- Taneja DP, Kaur D. Study on hepatotoxicity and other side-effects of antituberculosis drugs. *J Indian Med Assoc* 1990; 88(10):278-80.
- Tanser F, Wilkinson D. Spatial implications of the tuberculosis DOTS strategy in rural South Africa: a novel application of geographical information system and global positioning system technologies. *Trop Med Int Health* 1999; 4(10):634-8.

- Tao JC. Tuberculosis. Training, supervision and motivation of personnel. *Bull Int Union Tuberc* 1970; 43:87-92.
- Taylor EM. Mantoux screening for tuberculosis. *Lancet* 1995; 345:930-1.
- Taylor C. *Nutritional Abnormalities in Infectious Diseases*. Binghamton: Halworth Medical Press, 1997.
- Taylor JP, Bergmire-Sweet D, Suárez L. Epidemiology of drug-resistant tuberculosis in Texas. *Am J Epidemiol* 1999; 149(4):359-65.
- Teale C, Cundall DB, Pearson SB. Time of development of tuberculosis in contacts. *Respir Med* 1991; 85(6):475-7.
- Teixeira L, Perkins MD, Johnson JL et al. Infection and disease among household contacts of patients with multidrug-resistant tuberculosis. *Int J Tuberc Lung Dis* 2001; 5(4):321-8.
- Teklu B. Reasons for failure in treatment of pulmonary tuberculosis in Ethiopians. *Tubercle* 1984; 65(1):17-21.
- Teklu B. Symptoms of pulmonary tuberculosis in consecutive smear-positive cases treated in Ethiopia. *Tuber Lung Dis* 1993; 74(2):126-8.
- Telenti A. Genetics of drug resistance in tuberculosis. *Clin Chest Med* 1997; 18(1):55-64.
- Telenti A, Honoré N, Bernasconi C et al. Genotypic assessment of isoniazid and rifampin resistance in *Mycobacterium tuberculosis*: a blind study at reference laboratory level. *J Clin Microbiol* 1997; 35(3):719-23.
- Telenti A, Marckesi F, Balz M, Bally F, Bottger EC, Bodmer T. Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis. *J Clin Microbiol* 1993; 31(2):175-8.
- Telzak EE, Sepkowitz KA, Alpert P et al. Multidrug-resistant tuberculosis in patients without HIV infection. *N Engl J Med* 1995; 333(14):907-11.
- Tempel CW. Tuberculosis prevention: the child-centered program. *GP* 1968; 37(5):99-104.
- ten Dam HG. Research on BCG vaccination. *Adv Tuberc Res* 1984; 21:79-106.
- Tenover FC, McGowan JE. Reasons for the emergence of antibiotic resistance. *Am J Med Sci* 1996; 11(1):9-16.
- Thébaud A, Lert F. [Submitting to disease, controlling disease, industrialization and medical technology: the case of tuberculosis]. [French]. *Soc Sci Med* 1985; 21(2):129-37.
- Thillagavathie P. Current issues in maternal and perinatal tuberculosis: impact of the HIV-1 epidemic. *Semin Neonatol* 2000; 5(3):189-96.
- Third East African/British Medical Research Council Study. Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis: second report. *Tubercle* 1980; 61(2):59-69.
- Thomas SB, Quinn SC, Billingsley A, Caldwell C. The characteristics of northern black churches with community health outreach programs. *Am J Public Health* 1994; 84(4):575-9.
- Thompson NP, Caplin ME, Hamilton MI et al. Anti-tuberculosis medication and the liver: dangers and recommendations in management. *Eur Respir J* 1995; 8:1384-88.
- Thomson C, Ritenbaugh C, Kerwin J et al. *Preventive and Therapeutic Nutrition Handbook*. New York: Chapman and Hall, 1996.
- Thomson EM, Myrdal S. The implementation of tuberculosis policy in three areas in South Africa. *S Afr Med J* 1986a; 70(5):258-62.
- Thomson EM, Myrdal S. Tuberculosis – the patients' perspective. *S Afr Med J* 1986b; 70(5):263-4.
- Timperi R, Sloutsky A, Farmer PE. Global laboratory testing capacity for tuberculosis. *Int J Tuberc Lung Dis* 1998; 2(11):S290-S291.
- Toman K. *Tuberculosis case-finding and chemotherapy*. Geneva: World Health Organization, 1979.
- Toman K. Tuberculosis. The training of key-organizers. *Bull Int Union Tuberc* 1970; 43:165-9.
- Treasure RL, Seaworth BJ. Current role of surgery in *Mycobacterium tuberculosis*. *Ann Thorac Surg* 1995; 59(6):1405-7.
- Trébuq A. Should ethambutol be recommended for routine treatment of tuberculosis in children? A review of the literature. *Int J Tuberc Lung Dis* 1997; 1(1):12-5.
- Trébuq A, Ait-Khaled N, Gninafon M, Louis JP. Information management in national tuberculosis control programmes and national health information systems. *Int J Tuberc Lung Dis* 1998; 2(10):852-6.
- Trébuq A, Anagonou S, Gninafon M, Lambregts K, Boulahbal F. Prevalence of primary and acquired resistance of *Mycobacterium tuberculosis* to antituberculosis drugs in Benin after 12 years of short-course chemotherapy. *Int J Tuberc Lung Dis* 1999; 3(6):466-70.
- Trébuq A, Rieder HL. Two excellent management tools for national tuberculosis programmes: history of prior treatment and sputum status at two months. *Int J Tuberc Lung Dis* 1998; 2(3):184-6.
- Tripathy SP, Menon NK, Mitchison DA et al. Response to treatment with isoniazid plus PAS of tuberculous patients with primary isoniazid resistance. *Tubercle* 1969; 50(3):257-68.
- Trnka L, Dankova D, Erban J. Surveillance systems and public health priority actions. *Bull Int Union Tuberc Lung Dis* 1990; 65(1):37-8.
- Truffot-Pernot C, Lounis N, Grosset JH, Ji B. Clarithromycin is inactive against *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 1995; 39(12):2827-8.
- Tsevat J, Taylor WC, Wong JB, Pauker SG. Isoniazid for the tuberculin reactor: take it or leave it. *Am Rev Respir Dis* 1988; 137(1):215-20.
- Tsukamura M. Cross-resistance relationships between capreomycin, kanamycin, and viomycin resistances in tubercle bacilli from patients. *Am Rev Respir Dis* 1969; 99(5):780-2.
- Tsukamura M, Kita N, Shimoide H, Arakawa H, Kuze A. Studies on the epidemiology of nontuberculous mycobacteriosis in Japan. *Am Rev Respir Dis* 1988; 137(6):1280-4.

- Tsukamura M, Mizuno S. Studies on cross-resistance of *Mycobacterium tuberculosis*, strain H37Rv, to aminoglycoside- and peptide-antibiotics. *Microbiol Immunol* 1980; 24(9):777-87.
- Tuberculosis Research Center of Madras, National Tuberculosis Institute of Bangalore. A controlled clinical trial of 3 and 5 monthly regimens in the treatment of sputum-positive pulmonary tuberculosis in South India. *Am Rev Respir Dis* 1986; 134:27-33.
- Turett GS, Fazal BA, Justman JE, Alland D, Duncalf RM, Telzak EE. Exogenous reinfection with multidrug-resistant *Mycobacterium tuberculosis*. *Clin Infect Dis* 1997; 24(3):513-4.
- Turett GS, Telzak EE, Millett WG, Daya NK, Lorian V. Changes in susceptibility of *Mycobacterium tuberculosis* at an inner-city hospital in New York City [abstract 251]. Abstracts of the 1993 IDSA Annual Meeting. *Clin Infect Dis* 1993; 17:572.
- Turett GS, Telzak EE, Torian LV et al. Improved outcomes for patients with multidrug-resistant tuberculosis. *Clin Infect Dis* 1995; 21(5):1238-44.
- Udani PM, Bhat US, Bhavne SK, Ezuthachan SG, Shetty VV. Problem of tuberculosis in children in India epidemiology, morbidity, mortality and control programme. *Indian Pediatr* 1976; 13(12):881-90.
- Uehara M. [Case finding in tuberculosis – from the viewpoint of the public health nurse]. [Japanese]. *Kangogaku Zasshi* 1967; 19(4):60-7.
- Uplekar M, Walley J, Newell J. Directly observed treatment for tuberculosis. *Lancet* 1999; 353:145.
- Uplekar MW, Rangan S. Private doctors and tuberculosis control in India. *Tuber Lung Dis* 1993; 74(5):332-7.
- Urbanczik R. Antimycobacterial activity of isoniazid + prothionamide + dapsone against a number of randomly selected 'wild' strains of *Mycobacterium tuberculosis*. *Chemotherapy* 1980; 26(4):276-81.
- Urbanczik R. Experimental data on the antimicrobial activity of isoprodian (PTH). *Scand J Respir Dis* 1978; 102(Suppl.):58-9.
- Urbanczik R. Present position of microscopy and of culture in diagnostic mycobacteriology. *Zentralbl Bakteriol Mikrobiol Hyg [A]* 1985; 260(1):81-7.
- Ussery XT, Bierman JA, Valway SE, Seitz TA, DiFerdinando GT, Ostroff SM. Transmission of multidrug-resistant *Mycobacterium tuberculosis* among persons exposed in a medical examiners office, New York. *Infect Control Hosp Epidemiol* 1995; 16(3):160-5.
- Vaillancourt PD, Langevin HM. Painful peripheral neuropathies. *Med Clin N Am* 1999; 83(3):627-42, vi.
- Valenzuela MT, Scheel G, Ponce J, Lepe R, Velasco M, Valenzuela P. [Resistance to antitubercular drugs in Chile]. [Spanish]. *Rev Med Chil* 1984; 112(1):76-80.
- Valenzuela P. [Usefulness of studies on antitubercular drug resistance]. [Spanish]. *Rev Panam Salud Publica* 1997; 1(1):62-7.
- Valenzuela P, Lepe R, Ponce de León L, Ponce J, Saldias P, Silva S. [Development of resistance to *Mycobacterium tuberculosis* in Chile]. [Spanish]. *Rev Med Chil* 1973; 101:30-3.
- Valenzuela P, Lepe R, Ponce J, Ponce de León L, Velasco M, Barrios J. [Relationship between acquired antituberculosis drug resistance and clinical situation of patients regarding chemotherapy]. [Spanish]. *Boletín Del Instituto Bacteriológico De Chile* 1977; XIX(7-12).
- Valenzuela P, Piffardi S. [Secondary resistance to antituberculosis drugs]. [Spanish]. *Rev Chil Enf Respir* 1995; 11:73-8.
- Valenzuela P, Rojas M, Zuñiga M. [Evaluation of antituberculosis treatment in previously treated patients]. [Spanish]. *Rev Chil Enf Respir* 1995; 11:113-6.
- Vallejo JG, Ong LT, Starke JR. Clinical features, diagnosis, and treatment of tuberculosis in infants. *Pediatrics* 1994; 94(1):1-7.
- Vallejo JG, Starke JR. Tuberculosis and pregnancy. *Clin Chest Med* 1992; 13(4):693-707.
- Valvassori P. Controlling the rise in tuberculosis among the homeless. *NP News* 1995; 3(2):3, 6.
- Valway SE, Greifinger RB, Papania M et al. Multidrug-resistant tuberculosis in the New York state prison system, 1990-1991. *J Infect Dis* 1994; 170(1):151-6.
- Valway SE, Richards SB, Kovacovich J, Greifinger RB, Crawford JT, Dooley SW. Outbreak of multi-drug-resistant tuberculosis in a New York state prison, 1991. *Am J Epidemiol* 1994; 140(2):113-22.
- Valway SE, Sanchez MPC, Shinnick TF et al. An outbreak involving extensive transmission of a virulent strain of *Mycobacterium tuberculosis*. *N Engl J Med* 1998; 338(10):633-9.
- Van Blerkom LM. Clown doctors: shaman healers of Western medicine. *Med Anthropol Q* 1995; 9(4):462-75.
- van der Linde I. Izindaba: stop the TB scourge. *S Afr Med J* 1996; 86(8):897-8.
- van der Werf TS, Dade GK, van der Mark TW. Patient compliance with tuberculosis treatment in Ghana: factors influencing adherence to therapy in a rural service programme. *Tubercle* 1990; 71(4):247-52.
- Van Deun A. Creation of drug resistance under DOTS programmes. *Int J Tuberc Lung Dis* 1999; 2(11):S366.
- van Embden JD, Cave MD, Crawford JT et al. Strain identification of *Mycobacterium tuberculosis* by DNA fingerprinting: recommendations for a standardized methodology. *J Clin Microbiol* 1993; 31(2):406-9.
- van Embden JD, van Soolingen D, Small PM, Hermans PW. Genetic markers for the epidemiology of tuberculosis. *Res Microbiol* 1992; 143(4):385-91.
- van Kralingen KW, van Kralingen-Heijboer AC, Zimmerman M, Postmus PE. Management of hemoptysis in a Third World city hospital: a retrospective study. *Tuber Lung Dis* 1995; 76(4):344-8.
- van Rie A, Warren R, Beyers N et al. Transmission of a multidrug-resistant *Mycobacterium tuberculosis* strain resembling "Strain W" among non-institutional, HIV seronegative patients. *Int J Tuberc Lung Dis* 1999; 3(9 Suppl. 1):S126.
- van Rie A, Warren R, Richardson M et al. Transmission of drug-resistant *Mycobacterium tuberculosis* strains in an epidemic area. *Int J Tuberc Lung Dis* 1999; 3(9 Suppl. 1):S126.

- van Soolingen D. Utility of molecular epidemiology of tuberculosis. *Eur Respir J* 1998; 11:795-7.
- van Soolingen D, Hermans PW. Epidemiology of tuberculosis by DNA fingerprinting. *Eur Respir J* 1995; 8(Suppl. 20):649s-56s.
- van Soolingen D, Hermans PW, Haas PE, Soll DR, van Embden JD. Occurrence and stability of insertion sequences in *Mycobacterium tuberculosis* complex strains: evaluation of an insertion sequence-dependent DNA polymorphism as a tool in the epidemiology of tuberculosis. *J Clin Microbiol* 1991; 29(11):2578-86.
- van Zwanenberg D. The influence of the number of bacilli on the development of tuberculous disease in children. *Am Rev Respir Dis* 1960; 82:31-44.
- Vareldzis BP, Grosset J, de Kantor I et al. Drug-resistant tuberculosis: laboratory issues. World Health Organization recommendations. *Tuber Lung Dis* 1994; 75(1):1-7.
- Vargas Machuca R. [The magnitude of tuberculosis: social factors unleashed]. [Spanish]. *Diagnostico* 1980; 5(2):62-76.
- Vargas Machuca R. [Tuberculosis in Peru and the world]. [Spanish]. *Diagnostico* 1985; 15(4):92-104.
- Vasil'ev AV, Golubeva TM, Zolotukhin VA, Galkin VB, Lebedev VB. [Medico-social aspects of epidemiology of tuberculosis in the extreme north]. [Russian]. *Probl Tuberk* 1992; (7-8):4-6.
- Vaughan JP. Barefoot or professional? Community health workers in the Third World: some important questions concerning their function, utilization, selection, training and evaluation. *J Trop Med Hyg* 1980; 83(1):3-10.
- Veen J. Methods of tuberculosis case-finding in The Netherlands. *Bull Int Union Tuberc Lung Dis* 1990; 65(2-3):67-9.
- Vekilov F. [Organization of tuberculosis control in the Azerbaijan SSR]. [Russian]. *Probl Tuberk* 1972; 50(12):21-4.
- Vekilov F. [Status of tuberculosis control in Azerbaijan]. [Russian]. *Probl Tuberk* 1966; 44(1):3-7.
- Veselov AY, Krasnikova EI, Zavadovsky IM. [Drug resistance of *Mycobacterium tuberculosis*]. [Russian]. *Antibiot Khimioter* 1992; 37(3):13-5.
- Vestal AL. *Procedures for the Isolation and Identification of Mycobacteria*. Atlanta: Centers for Disease Control, U.S. Department of Health, Education, and Welfare, 1973.
- Victor TC, Warren R, Beyers N, van Helden PD. Transmission of multidrug-resistant strains of *Mycobacterium tuberculosis* in a high incidence community. *Eur J Clin Microbiol Infect Dis* 1997; 16(7):548-9.
- Victor TC, Warren R, Butt JL et al. Genome and MIC stability in *Mycobacterium tuberculosis* and indications for continuation of isoniazid in multidrug-resistant tuberculosis. *J Med Microbiol* 1997; 46(10):847-57.
- Viljanen MK, Vyshnevskiy BI, Otten TF et al. Survey of drug-resistant tuberculosis in Northwestern Russia from 1984 through 1994. *Eur J Clin Microbiol Infect Dis* 1998; 17(3):177-83.
- Villalbi JR, Cayla JA, Iglesias B, Ferrer A, Casanas P. The evolution of tuberculosis infection among schoolchildren in Barcelona and the HIV epidemic. *Tuber Lung Dis* 1994; 75(2):105-9.
- Villarino ME, Geiter LJ, Simone PM. The multidrug-resistant tuberculosis challenge to public health efforts to control tuberculosis. *Public Health Rep* 1992; 107(6):616-25.
- Voelker R. "Ebola with wings". *JAMA* 1998; 280(14):1216.
- Volkova VD, Gunner AP, Erbosynov EE, Kadyrkhanova UT, Krivtsova AE. [Dynamics of the frequency of drug resistance in *Mycobacterium tuberculosis*]. [Russian]. *Probl Tuberk* 1983; (3):54-8.
- Volpes D, Di Rosa T, Menozzi M. Multi-drug resistant TB in Sicily (Italy). *Tuber Lung Dis* 1996; 77(Suppl. 2):64.
- von Hoegen A. [Establishment and work of a modern tuberculosis community health service]. [German]. *Offentl Gesundheitswes* 1971; 33(Suppl. 2):49-57.
- Vynnycky E, Fine P. The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. *Epidemiol Infect* 1997; 119(2):183-201.
- Waalder H. Cost-benefit analysis of BCG-vaccination under various epidemiological situations. *Proceedings of the 19th International Tuberculosis Conference*. Amsterdam: Medica Foundation, 1968: 42-52.
- Waalder H. Some aspects of cost of tuberculosis. *Bull Int Union Tuberc* 1966; 37:137-51.
- Wallace R. A synergism of plagues: "planned shrinkage," contagious housing destruction, and AIDS in the Bronx. *Environ Res* 1988; 47(1):1-33.
- Wang'ombe J, Mwabu G. Economics of essential drugs schemes: the perspectives of the developing countries. *Soc Sci Med* 1987; 25(6):625-30.
- Wanlin M, Uydebrouck M, Fortuin M, de Saint Hubert B. Anti-tuberculosis drug resistance surveillance in Belgium. *Int J Tuberc Lung Dis* 1999; 2(11 Suppl. 2):S296.
- Warburton ARE, Jenkins PA, Waight PA, Watson JM. Drug resistance in initial isolates of *Mycobacterium tuberculosis* in England and Wales, 1982-1992. *CDR (Lond Engl Rev)* 1993; 3(13):R175-R179.
- Wares DF, Clowes CI. Tuberculosis in Russia. *Lancet* 1997; 350:957.
- Warren R, Hauman J, Beyers N et al. Unexpectedly high strain diversity of *Mycobacterium tuberculosis* in a high-incidence community. *S Afr Med J* 1996; 86(1):45-9.
- Warren R, Richardson M, Sampson S et al. Genotyping of *Mycobacterium tuberculosis* with additional markers enhances accuracy in epidemiological studies. *J Clin Microbiol* 1996; 34(9):2219-24.
- Warren RW. Rheumatologic aspects of pediatric cystic fibrosis patients treated with fluoroquinolones. *Pediatr Infect Dis J* 1997; 16(1):118-22; discussion 123-6.
- Wartski SA. Epidemiology and control of tuberculosis in Israel. *Public Health Rev* 1995; 23(4):297-341.
- Wartski SA. Tuberculosis case finding and treatment in Ethiopian immigrants to Israel, 1989-91. *Is J Med Sci* 1993; 29(6-7):376-80.
- Watt B, Edwards JR, Rayner A, Grindey AJ, Harris G. In vitro activity of meropenem and imipenem against mycobacteria: development of a daily antibiotic dosing schedule. *Tuber Lung Dis* 1992; 73(3):134-6.

- Watterson SA, Wilson SM, Yates MD, Drobniowski FA. Comparison of three molecular assays for rapid detection of rifampin resistance in *Mycobacterium tuberculosis*. *J Clin Microbiol* 1998; 36(7):1969-73.
- Watts T. A pilot study in case finding and control of tuberculosis in Uganda by giving BCG to primary school children and using accelerated reactors as index cases. *J Trop Pediatr Environ Child Health* 1974; 20(2):71-2.
- Webb AH. The delivery of a total tuberculosis service in a scattered rural community with poor communications. *N Z Med J* 1973; 78:412-4.
- Webb R, Fernández Baca G. Perú en números 1997: anuario estadístico [Peru in numbers 1997: annual statistics]. Lima: Cuánto S.A., 1997.
- Webb R, Fernández Baca G. Perú en números 2001: anuario estadístico [Peru in numbers 2001: annual statistics]. Lima: Cuánto S.A., 2001.
- Weber DJ, Rutala WA, Samsa GP, Sarubbi FA Jr, King LC. Epidemiology of tuberculosis in North Carolina, 1966 to 1986: analysis of demographic features, geographic variation, AIDS, migrant workers, and site of infection. *South Med J* 1989; 82(10):1204-14.
- Weil DC. Drug supply: meeting a global need. In: Porter J, McAdam K, eds. *Tuberculosis: Back to the Future*. New York: John Wiley and Sons Ltd., 1994: 123-49.
- Weiner ID, Wingo CS. Hypokalemia – consequences, causes, and correction. *J Am Soc Nephrol* 1997; 8(7):1179-88.
- Weis SE, Slocum PC, Blais FX et al. The effect of directly observed therapy on rates of drug resistance and relapse in tuberculosis. *N Engl J Med* 1994; 330(17):1179-84.
- Weissler JC. Tuberculosis – immunopathogenesis and therapy. *Am J Med Sci* 1993; 305(1):52-65.
- Weisz S. [The importance of after-treatment and after care of tuberculosis patients following discharge from the sanatorium]. [German]. *Wiener Med Wochenschr* 1967; 117(24):593-8.
- Weltman AC, Rose DN. Tuberculosis susceptibility patterns, predictors of multidrug resistance, and implications for initial therapeutic regimens at a New York City hospital. *Arch Intern Med* 1994; 154(19):2161-7.
- Wenger PN, Otten J, Breedon A, Orfas D, Beck-Sague CM, Jarvis WR. Control of nosocomial transmission of multidrug-resistant *Mycobacterium tuberculosis* among healthcare workers and HIV-infected patients. *Lancet* 1995; 345:235-40.
- Westaway MS. Knowledge and attitudes about tuberculosis of black hospitalized TB patients. *Tubercle* 1990; 71(1):55-9.
- Westaway MS, Conradie PW, Remmers L. Supervised out-patient treatment of tuberculosis: evaluation of a South African rural programme. *Tubercle* 1991; 72(2):140-4.
- Westaway MS, Wessie GM. Tuberculosis diagnosis and treatment of young South African children: experiences and perceptions of care-givers. *Tuber Lung Dis* 1994; 75(1):70-4.
- Westaway MS, Wolmarans L. Acceptability of the tuberculosis service: scale development. *Int J Epidemiol* 1993; 22(3):543-7.
- Westaway MS, Wolmarans L. Cognitive and affective reactions of black urban South Africans towards tuberculosis. *Tuber Lung Dis* 1994; 75(6):447-53.
- Westheimer R, Cattell S, Connell et al. Use of paraprofessionals to motivate women to return for postpartum checkup. *Public Health Rep* 1968; 83:3-10.
- Westwater ML. Multidrug-resistant tuberculosis in South Africa. *Lancet* 1996; 347:1837.
- Weyer K, Groenewald P, Zwarenstein M, Lombard CJ. Tuberculosis drug resistance in the Western Cape. *S Afr Med J* 1995; 85(6):499-504.
- Weyer K, Kleeberg HH. Primary and acquired drug resistance in adult black patients with tuberculosis in South Africa: results of a continuous national drug resistance surveillance programme involvement. *Tuber Lung Dis* 1992; 73(2):106-12.
- Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. *Am J Respir Crit Care Med* 1995; 151(1):129-35.
- White GL Jr, Henthorne BH, Barnes SE, Segarra JT. Tuberculosis: a health education imperative returns. *J Community Health* 1995; 20(1):29-57.
- Wiedorn W, Ervin F. Schizophrenic-like psychotic reactions with administration of isoniazid. *AMA Archives of Neurology and Psychiatry* 1954; 72:321-4.
- Wilcox MH. Protection against hospital-acquired tuberculosis, American style: a report on the 4th annual meeting of the Society for Hospital Epidemiology of America (SHEA), New Orleans, 1994. *J Hosp Infect* 1995; 29(3):165-8.
- Wilcox WD, Laufer S. Tuberculosis in adolescents. A case commentary. *Clin Pediatr (Phila)* 1994; 33(5):258-62.
- Wilkinson D. High-compliance tuberculosis treatment programme in a rural community. *Lancet* 1994; 343:647-8.
- Wilkinson D. Sputum microscopy at 2 and 3 months. *Int J Tuberc Lung Dis* 1998; 2(10):862.
- Wilkinson D, Bechan S, Connolly C, Standing E, Short GM. Should we take a history of prior treatment, and check sputum status at 2-3 months when treating patients for tuberculosis? *Int J Tuberc Lung Dis* 1998; 2(1):52-5.
- Wilkinson D, Davies G. The increasing burden of tuberculosis in rural South Africa – impact of HIV epidemic. *S Afr Med J* 1997; 87(4):447-50.
- Wilkinson D, Davies G, Connolly C. Directly observed therapy for tuberculosis in rural South Africa, 1991 through 1994. *Am J Public Health* 1996; 86(8):1094-7.
- Wilkinson D, Floyd K, Gilks CF. Costs and cost-effectiveness of alternative tuberculosis management strategies in South Africa – implications for policy. *S Afr Med J* 1997; 87(4):451-5.
- Wilkinson D, Pillay M, Crump J, Lombard C, Davies GR, Sturm AW. Molecular epidemiology and transmission dynamics of *Mycobacterium tuberculosis* in rural Africa. *Trop Med Int Health* 1997; 2(8):747-53.
- Wilkinson D, Pillay M, Davies GR, Sturm AW. Resistance to antituberculosis drugs in rural South Africa: rates, patterns, risks, and transmission dynamics. *Trans R Soc Trop Med Hyg* 1996; 90(6):692-5.

- Wilkinson D, Squire SB, Garner P. Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of randomised placebo controlled trials. *BMJ* 1998; 317:625-9.
- Wilkinson RG. *Unhealthy Societies: The Afflictions of Inequality*. London: Routledge, 1996.
- Williams DL, Spring L, Collins L et al. Contribution of rpoB mutations to development of rifamycin cross-resistance in *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 1998; 42(7):1853-7.
- Williams J, Schneider N, Gilligan M. Implementing a tuberculosis control program. *Am J Infect Control* 1995; 23(2):152-5.
- Williams RL, Reid SJ, Myeni C, Pitt L, Solarsh G. Practical skills and valued community outcomes: the next step in community-based education. *Med Educ* 1999; 33(10):730-7.
- Wilson EA, Thelin TJ, Dilts PV. Tuberculosis complicated by pregnancy. *Am J Obstet Gynecol* 1973; 115(4):526-9.
- Wilson ME. Travel and the emergence of infectious diseases. *Emerg Infect Dis* 1995; 1(2):39-46.
- Wilson ME, Fineberg HV, Colditz GA. Geographic latitude and the efficacy of Bacillus Calmette-Guérin vaccine. *Clin Infect Dis* 1995; 20(4):982-91.
- Wilson ME, Levins R, Spielman A, eds. *Disease in Evolution: Global Changes and Emergence of Infectious Diseases*. Vol. 740. New York: New York Academy of Sciences, 1994.
- Wilson SM, al-Suwaidi Z, McNerney R, Porter JD, Drobniewski FA. Evaluation of a new rapid bacteriophage-based method for the drug susceptibility testing of *Mycobacterium tuberculosis*. *Nat Med* 1997; 3(4):465-8.
- Winker MA, Flanagan A, McLendon WW, Foege WH. Emerging and re-emerging global microbial threats. *JAMA* 1995; 273(3):241-2.
- Winstanley PA. The clinical pharmacology of antituberculosis drugs. In: Davies P, ed. *Clinical Tuberculosis*. New York: Chapman and Hall Medical, 1994: 129-40.
- Witmer A, Seifer SD, Finocchio L, Leslie J, O'Neil EH. Community health workers: integral members of the health care work force. *Am J Public Health* 1995; 85(8 Pt 1):1055-8.
- Woelffer GB, Bradford WZ, Paz A, Small PM. A computer-assisted molecular epidemiologic approach to confronting the reemergence of tuberculosis. *Am J Med Sci* 1996; 311(1):17-22.
- Woelk GB. Cultural and structural influences in the creation of and participation in community health programmes. *Soc Sci Med* 1992; 35(4):419-24.
- Woodard GR, Edouard L. Reaching out: a community initiative for disadvantaged pregnant women. *Can J Public Health* 1992; 83(3):188-90.
- World Health Organization. *Anti-tuberculosis drug resistance in the world: the WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance 1994-1997*. Geneva: World Health Organization, 1997a.
- World Health Organization. *Anti-tuberculosis drug resistance in the world. Report no. 2. The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance 2000*. Geneva: World Health Organization, 2000a.
- World Health Organization. *Coordination of DOTS-Plus pilot projects for the management of MDR-TB*. Geneva: World Health Organization, 1999a.
- World Health Organization. *DOTS-Plus and the Green Light Committee improving access to the second-line anti-TB drugs*, 2000b.
- World Health Organization. *Essential Drugs WHO Model List*. Geneva: World Health Organization, 1999b.
- World Health Organization. *Global Tuberculosis Control: WHO Report 1998*. Geneva: World Health Organization, 1998a.
- World Health Organization. *Global Tuberculosis Control: WHO Report 1999*. Geneva: World Health Organization, 1999c.
- World Health Organization. *Groups at risk. WHO report on the tuberculosis epidemic*. Geneva: World Health Organization, 1996a.
- World Health Organization. *Guidelines for the safe transport of infectious substances and diagnostic specimens*. Geneva: World Health Organization, 1997b.
- World Health Organization. *Guidelines for tuberculosis treatment in adults and children in national tuberculosis programmes*. Geneva: World Health Organization, 1991.
- World Health Organization. *Laboratory services in tuberculosis control*. Geneva: World Health Organization, 1998b.
- World Health Organization. *Progress in DOTS-Plus and the management of multidrug-resistant tuberculosis (MDR-TB)*. Geneva: World Health Organization, 2001a.
- World Health Organization. *Report: Basis for the development of an evidence-based case-management strategy for MDR TB within the WHO's DOTS strategy*. Geneva: World Health Organization, 1999d.
- World Health Organization. *Revised procedures for updating the WHO Model List of Essential Drugs: a summary of proposals and process*. Geneva: World Health Organization, 2001b.
- World Health Organization. *TB/HIV: A clinical manual*. Geneva: World Health Organization, 1996b.
- World Health Organization. *TB Treatment Observer 1997c*; March 24.
- World Health Organization. *Treatment of tuberculosis: guidelines for national programmes*. Geneva: World Health Organization, 1996c.
- World Health Organization. *Tuberculosis control: the DOTS strategy: an annotated bibliography compiled by the Global Tuberculosis Programme and the Regional Office for South-East Asia*. Geneva: World Health Organization, 1997d.
- World Health Organization. *Use DOTS more widely: WHO reports on the tuberculosis epidemic 1997*. Geneva: World Health Organization, 1997e.
- World Health Organization. *The use of essential drugs: ninth report of the WHO expert committee*. Geneva: World Health Organization, 2000c.
- World Health Organization. *What is DOTS? A guide to understanding the WHO-recommended TB control strategy known as DOTS*. Geneva: World Health Organization, 1999e.
- World Health Organization. *WHO report on the tuberculosis epidemic*. Geneva: World Health Organization, 1997f.
- World Health Organization. *WHO tuberculosis programme: framework for effective tuberculosis control*. Geneva: World Health Organization, 1994.

- World Health Organization, International Committee of the Red Cross. *Guidelines for the control of tuberculosis in prisons*. Geneva: World Health Organization, 1998.
- World Health Organization, International Union Against Tuberculosis and Lung Disease. *Guidelines for surveillance of drug resistance in tuberculosis*. *Int J Tuberc Lung Dis* 1998; 2(1):72-89.
- World Health Organization, Regional Office for Europe. *ATB epidemic in Europe*. Geneva: World Health Organization, 1999.
- World Health Organization, Scientific Panel of the Working Group on DOTS-Plus for MDR-TB. *Guidelines for establishing DOTS-Plus pilot projects for the management of multidrug-resistant tuberculosis (MDR-TB)*. Geneva: World Health Organization, 2000.
- World Health Organization, The International Union Against Tuberculosis and Lung Disease, The Royal Netherlands Tuberculosis Association. *Revised international definitions in tuberculosis control*. *Int J Tuberc Lung Dis* 2001; 5(3):213-5.
- Wright S. Anthropology: still the uncomfortable discipline? In: Ahmed A, Shore C, eds. *The Future of Anthropology: Its Relevance to the Contemporary World*. London: Athlone, 1995: 65-93.
- Wurtz R, White WD. The cost of tuberculosis: utilization and estimated charges for the diagnosis and treatment of tuberculosis in a public health system. *Int J Tuberc Lung Dis* 1999; 3(5):382-7.
- Yablokova O. Drug-resistant TB could reach 2M. *The Moscow Times*. 24 March 1999.
- Yeats JR. Attendance compliance for short course tuberculosis chemotherapy at clinics in Estcourt and surroundings. *S Afr Med J* 1986; 70(5):265-6.
- Yeh S, Wu SY, Levine DM et al. Quality of life and stimulation of weight gain after treatment with megestrol acetate: correlation between cytokine levels and nutritional status, appetite in geriatric patients with wasting syndrome. *J Nutr Health Aging* 2000; 4(4):246-51.
- Yew WW, Chan CK, Chau CH et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. *Chest* 2000; 117(3):744-51.
- Yew WW, Chau CH. Drug-resistant tuberculosis in the 1990s. *Eur Respir J* 1995; 8(7):1184-92.
- Yew WW, Piddock LJ, Li MS, Lyon D, Chan CY, Cheng AF. *In vitro* activity of quinolones and macrolides against mycobacteria. *J Antimicrob Chemother* 1994; 34(3):343-51.
- Yew WW, Wong CF, Wong PC, Lee J, Chau CH. Adverse neurological reactions in patients with multidrug-resistant pulmonary tuberculosis after co-administration of cycloserine and ofloxacin. *Clin Infect Dis* 1993; 17(2):288-9.
- Young FE, Norris JA. *From Test Tube to Patient: New Drug Development in the United States*. Rockville: Department of Health and Human Services, 1988.
- Youngleson SM, Joubert G. A comparison of cross-sectional and longitudinal survey methods in measuring patient compliance with tuberculosis treatment. *S Afr Med J* 1991; 80(7):331-5.
- Yuan L, Richardson E, Kendall PR. Evaluation of a tuberculosis screening program for high-risk students in Toronto schools. *CMAJ* 1995; 153(7):925-32.
- Zafran N, Heldal E, Pavlovic S, Vuckovic D, Boe J. Why do our patients die of active tuberculosis in the era of effective therapy? *Tuberc Lung Dis* 1994; 75(5):329-33.
- Zajackowska J, Kaminska E, Babiuch L. [AIDS and tuberculosis]. [Polish]. *Przegl Epidemiol* 1991; 45(4):361-3.
- Zakin MM, Sherman ASH. [Pneumologic functions of the tuberculosis dispensary]. [Russian]. *Klin Med (Mosk)* 1970; 48(12):124-5.
- Zalesky R, Abdullajev F, Khechinashvili G et al. Tuberculosis control in the Caucasus: successes and constraints in DOTS implementation. *Int J Tuberc Lung Dis* 1999; 3(5):394-401.
- Zalutskaya O, Surkova L, Nikolenko E, Pechkovsky D. Surveillance of *M. tuberculosis* drug resistance in Minsk Central TB Hospital, Belarus. *Int J Tuberc Lung Dis* 1999; 2(11 Suppl. 2):S296.
- Zeit PS, Harrison LH, Lopez M, Cornale G. Community health worker competency in managing acute respiratory infections of childhood in Bolivia. *Bull Pan Am Health Organ* 1993; 27(2):109-19.
- Zellweger J-P. How can tuberculosis among immigrants be managed in Europe? *Int J Tuberc Lung Dis* 1999; 3(7):551-2.
- Zellweger J-P, Coulon P. Outcome of patients treated for tuberculosis in Vaud County, Switzerland. *Int J Tuberc Lung Dis* 1998; 2(5):372-7.
- Zhang LX. Treatment of multidrug-resistant tuberculosis in China. *Chemotherapy* 1996; 42(Suppl. 3):16-9.
- Zhang LX, Duanmu HJ, Tu DH. TB across the globe (1). Achievements and perspectives of the tuberculosis control programs in China. *Scott Med J* 2000; 45(5 Suppl):8-10.
- Zhang LX, Kan GQ. Tuberculosis control programme in Beijing. *Tuberc Lung Dis* 1992; 73(3):162-6.
- Zhang LX, Kan GQ, Tu DH, Li JS, Liu XX. Trend of initial drug resistance of tubercle bacilli isolated from new patients with pulmonary tuberculosis and its correlation with the tuberculosis programme in Beijing. *Tuberc Lung Dis* 1995; 76(2):100-3.
- Zierski M, Bek E. Side-effects of drug regimens used in short course chemotherapy for pulmonary tuberculosis: a controlled clinical study. *Tubercle* 1980; 61(1):41-9.
- Zuber PL, McKenna MT, Binkin NJ, Onorato IM, Castro KG. Long-term risk of tuberculosis among foreign-born persons in the United States. *JAMA* 1997; 278(4):304-7.
- Zumla A, Grange JM. Doing something about tuberculosis. *BMJ* 1999; 318:956.
- Zwarenstein M. Directly observed treatment for tuberculosis. *Lancet* 1999; 353:147-8.
- Zwarenstein M, Schoeman JH, Vundule C, Lombard CJ, Tatley M. Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis. *Lancet* 1998; 352:1340-3.